Abstract

Persistent depressive disorder is a depressive disorder in which depressed mood lasts for years. Its older name, dysthymic disorder, was the DSM-III and DSM-IV category and remains the name used by ICD-11 and MeSH; DSM-5 (2013) formed the broader persistent depressive disorder by merging DSM-IV dysthymic disorder with chronic major depressive disorder, and its course specifiers overlap the older research label double depression. Prevalence estimates vary with definition and method, and long naturalistic follow-ups show slow recovery and frequent relapse. Mostly small, cross-sectional studies link chronic depression to differences in social cognition, rumination and avoidance and to early adversity, leaving open whether these are causes or consequences. Combined psychotherapy and medication did best in the large trials, CBASP's edge over other psychotherapy was small to moderate and faded, and antidepressants outperform placebo in dysthymia.

Keywords: persistent depressive disorder, dysthymia, dysthymic disorder, chronic depression, double depression

Persistent depressive disorder is the name DSM-5-TR gives to depression defined by its long course, a depressed mood that persists for years alongside other depressive symptoms (American Psychiatric Association, 2022). Dysthymia and dysthymic disorder are its older names, and dysthymic disorder remains the category name in ICD-11 (World Health Organization, 2024) and the MeSH heading, whose entry terms include dysthymia, persistent depressive disorder, neurotic depression and dysthymia and chronic depression (MeSH, D019263). DSM-5 joined DSM-IV dysthymic disorder and chronic major depressive disorder in one diagnosis, a merger that a survey analysis examined while it was still a proposal draft (Murphy & Byrne, 2012); a recent review treats the resulting category as spanning dysthymia and chronic major depression (Schramm et al., 2020), and a network meta-analysis describes it as subsuming four subtypes whose grouping has had its validity challenged (Meister et al., 2016). The newer category is therefore broader than the dysthymia it replaced, and one review that set the two side by side doubted the validity of dysthymia and judged persistent depressive disorder at similar risk of being heterogeneous (Rhebergen & Graham, 2014). This page covers depression that lasts for years; depressive mood in general is covered on the depression page, episodic major depression on the major depressive disorder page, and depression beginning around childbirth on the postpartum depression page.

The article opens with what persistent depressive disorder is and whether the category is valid, then follows the history of the concept from the Greek roots of dysthymia to the DSM-5 merger. It turns to symptoms, diagnosis and assessment, to the experience of persistent depression as patients, partners and clinicians describe it, and to the types of persistent depressive disorder, from the course and onset specifiers to double depression, late-life forms and the older subtypes. Prevalence and burden, and course and prognosis, come next. Four sections then take up explanations of persistence: the CBASP model of chronic depression; personality, temperament and persistence; childhood maltreatment and early adversity; and social cognition and interpersonal functioning. They are followed by rumination, cognitive reactivity and other accounts, by cognitive processes, by testing whether cognition is cause or consequence, and by the validity of laboratory and daily-life measures. The biology of persistent depressive disorder, sleep, and brain networks and imaging precede comorbidity and suicide and self-harm. The treatment sections cover psychological treatments, how the psychological treatments work, medication, and emerging and less-tested approaches, and the article closes with culture and social context, family, partners and support, related conditions, a worked example and current directions.

Key Takeaways

  • Persistent depressive disorder is the DSM-5 (2013) name for depression that lasts for years. It merged DSM-IV dysthymic disorder with chronic major depressive disorder, so it is broader than dysthymia, and ICD-11 and MeSH still use the name dysthymic disorder.
  • Reviews find that the chronic forms of depression differ little from one another but, as a group, differ from nonchronic depression in comorbidity and suicidality, though not in symptom severity. Whether the category is a valid, separate condition remains contested.
  • Double depression, a major depressive episode superimposed on a chronic depressive disorder, was linked to poorer recovery and more relapse in early follow-ups; a three-year Dutch cohort found dysthymia and double depression ran similar courses, both worse than major depression alone.
  • In a 10-year naturalistic follow-up of early-onset dysthymic disorder, the median time to recovery was 52 months and most of those who recovered relapsed.
  • Findings on theory of mind, empathy, alexithymia, avoidance and a hostile-submissive interpersonal style in chronic depression come mostly from small, cross-sectional studies, and the theory-of-mind results conflict, so whether these differences cause persistence or follow from it remains open.
  • Childhood maltreatment was associated with a recurrent or persistent course and poorer treatment response in a meta-analysis of depression in general, although a review comparing chronic with nonchronic depression found the link inconsistent and much of the evidence rests on recalled childhoods.
  • Combined psychotherapy and medication beat either alone in pooled analyses that rest on few trials, but adding psychotherapy after non-response to medication did not help in the REVAMP trial. In the largest trial against supportive psychotherapy, CBASP's advantage was small to moderate and faded during the second year, and adding psychotherapy after medication had failed did not improve outcomes.
  • Antidepressants outperformed placebo in dysthymia in meta-analysis, while a Cochrane review judged the benefit of continuing them to prevent relapse uncertain.
  • Augmentation, brain stimulation, ketamine and esketamine, and the newer web-based and psilocybin treatments have been tested in treatment-resistant depression or mixed samples rather than in persistent depressive disorder, so whether their results apply to it is untested.

What Persistent Depressive Disorder Is

Persistent depressive disorder is the name the American Psychiatric Association's manual has used since 2013 for depression that lasts for years; its older name, dysthymia or dysthymic disorder, is still the name used by the World Health Organization's classification and by the National Library of Medicine. MeSH files the condition as Dysthymic Disorder, describes it as depressed mood lasting at least two years in adults, or one year in children, accompanied by other depressive symptoms, and credits the definition to DSM-IV (MeSH, D019263). Its entry terms include dysthymia, persistent depressive disorder and neurotic depression, and it sits under depressive disorder in the MeSH tree.

From Dysthymia to Persistent Depressive Disorder

The modern category is wider than the old one. DSM-5, published in 2013, took two separate DSM-IV diagnoses, dysthymic disorder and major depressive disorder carrying the chronic specifier, and joined them as a single diagnosis, persistent depressive disorder; a survey analysis written while that change was still at the proposal-draft stage described the planned merger (Murphy & Byrne, 2012), and a later narrative review treats both dysthymia and long-lasting major depression, with or without recovery between episodes, as forms within the newer category (Schramm et al., 2020). Persistent depressive disorder is therefore a broader concept than dysthymia as it was understood before DSM-5, a shift examined in a review of the manual's changes to depression diagnoses (Uher et al., 2014). A third review set the DSM-5 category beside the dysthymic disorder it replaced (Rhebergen & Graham, 2014). The current text revision of the American manual, DSM-5-TR, retains persistent depressive disorder as its category name (American Psychiatric Association, 2022). One consequence matters for anyone searching the literature: the MeSH scope note quoted above describes DSM-IV dysthymia, so it is narrower than the DSM-5 category, which also takes in long-lasting major depression.

The international classification went the other way on the name. ICD-11 keeps dysthymic disorder as the label for its category (World Health Organization, 2024), so the same patient may carry the older name in one system and the newer one in the other.

At its core the diagnosis asks for one thing above all: a depressed mood that has persisted for a long time. Studies that separate chronic from non-chronic depression set the line at an episode lasting at least two years; a national household survey that applied that threshold with the WMH-CIDI 3.0 interview labelled the group chronic depressive disorder rather than PDD (Murphy & Byrne, 2012). The manual then adds further depressive symptoms that must accompany the low mood and specifies how full major depressive episodes may occur within the long period; those requirements are set out in DSM-5-TR (American Psychiatric Association, 2022) and are not reproduced here.

That a major episode can sit on top of a chronic one was recognised long before DSM-5. Keller and Shapiro described the combination as double depression: a major depressive episode superimposed on a chronic depressive disorder (Keller & Shapiro, 1982). In their clinical cohort of patients who met criteria for major depression, the superimposed pattern was frequent; how often patients who had both disorders recovered depended on whether recovery meant recovery from the major episode only or from both disorders, and when they did recover they were more likely to relapse. The authors noted that the concept was poorly worked out clinically and had rarely been described in research at the time.

The reasoning behind the merger came from comparisons of chronic and nonchronic depression. A review of that evidence found that the chronic forms of non-bipolar depression resembled one another closely, whatever their label, while as a group they stood apart from nonchronic depression (Klein, 2010). The gap showed up in two places. Clinically, people with chronic depression were the more impaired, more often had other disorders alongside the depression, and more often reported suicidality. In their histories, maltreatment in childhood was more common, and so was psychopathology among relatives. Klein concluded that the chronic forms could possibly be merged into a single category, while noting that the existing distinctions among them had little support and that evidence on subtyping was still accumulating.

A later systematic review of twenty-eight cohort and cross-sectional studies, whose samples were defined as chronic depression under DSM-IV or DSM-5 rather than as PDD, broadly agreed (Köhler et al., 2019). Compared with nonchronic major depression, chronic depression began earlier and came with more psychiatric comorbidity, more suicidality and more submissive and hostile styles of relating to others. It did not differ in symptom severity, nor on most sociodemographic factors. The link with childhood maltreatment was inconsistent across studies. The authors judged the differences to be verified, noted some inconsistencies overall, and called for more research on the psychopathology specific to chronic depression. The Australian survey reached a similar verdict for the general population: the chronic group had more psychiatric comorbidity, an earlier age of onset, more frequent episodes and more often a bereavement before the first episode, and the authors judged the chronic versus non-chronic distinction to seem warranted (Murphy & Byrne, 2012).

Is the Category Valid?

Whether persistent depressive disorder marks a real and separate condition has been argued for decades. The doubts began with the earlier category. A critical review of DSM-III dysthymia argued that its criteria lumped together different chronic depressive conditions and needed subcategories, among them an insidious form beginning early in life, and it left open how dysthymia related to personality disorders and whether the subcategories responded differently to treatment (Kocsis & Frances, 1987).

The case against the newer category rests on the same ground. A narrative review judged the validity of dysthymia doubtful: the diagnosis overlapped with other mood and anxiety disorders, it did not predict how the illness would turn out, and no validation strategy had been shown to pick out a depressive entity of this kind (Rhebergen & Graham, 2014). The authors judged PDD at similar risk of being a heterogeneous diagnosis. A review of the DSM-5 changes to depression made a narrower point: the manual left the relationship between persistent depressive disorder and major depressive disorder ambiguous, with conflicting statements about whether the two could be diagnosed together (Uher et al., 2014).

Two lines of data bear on the question directly. In youth, a community probability sample from four geographic areas, 1,285 parent and child pairs with children aged 9 to 17 interviewed with the Diagnostic Interview Schedule for Children, could not tell major depression and dysthymia apart (Goodman et al., 2000). The two diagnoses, and the combination of both, did not differ significantly on sociodemographic, clinical or family variables or on life events. What did distinguish a group was comorbidity: young people with both diagnoses were more impaired and less competent than those with either one alone.

Family data point both ways. A family study interviewed the 882 first-degree relatives of 97 outpatients with early-onset dysthymia, 45 with episodic major depression and 45 healthy controls (Klein et al., 1995). Major depression was more common among relatives of the dysthymic patients than among relatives of controls, and the excess over relatives of the episodically depressed patients did not reach significance, which suggests a strong familial tie between the two conditions. Dysthymia itself, though, clustered in the families of dysthymic patients more than in either comparison group, and whether a dysthymic patient had ever had major depression made no difference to the rates among relatives. Personality disorders were more frequent among relatives of both patient groups than of controls; a higher rate in the dysthymic families than in the episodic ones vanished once the patients' own personality disorders were controlled. The authors read the pattern as close kinship with major depression, with dysthymia still somewhat distinct.

The separate validity of the category therefore remains contested. In practice the manuals have settled on how to classify it rather than on whether it is distinct: DSM-5-TR uses the single category persistent depressive disorder (American Psychiatric Association, 2022), and ICD-11 keeps dysthymic disorder (World Health Organization, 2024).

Scale and Seriousness

In a narrative review, persistent depressive disorder emerged as a common condition that frequently carries more disability than the episodic form of major depression; its causes are probably multifactorial, and its dysthymic form is hard to detect (Schramm et al., 2020). Introducing a journal issue on the subject, an earlier review called chronic depression common, impairing and under-recognised (Klein & Santiago, 2003). In a cross-sectional Canadian national survey of 36,984 people aged 15 and older, chronic major depression, as the sample was labelled, carried more disability, heavier health service use, more psychiatric and medical comorbidity and more suicidal ideation and attempts than nonchronic major depression (Satyanarayana et al., 2009). In a cross-sectional German survey of 4,408 adults, people with PDD scored lower than those with nonchronic major depression on the mental component of the SF-36 (34.5 versus 43.8) and reported more days limited by mental health and more psychiatric contacts, though the physical component did not differ significantly and the prevalence of PDD itself could not be estimated (Nübel et al., 2020).

History of the Concept

MeSH's own indexing history records how recently the condition gained a heading of its own: Dysthymic Disorder dates from 1997, and before that the literature was indexed under depressive disorder (1981 to 1996) (MeSH, D019263).

Greek Roots and Kraepelin's Temperaments

The word is far older than the heading. A historical review traced both dysthymia and its sibling cyclothymia to Greek roots and showed that each entered psychiatric usage as a term during the nineteenth century (Brieger & Marneros, 1997). The same review found the cyclothymia term poorly defined, carrying three senses that partly contradict one another, and judged that cyclothymia is likely a precursor of bipolar II disorder. Kraepelin described lasting temperamental dispositions, among them depressive and cyclothymic types whose extreme forms are today diagnosed as dysthymic and cyclothymic, and a narrative review by Akiskal argued that recent research supports this scheme: both dispositions were linked to later major episodes, and Kraepelin's vision was held to still guide work on cause and prevention (Akiskal, 2001). Two qualifications came with that verdict. Kraepelin drew his observations from hospitalised, severely ill patients, and two of his other temperaments, the irritable and the hyperthymic, have no official diagnostic standing.

Characterological Depression and Its Subtypes

Long-lasting low mood was once described with labels such as characterological depression. Akiskal's group examined what that label covered. In a clinical study that included sleep EEG recordings, characterological depressions divided into two subtypes (Akiskal et al., 1980). Patients with subaffective dysthymia had a rapid eye movement (REM) latency shorter than normal, more often developed superimposed depressive episodes, and responded better to tricyclic or lithium treatment. Patients with character spectrum disorder showed more alcohol and drug abuse and a poorer outcome. Akiskal then placed dysthymic, cyclothymic and bipolar II disorders together as subaffective disorders lying in the borderline realm (Akiskal, 1981). A 1983 theory paper extended the framework to low-grade chronic depression in general, proposing three subtypes: early-onset characterologic depressions (containing the subaffective dysthymic and character-spectrum forms), chronic secondary dysphorias, and late-onset primary depressions (Akiskal, 1983). The paper reported that these subtypes differ in family history, REM latency and responsiveness to medication, and it offered operational criteria for subaffective dysthymia.

Dysthymic Disorder in DSM-III

DSM-III gave the condition a formal category, dysthymic disorder, and the category drew early criticism. A critical review held that the DSM-III criteria needed to be divided into subcategories, singling out insidious onset at an early age as a feature worth separating (Kocsis & Frances, 1987). The authors left two questions for research: how dysthymia relates to personality disorders, and whether the subcategories respond differently to treatment. A related construct was studied in parallel. In a validation study of 177 outpatients followed for 6 months, depressive personality, a construct going back to Schneider, could be assessed reliably and showed preliminary evidence of validity (Klein, 1990). It overlapped only partly with dysthymia, and patients' current clinical state did not significantly affect the trait ratings, which led the author to conclude that depressive personality is not wholly absorbed by the mood disorders.

Double Depression

The combination of a chronic low-grade course with acute episodes acquired its own name. In a clinical cohort of patients meeting criteria for major depression, followed over time, Keller and Shapiro found that double depression, a major depressive episode superimposed on a chronic depressive disorder, was frequent (Keller & Shapiro, 1982). That sample was defined by chronic depressive disorder rather than by a dysthymia diagnosis. For patients with both disorders, how many counted as recovered hinged heavily on the definition used (getting over the major depressive disorder alone, or getting over both), and relapse after recovery was likelier among those carrying the underlying chronic condition. The authors noted that the concept had been poorly formulated clinically and rarely described in research. A narrative review fifteen years later distinguished double depression from unipolar major depression and dysthymia, while cautioning that its value for predicting course was unclear and that the nosology still needed validation (Keller et al., 1997).

The DSM-5 Merger and Its Critics

DSM-5 introduced a single category, persistent depressive disorder, which a recent review describes as spanning dysthymia and chronic major depression (Schramm et al., 2020). The change had critics. One narrative review argued that the validity of dysthymia as a diagnosis was doubtful: it overlapped with other mood and anxiety disorders, it failed to predict illness outcome, and no strategy had validated it as a separate depressive entity (Rhebergen & Graham, 2014). The authors judged the new category at similar risk of proving heterogeneous. A review of the DSM-5 changes to major depressive disorder described them as small but consequential, and identified the relationship between persistent depressive disorder and major depressive disorder as ambiguous, with the manual making conflicting statements about whether the two can be diagnosed together (Uher et al., 2014).

The merged category remains in the current text revision as persistent depressive disorder (American Psychiatric Association, 2022). The Schramm review describes the condition as chronic and as often more disabling than episodic major depression, and, for future research, emphasises a course-based dimensional perspective (Schramm et al., 2020). The same review notes that dysthymia is difficult to detect and that information on cause is scarce; it judges the cause likely to be multifactorial and proposes a modular approach to treatment. Whether the single category is valid, or whether it gathers heterogeneous conditions as its critics predicted, remains an open question.

Symptoms, Diagnosis and Assessment

What the Diagnosis Requires

Persistent depressive disorder is the name DSM-5-TR gives to depression that is defined by its long course (American Psychiatric Association, 2022); ICD-11 sets out its own diagnostic requirements in a separate clinical manual (World Health Organization, 2024). In plain terms, the diagnosis describes a depressed mood that persists for a long period and is accompanied by other depressive symptoms. Studies applying the manual's definition (American Psychiatric Association, 2022) describe the core requirement as low mood present for most of the day, on more days than not, whether the person reports it or others observe it, sustained for at least two years (Stangier et al., 2021; Struck et al., 2021). Because the category brings together heterogeneous presentations, its validity has been challenged (Meister et al., 2016). Duration is the defining feature. A secondary analysis of the 2007 Australian National Survey, which interviewed 8841 households with the WMH-CIDI 3.0, classed depression as chronic when it had lasted at least two years (Murphy & Byrne, 2012). That study labelled its group chronic depression rather than PDD. Compared with non-chronic cases, the chronic group carried more psychiatric co-morbidity, was older, reported an earlier age of onset and more frequent episodes, and was more likely to have been bereaved before the first episode; the authors judged that separating chronic from non-chronic depression seems warranted (Murphy & Byrne, 2012). A later narrative review treats the category as spanning dysthymia and chronic major depression, and describes it from a dimensional perspective based on course (Schramm et al., 2020).

Dysthymia, still a MeSH entry term for the condition, has a symptom picture that is mainly psychological. Serretti and colleagues pooled two multicenter trials to examine 512 outpatients who met DSM-III-R dysthymia criteria without a concurrent major depression (Serretti et al., 1999). Low energy or fatigue was close to universal (96%), poor concentration or indecisiveness was reported by 88%, and hopelessness by only 42%. Factor analysis yielded two factors on each of two rating scales, the Montgomery Asberg Depression Rating Scale and the Hamilton Anxiety Rating Scale. Psychic anxiety outweighed somatic anxiety, and psychological symptoms outweighed neurovegetative ones. The authors concluded that the disorder's symptoms are mainly psychological rather than neurovegetative and raised the possibility of a neurasthenic subform, organised around mental fatigue rather than sadness, alongside a dysthymia proper marked by negative affectivity (Serretti et al., 1999). The sample is a restricted one: suicidal patients were excluded and only the milder range of symptoms was represented.

The concept itself has long been contested. In a narrative review, Akiskal described dysthymia as a subaffective mood disorder (Akiskal, 1994). He acknowledged that its validity had been questioned from opposite positions, and that patients often present without clinically observable signs of depression. His case rested in part on onset: dysthymia beginning in childhood or adolescence was linked with familial mood disorders and with later superimposed major depression, and he concluded that the evidence supported the concept's utility (Akiskal, 1994). The current classification places the condition in its depressive disorders section rather than among the personality disorders, now under the name persistent depressive disorder (American Psychiatric Association, 2022), which settles where the manual places it. Whether it is better understood as a mood disorder or as an enduring personality pattern is taken up under Personality, Temperament and Persistence.

Establishing Duration and Chronicity

Because the diagnosis turns on years of low mood, chronicity is judged largely from what a patient can report about the past. One practical response has been a short screening question for persistent depression. Brinkmann and colleagues tested such a screener, the persistent depression screener (PDS), against a structured clinical interview for DSM-5 in 90 patients at a depression clinic in Germany (Brinkmann et al., 2019). Agreement with the interview was moderate (κ = .48, 95%-CI .28, .68). The screener caught most interview-confirmed cases (sensitivity 85%) but produced many false alarms (specificity 63%), and 80% of answers agreed on retest (retest κ = .52). Raising the screener's duration threshold to more than five years improved overall accuracy slightly (Youden J .56 against .48) but cut sensitivity to 59%.

The authors described the PDS as possibly useful for screening, with any positive result confirmed by interview (Brinkmann et al., 2019). Its specificity fell below the range typical of screening tools and below that of the PHQ-2 (78%). Several limits narrow how far the figures travel: the study ran in a single specialised setting where 64% of patients had PDD, predictive values depend on that prevalence, the sample size was not set in advance, and asking the questions repeatedly may have inflated accuracy. Detection is a recognised difficulty more generally, since a narrative review notes that dysthymia is hard to detect (Schramm et al., 2020).

Severity and Rating

Trials in PDD rate severity on standardised depression scales, and the choice of instrument shapes what a trial can show (see psychometrics for the measurement principles involved). Among 268 outpatients with early-onset chronic depression who were taking no antidepressant medication, a multicenter psychotherapy trial with blinded evaluators made the HRSD-24 (24-item Hamilton Rating Scale for Depression) its primary outcome, and at 20 weeks the group given the Cognitive Behavioral Analysis System of Psychotherapy scored 17.19 while the supportive psychotherapy group scored 20.39 (Schramm et al., 2017). That sample was defined as early-onset chronic depression, and the trial is discussed fully under Psychological Treatments.

Different measures do not always move together. Patients with chronic nonmajor depression needed a Hamilton Depression Rating Scale (HDRS) score of 12 or more to enter a 10-week double-blind comparison of duloxetine with placebo; on the 24-item HDRS the drug did better, and 65.5% responded on duloxetine compared with 25.0% on placebo (Hellerstein et al., 2012). Ratings on the Clinical Global Impressions and the Cornell Dysthymia Rating Scale also favoured duloxetine. Scores on the Beck Depression Inventory did not differ between arms, and neither did the Global Assessment of Functioning or the Social Adjustment Scale. The authors concluded that duloxetine appears effective as acute treatment, a judgement that rests on the HDRS, Clinical Global Impressions and Cornell scale outcomes in 57 treated patients (Hellerstein et al., 2012).

The placebo arm is a further source of variation in measured severity. A meta-analysis of 194 randomised antidepressant trials found a lower placebo response in the 17 dysthymia trials than in the 177 major depression trials (29.9% against 37.9%, P = .042), and in meta-regression the drug's advantage over placebo was larger in dysthymia (Levkovitz et al., 2011); the authors called for longer-term data. Pooling 23 antidepressant trials in PDD, a later meta-regression put the placebo response rate at 31% and placebo remission at 22%; 57% of the patients given placebo reported adverse events, and 4% stopped treatment for that reason (Meister et al., 2017). Those authors judged PDD placebo and nocebo rates comparable to those in episodic depression. Placebo response was higher in trials with more early-onset patients and larger samples, and lower where the chance of receiving placebo was greater, so the authors advised that such modifiers be considered for effect estimates to be unbiased (Meister et al., 2017). The two analyses differ on whether placebo response in chronic depression is lower than in episodic depression, and the question remains open: the later analysis relied only on univariate tests and was limited by the number and quality of its trials.

The Experience of Persistent Depression

Two kinds of evidence describe what long-lasting depression means for the people who live with it. Qualitative interview studies record how it is experienced by patients, partners and clinicians; survey and trial data measure what it costs in work, relationships and schooling. The qualitative studies are small, and several recruited people described as chronically depressed rather than people diagnosed with persistent depressive disorder (PDD) or dysthymia, so their samples are stated with each finding.

Accounts from Patients, Partners and Clinicians

The inner experience of chronic depression was the subject of an interpretative phenomenological analysis of interviews with seven people, four women and three men, recruited as chronically depressed (Rhodes et al., 2019). Three themes emerged. One concerned a felt emptiness, another recurring episodes in which despair seemed to engulf the person, and a third the sense that life problems never came to an end. The authors concluded that chronic depression combines this emptiness with repeated self-destructive episodes, and that it alters motivation itself, a change they described as a weakening of will alongside a numbing of the self. Five of the seven participants framed their difficulties through negative accounts of themselves, whereas two focused on loss or threat (Rhodes et al., 2019). With seven participants, the study shows the range of experience in a small group, not its frequency.

A larger grounded-theory study interviewed 28 patients diagnosed with PDD and 9 informal caregivers, and found a high burden on both sides (Solis et al., 2025). Patients reported more problems in social life and at work than caregivers did, while caregivers held more positive attitudes toward self-management, wanted wider psychoeducation and voiced more concern about suicide risk. Shame, stigma and powerlessness featured among the themes. The authors recommended offering self-management early and supporting caregivers around suicide. The sample was mainly Dutch and highly educated, caregivers were fewer than patients, and some interviews took place by telephone only (Solis et al., 2025).

Partners carry part of the weight. In thematic analysis of interviews with thirteen partners of chronically depressed people, participants described social stigma, shifts in the roles they held within the relationship, and continuing uncertainty; the study framed chronic depression as, in part, a disease of the couple (Priestley et al., 2018).

Clinicians see a related picture from the other side of treatment. A four-round Delphi study that began with a focus group asked eight experts in chronic depression to score 35 problems on a 7-point scale, and the problems fell into five areas of long-term care (Koekkoek et al., 2008). Relapse, pessimism among professionals and demoralisation ranked as the major problems. The panel was very small, and the authors noted that little was known about these patients (Koekkoek et al., 2008).

Measured Impact on Functioning

Measured impairment in persistent low-grade depression can exceed that of an acute episode. In the cross-sectional National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) of 43,093 adults, 328 respondents with dysthymic disorder were compared with 712 with acute major depression (Hellerstein et al., 2010). Fewer of those with dysthymic disorder worked full time (36.2% vs. 44%; OR = 0.70), and more received Supplemental Security Income (13.9% vs. 4.5%; OR = 3.4) and Medicaid (20.2% vs. 13%; OR = 1.7). On the SF-12 they more often reported getting less done because of emotional problems and interference with social activities. Compared with the general population, the dysthymia group also more often received Supplemental Security Income (13.9% vs. 2.9%) and Medicaid (20.2% vs. 5.9%), more often reported getting less done because of emotional problems, and more often reported interference with social and work functioning. The authors judged the impairment linked to dysthymia a significant public health burden (Hellerstein et al., 2010); being cross-sectional, the survey cannot say whether the disorder produced these circumstances or followed them.

Social adjustment is impaired across the chronic and episodic forms. A cross-sectional comparison using interview and self-report measures set 41 outpatients with early-onset dysthymia alone, 56 with dysthymia plus major depression (double depression) and 45 with episodic major depression against 45 healthy controls (Leader & Klein, 1996). Every patient group was more impaired than the controls. The dysthymia group was impaired overall and in every role area, and double depression carried the greatest impairment of the three patient groups. Current depressive symptoms were the strongest predictor, and the authors concluded that chronic and acute symptoms appear to have similar and additive effects on adjustment (Leader & Klein, 1996).

Early onset may also cost schooling, though only for women in the one study available. A secondary analysis of a treatment trial with 531 chronically depressed patients aged 30 and older compared those whose depression began before age 22 with later-onset patients (Berndt et al., 2000). Early-onset women had less education than late-onset women, and, using 1995 census earnings data, the authors estimated their expected lifetime earnings at 12% to 18% below those of women with later onset or no depression. Among men, education did not differ significantly by age at onset. Age at onset also made no significant difference to response to sertraline or imipramine at 12 weeks or to its maintenance at 76 weeks (Berndt et al., 2000).

Impairment is not fixed. In a 12-week acute trial of sertraline and imipramine in patients with double depression or chronic major depression, psychosocial functioning was severely impaired at baseline and improved significantly by week 4 on interviewer-rated and self-report measures (Miller et al., 1998). At endpoint the sample as a whole still functioned below a community comparison group, but patients who remitted approached community levels in most areas. The authors concluded that successful antidepressant treatment can ease the impairment (Miller et al., 1998); the trial itself is described under Medication.

Types of Persistent Depressive Disorder

A type of persistent depressive disorder is a recognised presentation or a named classification, not necessarily a separate disease. The current manual sorts the years of low mood by course specifiers, which record whether and how major depressive episodes appear within that period, adds an onset specifier for early or late onset, and allows the episode-level specifiers used for major depression (American Psychiatric Association, 2022); ICD-11 keeps a separate category named dysthymic disorder (World Health Organization, 2024). Older subtypes and boundary constructs from the research literature follow the current specifiers, because much of the evidence on chronic low mood was gathered under those earlier labels.

Table 1

Types and Specifiers of Persistent Depressive Disorder

TypeStandingKey evidence
With pure dysthymic syndromeDSM-5-TR course specifierRarer than chronic major depression in a US survey
With persistent major depressive episodeDSM-5-TR course specifierWorse outcomes than nonchronic episodes, cross-sectional survey
With intermittent episodes, with current episodeDSM-5-TR course specifierOverlaps the older double-depression pattern
With intermittent episodes, without current episodeDSM-5-TR course specifierSlow recovery, frequent relapse over 10 years
Double depressionResearch label, distinctness contestedCourse similar to dysthymia in a Dutch cohort
Early onset and late onsetDSM-5-TR onset specifierEarly onset linked to chronicity, mostly cross-sectional data
Childhood and adolescent onsetDevelopmental presentationChildhood dysthymia often followed by later major depression
Late-life persistent depressionAge-defined presentationChronic depression in about 4% of older adults, estimate method-dependent
With anxious distressDSM-5-TR specifierAnxiety the commonest comorbidity in depressive disorders
With atypical featuresDSM-5-TR specifierCytokine differences in one small clinical comparison
With mixed featuresDSM-5-TR specifierNo dedicated evidence in this article
With melancholic featuresDSM-5-TR specifierNo dedicated evidence in this article
With psychotic featuresDSM-5-TR specifierNo dedicated evidence in this article
With peripartum onsetDSM-5-TR specifierCovered on the postpartum depression page
Severity and remissionDSM-5-TR specifiersTrials track severity with clinician ratings
ICD-11 dysthymic disorderICD-11 categoryValidity of the category questioned in review
Primary and secondary dysthymiaHistorical proposalThree proposed subtypes, theory paper
Subaffective dysthymia and character spectrum disorderHistorical proposalShortened REM latency in the subaffective group
Depressive personalityBoundary constructReliable, preliminary validity in outpatients

With Pure Dysthymic Syndrome

The pure dysthymic syndrome specifier marks years of low mood during which no full major depressive episode has occurred (American Psychiatric Association, 2022). It is the closest modern descendant of the older diagnosis of dysthymic disorder, or dysthymia, and most of the evidence about it was collected under that name.

Measured that way, the pure form is the less common of the two main chronic patterns. A cross-sectional survey of 43,093 US adults, interviewed in 2001-2002 for the National Epidemiologic Survey on Alcohol and Related Conditions, put the 12-month prevalence of dysthymic disorder at 0.5% and its lifetime prevalence at 0.9%, against 1.5% and 3.1% for chronic major depressive disorder (Blanco et al., 2010). Comorbidity on Axis I and Axis II ran almost equally high in the two groups, and most sociodemographic correlates were shared; treatment, however, reached people with dysthymic disorder less often, and the authors flagged that group as particularly undertreated (Blanco et al., 2010).

Dysthymia may be more prevalent in high-income countries than in low- and middle-income ones, a cross-national narrative review reported, though the disability it brought looked similar from one setting to the next (Gureje, 2011). The same review judged the prognosis of dysthymia worse than that of major depressive disorder and no better than that of other chronic depressions. It also cautioned that dysthymia remains relatively little studied and that cross-cultural validity studies are still awaited, so the country comparison describes how the diagnosis performs where it has been applied rather than establishing that it means the same thing everywhere (Gureje, 2011).

Cognitive Implications

No cognitive study in this article recruited a group defined by the pure dysthymic syndrome; the general cognitive evidence on chronic depression, most of it from mixed chronic samples, is discussed in the section on Executive Function and Other Cognitive Processes.

With Persistent Major Depressive Episode

The persistent major depressive episode specifier applies when a full major depressive episode lasts through the whole period of low mood (American Psychiatric Association, 2022). The older literature called this pattern chronic major depression or chronic major depressive disorder, and the studies below used that label.

In the same US survey, chronic major depressive disorder was about three times as common as dysthymic disorder, with a lifetime prevalence of 3.1%, and it was more often treated (Blanco et al., 2010). A Canadian national survey of 36,984 people aged 15 and older, drawn from the Canadian Community Health Survey on mental health and well-being, compared chronic with nonchronic major depression. The chronic group carried more psychiatric and medical comorbidity, more disability, heavier health-service use and more suicidal ideation and attempts (Satyanarayana et al., 2009). The authors argued that chronic major depression is an important subtype from a public-health standpoint, although the cross-sectional design cannot show whether chronicity produced these burdens or accompanied them (Satyanarayana et al., 2009).

Cognitive Implications

The cognitive evidence relevant here comes from samples described as chronically depressed, not from groups selected by the DSM-5-TR specifier, so it concerns chronic depression broadly rather than the persistent-episode pattern alone. In a case-control study of 30 chronically depressed patients and 30 matched healthy controls, patients performed markedly worse on two cartoon picture-story tests of theory of mind (the ability to infer other people's mental states) and on neuropsychological tasks (Zobel et al., 2010). No theory-of-mind task still distinguished patients from controls once logical memory and working memory were controlled, and the authors concluded that the mentalizing deficit may be tied to wider cognitive impairment (Zobel et al., 2010).

A later case-control study gave a false-belief cartoon task to 26 medication-free chronically depressed patients and 26 matched controls (Mattern et al., 2015). Patients were slower specifically on affective theory-of-mind items and also weaker on general theory-of-mind functions. The authors read this as an affective mentalization deficit sitting on top of a general decline that is probably cognitive in origin, and they noted that data on the question are scarce (Mattern et al., 2015). The section on Social Cognition and Interpersonal Functioning sets both studies against the wider evidence.

With Intermittent Major Depressive Episodes, With Current Episode

This course specifier describes low mood in which full major depressive episodes come and go, with one present at the time of assessment (American Psychiatric Association, 2022). It overlaps heavily with the older research label double depression, which named a major depressive episode superimposed on a chronic depressive disorder (Keller & Shapiro, 1982). The two are not the same kind of label. Double depression names the combination of chronic low mood and a superimposed episode, whatever the timing, whereas the intermittent specifiers sort the same combination by whether an episode is present now; a person with double depression at the height of an episode would usually fall under this specifier.

The early follow-up work on double depression is the main evidence on this pattern. Among patients who met criteria for major depression, those whose episode was superimposed on chronic depression were more likely to relapse after recovery (Keller & Shapiro, 1982). In a prospective sample of 316 patients with major depression, the 80 (25%) with a preexisting chronic minor depression had a poorer course over follow-ups of 6 months to 2 years (Keller et al., 1983). Both studies are described more fully under Double Depression below.

Cognitive Implications

No study in this article examined cognition in patients classified by this specifier; the general evidence is discussed in the section on Executive Function and Other Cognitive Processes.

With Intermittent Major Depressive Episodes, Without Current Episode

This specifier covers the same intermittent pattern at a point when no full episode is present, so that the person is between episodes while the low mood continues (American Psychiatric Association, 2022). It captures the phase after recovery from a superimposed episode, which long follow-ups show is often unstable. Reviews list recurrent major depression without recovery between episodes among the chronic presentations the DSM-5 category takes in (Schramm et al., 2020; Meister et al., 2016).

Relevant evidence comes from a prospective naturalistic study of dysthymic disorder lasting 10 years, which compared 97 adults whose dysthymic disorder began early against 45 whose major depressive disorder was nonchronic; participants were reassessed at 30, 60, 90 and 120 months with the Hamilton Depression Rating Scale and the Longitudinal Interval Follow-Up Evaluation, and roughly 90% stayed in the study (Klein et al., 2006). Symptoms in the dysthymic group improved more slowly, recovery was slow and relapse frequent, and at 10 years the dysthymic group remained more depressed than the nonchronic group (Klein et al., 2006). The pattern implies that a period without a current episode is, for many, a pause within the disorder rather than its end.

The course specifiers as timelines

Choose a course to see how the specifiers divide the same chronic diagnosis. The upper band marks months that meet full criteria for a major depressive episode.

Major depressive episode criteria mettwo yearsmonth 0month 36 (now)

Pure dysthymic syndrome. Depressed mood lasts more than two years, but full criteria for a major depressive episode are never met in that time. In this schematic, 0 of 36 months reach full episode criteria.

Schematic illustration of the course specifiers for persistent depressive disorder described in DSM-5-TR (American Psychiatric Association, 2022); the curves are invented for illustration and are not patient data.

Cognitive Implications

Cognition has not been studied separately in people between episodes of this pattern in the evidence reviewed here; the general evidence is discussed in the section on Executive Function and Other Cognitive Processes.

Double Depression

Double depression is dysthymia, or another chronic depressive disorder, with a major depressive episode superimposed on it. It is a research label, and it occupies a large part of the early literature on chronic depression.

The label entered the research literature through a clinical cohort of patients meeting criteria for major depression, about 26% of whom had the superimposed pattern (Keller & Shapiro, 1982). In the superimposed group, how many counted as recovered hinged heavily on the definition used (getting over the major depressive disorder alone, or getting over both), and that group also relapsed more readily once recovered. The authors also observed that the concept was poorly formulated clinically and rarely described in research, which is why they set it out (Keller & Shapiro, 1982). The prospective study of 316 patients that followed confirmed the poorer course: where chronic minor depression was already present, the chronic depression ran an especially pernicious course, and the longer the minor depression persisted once the major episode had remitted, the likelier it became that a new major depression would arrive before the chronic one had resolved (Keller et al., 1983).

On that basis, a later narrative review argued that double depression approximates a distinct subtype of unipolar depression (Keller et al., 1997). The review was explicit about the gaps: the predictive value of the label for course was unclear, and the proposed nosology still needed validation (Keller et al., 1997).

A test of that claim came from the Dutch NEMESIS survey, which followed 400 adults with major depressive disorder, dysthymic disorder or both over 3 years (Rhebergen et al., 2009). Dysthymia and double depression ran a similar course, and both did worse than major depressive disorder alone; neuroticism and poor functioning predicted an unfavourable course across groups. The authors concluded that the evidence did not support separating dysthymia from double depression, while warning that higher attrition in the dysthymic group may have understated differences in course (Rhebergen et al., 2009).

Trajectories within the chronic group vary widely. In a 10-year cohort of 87 outpatients with early-onset dysthymic disorder (onset before 21), with or without superimposed major depression, assessments every 30 months showed that a concurrent anxiety disorder and a family loading for chronic depression predicted poorer outcomes (Klein et al., 2008). Childhood adversity, including a poor relationship with the mother and sexual abuse, also predicted a worse course, and personality disorders predicted a poorer symptom trajectory (Klein et al., 2008).

The dispute over whether double depression is its own subtype therefore remains open. The cohort evidence favours treating it and dysthymia as one chronic group with a worse course than episodic major depression, and the subtype claim has not been validated against course, which is the test its own proponents set.

Cognitive Implications

No study in this article compared double depression with dysthymia or with major depression on a cognitive measure; work on cognitive reactivity in chronically depressed samples, which did not separate double depression, is discussed in the section on Rumination, Cognitive Reactivity and Other Accounts.

Early Onset and Late Onset

The onset specifier divides persistent depressive disorder into early-onset and late-onset forms at a cut-off age set by the manual (American Psychiatric Association, 2022). Individual studies have used their own cut-offs, so the age that defines early onset differs from one study to the next and is given below where a study stated it.

One test of the split comes from 340 outpatients in a 12-site, 12-week antidepressant trial, all of whom had dysthymic disorder with a superimposed major depressive episode; 73% had early onset and 27% late onset (Klein et al., 1999). The early-onset group had longer index episodes, more personality disorders, more lifetime substance use disorders and more family history of mood disorder. The groups did not differ in baseline severity, functional impairment or response to antidepressants. Because every patient had a superimposed episode, the study could not show whether the same split holds in dysthymia without an episode (Klein et al., 1999). A comparison of community residents with dysthymia found early-onset and late-onset groups mostly alike, differing only on some features of coping (McCullough et al., 1990). Taken together, onset age separates groups on history and comorbidity in a clinical sample but not on current severity or treatment response.

Early onset also bears on whether depression becomes chronic in the first place. A systematic review of 25 studies with 5,192 participants, using vote counting, found that a younger age at onset predicted chronicity, alongside a longer episode duration and a family history of mood disorders (Hölzel et al., 2011). Most of the studies were cross-sectional and few longitudinal studies showed significant effects, so the authors described these as identified risk factors whose causal role is hard to establish (Hölzel et al., 2011).

The cost of early onset can reach into education and income. A secondary analysis of 531 patients aged 30 and older with chronic depression, drawn from a sertraline and imipramine trial and linked to US Census Bureau earnings data, defined early onset as onset before age 22 (Berndt et al., 2000). Early onset was associated with less education in women but not, significantly, in men, and early-onset women had expected lifetime earnings 12% to 18% lower than women with later onset or none. Age at onset did not significantly predict treatment response at 12 weeks or its maintenance at 76 weeks (Berndt et al., 2000).

Early onset should not be confused with the two entries that follow. Early onset is a specifier applied to an adult or adolescent with the disorder, recording when it began; childhood and adolescent onset concerns the disorder as it is diagnosed and studied in young people themselves; and late-life persistent depression concerns the disorder in older adults, whatever its age of onset.

Cognitive Implications

Two studies of social and emotional cognition recruited early-onset patients only, so neither can say whether these findings differ from late onset. In a case-control study of 16 early-onset chronically depressed patients and 16 matched controls, patients showed no theory-of-mind deficit on the Movie for Assessment of Social Cognition but rated their own empathy lower on the Interpersonal Reactivity Index (Wilbertz et al., 2010). The sample was small and controls were not rated by clinicians, and theory-of-mind scores, empathy and therapist ratings did not correlate significantly (Wilbertz et al., 2010).

A three-group comparison of 30 patients with early-onset chronic depression, 30 with episodic depression and 30 never-depressed controls measured avoidance by self-report (Brockmeyer et al., 2015). The chronic group reported more avoidance than controls on every measure and more than the episodic group on cognitive-nonsocial, behavioural-nonsocial and behavioural-social avoidance; restricted emotional expression toward others separated chronic from episodic patients best. Because the data were self-reported and cross-sectional, the authors urged caution and did not claim avoidance causes chronicity, although they recommended it as a treatment focus (Brockmeyer et al., 2015).

Childhood and Adolescent Onset

Persistent low mood that begins in childhood is diagnosed and studied in young people, and its main interest is what it predicts. In a longitudinal naturalistic study, 55 children with dysthymic disorder and 60 with major depressive disorder were followed over intervals of 3 to 12 years (Kovacs et al., 1994). Dysthymia began earlier and involved less anhedonia and fewer neurovegetative symptoms, while affective dysregulation was similar in the two groups. Children with dysthymia carried a higher risk of any later affective disorder: 76% went on to major depression and 13% to bipolar disorder. Once a first major episode had occurred, rates of recurrent major depression and bipolar disorder were similar in both groups. The authors proposed childhood dysthymia as an early marker of recurrent illness (Kovacs et al., 1994).

Whether dysthymia and major depression are separable in youth is less clear. A community probability sample of 1,285 parent-youth pairs aged 9 to 17, from four areas of the United States, found no difference between major depression and dysthymia on sociodemographic, clinical, family or life-event variables (Goodman et al., 2000). Young people with both disorders were less competent and more impaired than those with either alone. The study therefore found little discriminant validity for the two diagnoses taken singly, while the comorbid form stood out by its burden (Goodman et al., 2000).

Comorbidity between the two is especially marked in adolescence. A community survey of 1,710 adolescents and 2,060 adults gave a lifetime odds ratio of 3.4 for comorbid major depression and dysthymia in adolescents against 1.6 in adults (Lewinsohn et al., 1991). Among those with a depressive disorder, 80% had major depression only, 10% dysthymia only and 10% both, and dysthymia more often preceded major depression than followed it (Lewinsohn et al., 1991).

The most recent synthesis concerns young people with depression in general rather than persistent depressive disorder. A meta-analysis of 46 studies covering 7,488 people aged 10 to 25 identified factors linked to a poor course, defined to include relapse, recurrence and chronicity (Tagliaferri et al., 2026). Female sex, more severe symptoms, lower global functioning, suicidal thoughts and behaviours (a borderline effect, p = .045) and a longer sleep-onset latency (a mean difference of 6.96 minutes) predicted a poorer course; relationships with friends and family looked promising but could not be pooled. Most reports carried a high risk of bias and the certainty of evidence was very low to moderate, although the authors concluded that demographic and clinical factors have prognostic value (Tagliaferri et al., 2026).

Cognitive Implications

The one imaging study of cognition here involved boys with dysthymic disorder and tested spatial working memory. In a cross-sectional fMRI study, 19 boys with dysthymic disorder (mean age 11.2) and 16 typically developing boys (mean age 10.5) performed a mental rotation task and a delay-match-to-sample task (Vilgis et al., 2014). During mental rotation, the boys with dysthymia showed less activation in left and medial frontal regions; during the delay-match-to-sample task, they showed more activation in the right precuneus and posterior cingulate. The authors read the pattern as evidence that the pathophysiology of dysthymic disorder is continuous with that of major depression across the lifespan, while noting that the small sample and cross-sectional design limit how far the results generalize (Vilgis et al., 2014).

Late-Life Persistent Depression

Chronic depression in older adults is common enough to matter, but how common depends on how it is measured. A systematic review of 38 studies of adults aged 60 and older pooled 20 articles in a meta-analysis that put the prevalence of chronic depression at 4.02%, with a 95% interval of 2.88% to 5.35% (Stratmann et al., 2025). Estimates were 2.30% under DSM-IV or DSM-III-R criteria, 7.12% under DSM-III or ICD-10 criteria and 5.52% with rating scales, and the pooled prevalence was higher in women (6.05%) than in men (4.24%). The authors cautioned that pooling across classification systems is debatable, that studies counting only dysthymia may underestimate and rating scales may overestimate, that heterogeneity was large and that institutionalized and impaired older people were underrepresented (Stratmann et al., 2025).

Dysthymia in old age appears to differ from dysthymia in younger adults. Of 224 consecutive elderly outpatients at a geriatric clinic, 40 (17.9%) had dysthymic disorder, with a mean age at onset of 55.2 years (Devanand et al., 1994). Compared with the young-adult pattern, the elderly cases were evenly split by gender rather than mostly female, were less often early in onset and had less Axis I and Axis II comorbidity; their symptoms were more cognitive and functional than vegetative. The data were cross-sectional, and the authors called for further study of pure dysthymia in late life (Devanand et al., 1994).

The burden is rising at the population level, although the estimate combines dysthymia with major depression. A secondary analysis of the Global Burden of Disease Study 2021 for adults aged 55 and older found that the burden of late-life depression increased between 1990 and 2021, with incidence higher in women than in men in every age group and a greater burden in women overall (Liu et al., 2025).

Treatment evidence in this age group is limited but direct. A randomized placebo-controlled trial in four primary-care practices enrolled 415 older patients (mean age 71), 211 with dysthymia and 204 with minor depression (Williams et al., 2000). Paroxetine resolved symptoms better than placebo, whereas problem-solving treatment for primary care did not differ significantly from placebo overall, though it improved faster in the later weeks. Among patients with dysthymia, paroxetine improved mental-health functioning in those with high or intermediate baseline functioning, and problem-solving treatment did not; 311 of the 415 patients completed the trial (Williams et al., 2000).

Cognitive Implications

The link to cognition here is an association with later dementia, not a demonstrated effect. In a retrospective cohort of 281,540 US veterans aged 55 and older, identified through Veterans Affairs records and ICD-9 codes between 1997 and 2007, dysthymia was associated with a higher risk of incident dementia (hazard ratio 1.96, 95% CI 1.71-2.25) and of death (hazard ratio 1.41, 95% CI 1.31-1.53) than having neither dysthymia nor depression (Byers et al., 2012). Major depression carried a similar or slightly higher dementia risk (hazard ratio 2.18). The design cannot show that dysthymia causes dementia, and whether treatment changes the risk was not tested; the authors recommended close monitoring of older adults with either condition (Byers et al., 2012).

With Anxious Distress

The anxious distress specifier records prominent anxiety accompanying the depressive picture (American Psychiatric Association, 2022). Its relevance to chronic depression rests on how often depression and anxiety co-occur. In a cross-sectional interview study of 260 patients with depressive disorders assessed with the Structured Clinical Interview for DSM-III-R, Axis I comorbidity was common and anxiety disorders were the most frequent comorbid diagnoses (Sanderson et al., 1990). The sample spanned depressive disorders generally rather than dysthymia alone, so the finding concerns depression and anxiety broadly. Concurrent anxiety disorder also predicted a poorer 10-year outcome in early-onset dysthymia, as described under Double Depression.

Cognitive Implications

No study in this article examined cognition in chronically depressed patients classified by anxious distress; the general evidence is discussed in the section on Executive Function and Other Cognitive Processes.

With Atypical Features

The atypical features specifier can be added to persistent depressive disorder as it can to major depression (American Psychiatric Association, 2022). A clinical group comparison of patients with major depression, atypical depression or dysthymia and healthy controls measured hormones and cytokines produced by stimulated lymphocytes (Anisman et al., 1999). Patients with dysthymia showed raised interleukin-1beta whether their profile was typical or atypical, and every depressive group showed reduced interleukin-2, though the reduction was smaller in atypical major depression. Atypical depressives also had higher ACTH and lower cortisol than controls. Neither depressed mood itself nor neurovegetative features accounted for the cytokine effect, and the authors judged it likely that chronicity or age of onset was associated with cytokine alterations, concluding that interleukins may play a role in certain subtypes (Anisman et al., 1999).

Cognitive Implications

No cognitive study in this article separated atypical features within chronic depression; the general evidence is discussed in the section on Executive Function and Other Cognitive Processes.

With Mixed Features

The mixed features specifier, which records some manic or hypomanic features within a depressive presentation, is also available for persistent depressive disorder (American Psychiatric Association, 2022). The specifier itself is described more fully in the article on major depressive disorder, and no evidence specific to its use in chronic depression is reviewed here.

Cognitive Implications

Cognition in persistent depression with mixed features has not been studied separately in the evidence reviewed here; the general evidence is discussed in the section on Executive Function and Other Cognitive Processes.

With Melancholic Features

The melancholic features specifier can likewise be applied to persistent depressive disorder (American Psychiatric Association, 2022). No study in this article examined melancholic features within a chronic sample.

Cognitive Implications

No cognitive findings specific to melancholic persistent depression are reviewed here; the general evidence is discussed in the section on Executive Function and Other Cognitive Processes.

With Mood-Congruent and Mood-Incongruent Psychotic Features

Psychotic features, divided into those whose content fits the depressed mood and those whose content does not, form a further specifier available for persistent depressive disorder (American Psychiatric Association, 2022). Evidence on psychotic features within chronic depression is not reviewed in this article.

Cognitive Implications

No cognitive findings specific to persistent depression with psychotic features are reviewed here; the general evidence is discussed in the section on Executive Function and Other Cognitive Processes.

With Peripartum Onset

The peripartum onset specifier marks depression that begins during pregnancy or after delivery (American Psychiatric Association, 2022). The evidence on depression in this period is covered in the article on postpartum depression rather than here.

Cognitive Implications

Cognition in perinatal depression is discussed in the postpartum depression article; no study reviewed here examined it in persistent depressive disorder.

Severity (Mild, Moderate, Severe) and Partial or Full Remission

Current severity can be specified as mild, moderate or severe, and a period of improvement as partial or full remission (American Psychiatric Association, 2022). Research tracks severity with clinician-rated scales rather than with these categories. In a multicentre evaluator-blinded trial, 268 medication-free outpatients with early-onset chronic depression were randomized to the Cognitive Behavioral Analysis System of Psychotherapy or to supportive psychotherapy, with severity measured on the 24-item Hamilton Rating Scale for Depression (Schramm et al., 2017). The disorder-specific therapy lowered scores more, by an adjusted 2.51 points at 20 weeks (Cohen d = 0.31) and 3.13 points at 48 weeks (d = 0.39), a small-to-moderate advantage, and remission was reached by 21.8% against 12.6% (Schramm et al., 2017). These are scale outcomes from a trial, not the manual's severity and remission categories, and the trial is discussed in full in the section on Psychological Treatments.

Cognitive Implications

No study reviewed here related cognitive measures to severity level or remission status in persistent depression; the general evidence is discussed in the section on Executive Function and Other Cognitive Processes.

ICD-11 Dysthymic Disorder

ICD-11 retains dysthymic disorder as a category in its own right (World Health Organization, 2024), while DSM-5 uses persistent depressive disorder. The validity of both categories has been questioned. A narrative review concluded that the evidence for dysthymic disorder as a valid entity is weak: the diagnosis fails to predict illness outcome, overlaps with other mood and anxiety disorders and lacks a validation strategy for a depressive entity (Rhebergen & Graham, 2014). The same review judged that DSM-5's persistent depressive disorder is likely to be heterogeneous too (Rhebergen & Graham, 2014). Whether either category carves chronic depression well remains an open question.

Cognitive Implications

No cognitive study in this article compared patients classified under ICD-11 dysthymic disorder with those under the DSM-5-TR category; the general evidence is discussed in the section on Executive Function and Other Cognitive Processes.

Primary and Secondary Dysthymia

Akiskal proposed that low-grade chronic depression is not one condition. His 1981 paper concerned subaffective disorders, taking in dysthymic, cyclothymic and bipolar II disorders in relation to the borderline realm (Akiskal, 1981). In a theory paper setting out a nosologic framework, he divided chronic low-grade depression into three subtypes (Akiskal, 1983). One was a late-onset primary depression. A second, the chronic secondary dysphorias, was low mood arising secondary to other illness. The third was an early-onset characterologic depression. He held that the subtypes differ in family history, REM latency and response to medication, and offered operational criteria for subaffective dysthymia (Akiskal, 1983). The framework was a proposal rather than a tested classification, and the late-onset group anticipates the modern onset specifier.

Cognitive Implications

No cognitive study in this article compared primary with secondary dysthymia; the general evidence is discussed in the section on Executive Function and Other Cognitive Processes.

Subaffective Dysthymia and Character Spectrum Disorder

Akiskal's best-known split divided characterological depression into two groups (Akiskal et al., 1980). Subaffective dysthymia looked like an attenuated mood disorder. In a clinical and sleep EEG study it showed shortened REM latency relative to normal, more superimposed depressive episodes and better response to tricyclics or lithium. Character spectrum disorder showed more alcohol and drug abuse and a worse outcome (Akiskal et al., 1980).

A polysomnographic comparison of 20 patients with primary dysthymia, 22 with anxious depression and 11 controls extended the sleep work (Akiskal et al., 1984). REM percentage and REM latency separated the groups. The anxious patients had less REM sleep and longer REM latency on the first night, poorer sleep efficiency and more insomnia (82%), while the dysthymic patients reported more hypersomnia. Beck and MMPI depression scores did not differ between the groups. The authors concluded that the subtypes seemed distinguishable within the atypical depressions, though the second-night differences were smaller and the groups overlapped clinically in depressive symptoms (Akiskal et al., 1984).

Akiskal later linked the subaffective form to temperament. A narrative review argued that recent research backed Kraepelin's idea of temperamental dispositions, with dysthymic and cyclothymic temperaments predisposing to major episodes, and that this view still guides work on aetiology and prevention (Akiskal, 2001). The review also acknowledged that Kraepelin's samples were hospitalized and severely ill, and noted that the irritable and hyperthymic temperaments lack official diagnostic standing (Akiskal, 2001).

Cognitive Implications

No study in this article tested cognition in these two groups; the REM findings are taken up in the section on Sleep and the temperament account in the section on Personality, Temperament and Persistence.

Depressive Personality

Depressive personality, a construct going back to Schneider, sits at the boundary of persistent depressive disorder and personality (Klein, 1990). In a validation study of 177 outpatients with a 6-month follow-up, using structured diagnostic and family history interviews, depressive personality was assessed reliably and showed preliminary evidence of validity (Klein, 1990). It overlapped only partly with dysthymia, so that many people with depressive personality did not meet criteria for dysthymia, and the assessment of the trait was not significantly affected by current clinical state. The author concluded that the construct is not wholly absorbed by the mood disorders, while describing the validity evidence as preliminary (Klein, 1990).

Cognitive Implications

No cognitive study in this article recruited people with depressive personality; the relation between personality and persistent low mood is discussed in the section on Personality, Temperament and Persistence.

Prevalence and Burden

How common persistent depression is depends heavily on what each survey counted. The population studies below used different labels (dysthymia, chronic major depression, chronic depression and, most recently, persistent depressive disorder), different diagnostic manuals and different interviews. Their figures are therefore not interchangeable. Each figure below is given with the survey that produced it and the definition that survey applied.

Community and National Surveys

The earliest large community estimate put dysthymia at approximately 3% of adults. It came from a survey of five U.S. communities (Weissman et al., 1988). Risk was not spread evenly. Women under age 65 carried more of it than men. So did unmarried adults compared with married ones, and young people on low incomes compared with other groups. People with dysthymia also used health services and psychotropic drugs more often than those without it. The authors read the dysthymia found in middle and old age as a residual state, and offered this as a suggestion rather than a demonstrated account (Weissman et al., 1988).

The U.S. National Epidemiologic Survey on Alcohol and Related Conditions separated two chronic forms in a cross-sectional sample of 43,093 adults interviewed in 2001-2002 (Blanco et al., 2010). Chronic major depressive disorder was the more common of the two, at 1.5% over 12 months and 3.1% over the lifetime. Dysthymic disorder stood at 0.5% and 0.9% on the same windows. The two disorders did not differ in their Axis I and Axis II comorbidity or in their sociodemographic correlates. They did differ in treatment. People with chronic major depression received treatment at higher rates, and dysthymic disorder stood out as especially undertreated (Blanco et al., 2010).

An Australian survey analysed chronic depression rather than dysthymia alone. In a secondary analysis of the 2007 Australian National Survey, covering 8841 households and ages 16 to 85, depression lasting at least two years had a lifetime prevalence of 4.6% (95% CI: 3.9-5.3%). That was 29.4% of all lifetime depressive disorder (Murphy & Byrne, 2012). Compared with non-chronic cases, the chronic group had more psychiatric comorbidity and was older. It also had an earlier age of onset, more frequent episodes and more often a bereavement before the first episode. The authors judged that separating chronic from non-chronic depression seems warranted (Murphy & Byrne, 2012).

Canada's national survey (CCHS 1.2) offers a further figure. It used chronic major depression as its category, in 36,984 people aged 15 years and older (Satyanarayana et al., 2009). Chronic major depression affected 2.7% of respondents. Set against nonchronic major depression, it came with more psychiatric and medical comorbidity, greater disability, heavier use of health services, and more suicidal ideation and attempts. Because the survey was cross-sectional, these are associations at one time point, not outcomes followed forward. The authors nonetheless treated chronic major depression as an important subtype for public health (Satyanarayana et al., 2009).

The German health survey DEGS1-MH operationalized the DSM-5 definition from interview-based DSM-IV diagnoses, comparing persistent depressive disorder with non-chronic major depression in 4,408 adults (Nübel et al., 2020). Lifetime major depression was found in 14.5% of the sample. Of those lifetime cases, 36.5% were classed as chronic and 63.5% as non-chronic. The authors stated that the prevalence of persistent depressive disorder itself could not be estimated, because many respondents left episode duration unanswered. Against non-chronic cases, those with the disorder scored lower on the SF-36 mental component (34.5 vs. 43.8). They also reported more days limited by mental health (IRR = 2.6), more outpatient psychiatric contacts (IRR = 2.7) and more often two or more somatic conditions (RRR = 3.2). The groups did not differ significantly on the physical component score, or on sick days and physician visits once adjusted. Hospital nights showed only a trend (p = 0.065). A small clinical comparison group of 45 inpatients had an earlier onset than population cases and more treatment resistance. More of them also described a persistent course (50.0% vs. 24.6%). The design was cross-sectional and the clinical sample small. The authors concluded that distinguishing the two conditions seems warranted (Nübel et al., 2020).

The third wave of the U.S. survey, NESARC-III, is evidence about DSM-5 major depressive disorder as a whole, not about its chronic forms. For that disorder taken as a whole, the survey reported a 12-month prevalence of 10.4% and a lifetime prevalence of 20.6%; neither figure isolates persistent forms. In 36,309 adults interviewed in person, the disorder was less common in men (OR, 0.5). It was also less common in African American and Asian or Pacific Islander adults (OR, 0.6 each) and Hispanic adults (OR, 0.7) than in white adults. It was more common at ages 18 to 29 than at older ages (OR, 3.0) and at incomes of $19,999 or less (OR, 1.7). It was strongly comorbid with other psychiatric disorders (aOR 2.1 to 5.7) and with substance use disorders (aOR 1.8 to 3.0). The authors called major depression prevalent, comorbid and disabling. They added that population knowledge of the DSM-5 specifiers remains limited, so the survey offered only initial information on them (Hasin et al., 2018).

Finland's two-wave national survey of adults aged 30 and over suggests that prevalence rose over a decade (Markkula et al., 2015). Using the M-CIDI, the 12-month prevalence of depressive disorders (major depressive disorder and dysthymia) increased from 7.3% in 2000 to 9.6% in 2011. Women had higher risk (OR 2.33), and so did unmarried adults (OR 1.54). The trend needs one caution. Response fell from 75% to 57% between waves, and people treated in hospital were more likely not to take part. The estimates also shifted with the method used for nonresponse: multiple imputation gave figures about 2 points above statistical weighting. Nonparticipation by people with severe disorders may therefore bias the figures. The authors still read the trend as a growing public health concern (Markkula et al., 2015).

In adults aged 60 and over, a systematic review of 38 studies, 20 articles of which were meta-analysed, put the pooled prevalence of chronic depression at 4.02% [2.88%–5.35%] (Stratmann et al., 2025). The figure depended on the classification used. Studies applying DSM-IV or DSM-III-R produced 2.30%, those applying DSM-III or ICD-10 produced 7.12%, and rating scales produced 5.52%. Pooled prevalence was higher in women (6.05%) than in men (4.24%), and lower in North America than in Europe. Lower physical activity and impairment in daily life were associated with chronic depression, whereas socioeconomic status and marital status were not. Heterogeneity was large. The authors also noted that pooling across classification systems is debatable, and that studies of dysthymia alone may underestimate the rate while rating scales may overestimate it. Institutionalized and impaired older people were underrepresented. The section Types of Persistent Depressive Disorder treats late-life presentations as a type in their own right.

Global Burden of Disease 2021 estimates for adults aged 55 and older show late-life depression burden rising between 1990 and 2021 (Liu et al., 2025). This analysis covers major depressive disorder and dysthymia together, so it describes late-life depression broadly rather than persistent depressive disorder alone. Incidence was higher in women than in men at every age from 55, and women carried a greater burden overall. In middle and lower Socio-demographic Index regions, the gap between the sexes narrowed with age. Regions of medium Socio-demographic Index showed the steepest rise in incidence (AAPC = 0.5). Incidence in low-index regions was high and showed no decline. In high-index regions, onset shifted earlier, toward the younger elderly (Liu et al., 2025).

Where incomes are high, a narrative review spanning several countries found that dysthymia may be more prevalent than in low- and middle-income settings, yet the disability attached to it was comparable wherever it occurs (Gureje, 2011). The review cautioned that dysthymia remains relatively little studied. It also noted that studies testing whether the diagnosis is valid across cultures were still awaited. Whether the income gap reflects true differences or differences in how the condition is recognised and measured therefore remains open (Gureje, 2011).

Why the Estimates Differ

Three sources of variation run through these figures. The first is definition. The surveys counted dysthymia, chronic major depression, chronic depression of any kind, or persistent depressive disorder. These categories overlap without coinciding, so the narrowest (dysthymic disorder at 0.9% lifetime in the United States) and the broadest (chronic depression at 4.6% lifetime in Australia) are not measuring the same thing (Blanco et al., 2010; Murphy & Byrne, 2012). The second is the diagnostic era. In older adults, studies using DSM-III or ICD-10 produced a higher pooled estimate (7.12%) than studies using DSM-IV or DSM-III-R (2.30%) (Stratmann et al., 2025). The section History of the Concept traces how the categories themselves changed. The third is method. Nonresponse corrections and missing duration data each moved the figures: in Germany, missing duration data prevented any prevalence estimate for the DSM-5 category at all (Nübel et al., 2020; Markkula et al., 2015). The surveys agree more on burden than on rates. In the Canadian and German surveys that compared chronic with non-chronic depression, the chronic forms carried more comorbidity and disability (Satyanarayana et al., 2009; Nübel et al., 2020).

Course and Prognosis

Most of what is known about the course of persistent depression comes from cohorts that were followed rather than treated to a protocol. Few of them used the present diagnostic label. Older studies sampled people with dysthymic disorder, or with double depression (dysthymia on which major depressive episodes are superimposed), while several newer ones defined a group by the length of illness and called it chronic depression or long-term depression. The labels are kept as each study used them below, because the groups they define overlap but are not identical.

The Long Follow-Ups

The longest clinical follow-ups describe dysthymia as protracted, with a worse course than episodic major depression. Klein and colleagues assessed 86 outpatients with early-onset dysthymia and 39 with episodic major depressive disorder at 30 and 60 months; across five years the dysthymic group had higher symptom levels, poorer functioning, more suicide attempts and more hospitalizations (Klein et al., 2000). The authors estimated that 52.9% of the dysthymic patients recovered within five years and that 45.2% of those who recovered relapsed over a mean of 23 months; full criteria for a mood disorder were met during roughly 70% of the follow-up, and for patients with no major depressive episode before entry the estimated risk of a first one was 76.9% (Klein et al., 2000). At ten years, with assessments at 30, 60, 90 and 120 months of 97 adults with dysthymia and 45 with nonchronic major depression and follow-up data for 90% of the cohort, the dysthymic group had improved more slowly and remained more depressed (Klein et al., 2006). Its Kaplan-Meier recovery rate was 73.9%, the median time to recovery was 52 months, and among those who recovered the risk of relapse was 71.4%, a picture of slow recovery and frequent relapse (Klein et al., 2006).

Baseline features carried prognostic weight. Among the 86 early-onset patients followed for five years, a comorbid anxiety disorder, cluster C or depressive personality features and chronic stress lowered the chance of recovery, while a family history of bipolar disorder raised it; a family history of dysthymia, poor relationships with either parent, childhood sexual abuse and neuroticism went with more severe later depression, and the authors fitted the course to a multifactorial model spanning many domains (Hayden & Klein, 2001). In 87 of these outpatients, seen five times at 30-month intervals over ten years, growth curve models tied a poorer outcome to concurrent anxiety disorder, familial loading for chronic depression, a poor maternal relationship and childhood sexual abuse, and tied older age and less education to greater severity and impairment; several such variables, the authors judged, aid long-term prognosis (Klein et al., 2008). Adversity and personality are taken up in Childhood Maltreatment and Early Adversity and in Personality, Temperament and Persistence.

Among 626 adult outpatients of 523 mental health specialists and general medical providers, a two-year cohort found the worst outcomes in dysthymia, with or without major depression, then in major depression alone, then in subthreshold symptoms; double depression began with the most severe symptoms, and initial functioning was poor in dysthymia whether or not major depression was also present (Wells et al., 1992). Initial severity and functional status explained more of the outcome variance than disorder type did, and even the subthreshold group had a 25% incidence of major depressive episode over two years (Wells et al., 1992).

In the Zurich community cohort, interviewed six times over twenty years from age 20/21 to 40/41, long-term depression proved more serious than episodic major depressive episodes: it began earlier and brought more disturbed memory, hopelessness and inferiority, more social phobia and benzodiazepine abuse, more unemployment and social benefits, less marriage and full-time work, lower somatic and psychological well-being, and more lifetime treatment (82% against 61%) (Angst et al., 2009). The sample was relatively small, attrition was 38.5%, the results do not extend past age 40, and they may depend on how long-term depression is defined (Angst et al., 2009).

In the Dutch NEMESIS survey, 400 adults with major depression, dysthymia or both were followed for three years. Dysthymia and double depression ran similar courses, both worse than major depression alone, neuroticism and poor functioning predicted an unfavourable course, and the authors found no support for treating the two as distinct (Rhebergen et al., 2009); higher attrition in the dysthymic group may have understated the differences (Rhebergen et al., 2009). Among 241 recovered respondents, the major depression (n = 102), dysthymia (n = 66) and double depression (n = 73) groups all had poorer social and physical functioning than 4,140 respondents with no diagnosis, and the dysthymia and double depression groups regained physical functioning more slowly than the major depression group (Rhebergen et al., 2010). The dysthymia deficit relative to major depression was significant at one year (B = -13.8, p = .002) but not at three years (B = -8.11, p = .09), and drop-outs probably functioned worse than those who stayed (Rhebergen et al., 2010).

Two further studies question how stable the categories are. Of 210 general practice patients, 65 with dysthymic disorder, followed for 12 years, 201 (96%) were traced and 17 had died; 73 (36%) met no DSM diagnosis, diagnoses shifted often, and the initial diagnosis did not predict outcome (Tyrer et al., 2004). Cothymia, personality disorder, recurrent episodes and higher baseline ratings went with worse outcomes, and only about two in five patients did well (Tyrer et al., 2004). Among 8,622 Stockholm County adults aged 20 to 64, surveyed twice three years apart, major depression or dysthymic disorder, counted together, was the most stable state: 35.9% of that group reported no more than one symptom at follow-up, against 58.9% with minor depression and 56.5% with subsyndromal depression, and its relative risk of later major depression or dysthymia was 22.4, against 4.8 after minor and 5.0 after subsyndromal depression (Forsell, 2007). Forsell concluded that depression is dimensional, with people moving between subtypes (Forsell, 2007).

The interactive demonstration below lets the reader compare recovery curves of the kind these cohorts describe.

Recovery and relapse over five and ten years

Choose a follow-up to see what its estimated recovery and relapse rates mean for 100 patients with early-onset dysthymic disorder.

0100 patients
Estimated recovery rate52.9%
Estimated relapse risk among the recovered45.2%
Per 100 patients: recovered and stayed wellabout 29
Per 100 patients: recovered, then relapsedabout 24
Per 100 patients: not recoveredabout 47

The relapse figure is the relapse risk over a mean of 23 months of observation after recovery.

Recovery and relapse rates are the Kaplan-Meier estimates reported by Klein et al. (2000) and Klein et al. (2006); the counts per 100 patients are arithmetic on those rates, not reported figures.

How Episodes Become Chronic

A second line of evidence follows ordinary major depressive episodes and asks when they turn chronic. In the NIMH Collaborative Depression Study, 431 people with major depression were followed for five years, and the chance of recovery fell the longer the illness had already lasted: about 15% recovered per month in the first three months of follow-up, against 1% to 2% per month in years three to five (Keller et al., 1992). Current severity mattered too, since people whose symptoms had eased below full major depression were 18 times as likely to begin recovering as those still meeting the full criteria (Keller et al., 1992). An earlier prospective report on 101 patients with nonbipolar major depression found that chronicity did not belong only to the episode that brought people into the study: 21% of index episodes had become chronic, and the first new episode during follow-up had a 22% probability of lasting at least a year (Keller et al., 1986). That outcome was more likely in older patients, in those whose family income was low, and after a lengthy previous episode (Keller et al., 1986).

Whether a persistent course within major depression changes the long-term picture was tested in a 10-year cohort of 290 outpatients with major depressive disorder, 117 of whom also met criteria for persistent depressive disorder. Those with the comorbid diagnosis had more severe depressive, anxiety and somatic symptoms at the six-month, two-year and 10-year points, independent of baseline severity, a lower remission rate and longer pharmacotherapy (Hung et al., 2019). The severity difference held only among patients not taking medication and was not significant among those who were, which led the authors to conclude that the harm of the persistent diagnosis lasts and that drug treatment offsets it only incompletely; about half the cohort was lost to follow-up, and the intervals were unequal (Hung et al., 2019).

Inpatient care shows the same gap. In a naturalistic multicentre study of 954 inpatients in a German depression network, 113 (11.8%) had chronic depression, defined by an illness of two or more years, and they stayed in hospital longer, remitted less often, reported more suicidal ideation and left with higher depression and neuroticism scores and lower extraversion than the 841 with non-chronic depression (Seemüller et al., 2022). This was a post-hoc analysis of prospectively collected data, and the authors suggested that chronicity may be useful as a marker for stratifying treatment (Seemüller et al., 2022).

Predictors of a Chronic Course

Reviews agree on a few predictors and disagree on others. A systematic review of 25 studies with 5,192 participants, which counted significant findings rather than pooling effect sizes, identified younger age at onset, longer episode duration and a family history of mood disorders as risk factors for a chronic course; comorbid anxiety, personality and substance use disorders, low social integration and negative social interaction were also associated (Hölzel et al., 2011). Most of the included studies were cross-sectional, so the comorbidity and social factors could be shown only to co-occur with chronicity, few longitudinal studies were significant, and the authors judged causal conclusions difficult (Hölzel et al., 2011). An earlier narrative review weighed six putative determinants and found developmental factors, early adversity among them, the strongest; chronic stressors and stress reactivity had some support, and comorbidity, biological and cognitive factors little (Riso et al., 2002). The authors judged chronic and acute depression qualitatively alike and proposed that people with the chronic form possibly experienced more adversity and react more strongly to stress, while warning that retrospective data collection invites bias and that longer prospective follow-ups are needed (Riso et al., 2002).

Personality and cognitive style were examined in the baseline data of the Netherlands Study of Depression and Anxiety, in which 312 (31%) of 1,002 adults aged 18 to 65 with major depression had been depressed for 24 months or more (Wiersma et al., 2011). Taken one at a time, neuroticism (OR = 1.81), external locus of control (OR = 1.94), hopelessness, rumination and risk aversion were higher in the chronic group, and extraversion (OR = 0.57) and conscientiousness were lower. In the multivariable model only low extraversion (OR = 0.73), rumination (OR = 1.24) and external locus of control (OR = 1.48) remained, neuroticism did not, and adjusting for severity, age at onset, comorbidity and treatment left these results unchanged (Wiersma et al., 2011). The authors suggested that these traits may point to more specific interventions; the analysis was cross-sectional, so it cannot show whether the traits precede chronicity. Rumination is discussed further in Rumination, Cognitive Reactivity and Other Accounts.

In young people the evidence is broader but weaker. A meta-analysis of 46 studies of 7,488 people aged 10 to 25 with depression, followed for at least three months, examined relapse, recurrence and chronicity together rather than persistent depression as such (Tagliaferri et al., 2026). In an adjusted analysis, female sex predicted a poor course (OR = 1.49), and in unadjusted analyses more severe symptoms (SMD = 0.53), lower global functioning (SMD = -0.35) and longer sleep-onset latency (by 6.96 minutes) also did; the effect of suicidal thoughts and behaviours was borderline (SMD = 0.52, p = .045), and friend and family relationships looked promising but could not be pooled (Tagliaferri et al., 2026). Of the reports, 87% were at high risk of bias and the certainty of evidence ranged from very low to moderate, although the authors concluded that demographic and clinical factors have prognostic value (Tagliaferri et al., 2026).

A community sample offers a population view. In the Lausanne cohort, 563 of 3,618 adults had a lifetime history of chronic major depression, and in cross-sectional comparisons with 1,060 adults whose depression was non-chronic they had more neuroticism (OR 1.50), less extraversion (OR 0.77), less informal help-seeking (OR 0.77), more impact from adult life events and more suicide attempts (OR 1.67) (Ambresin et al., 2023). Problem-focused coping and childhood trauma did not distinguish the groups, and, against the clinical reviews, a family history of major depression was less common in the chronic group (Ambresin et al., 2023). The study used a lenient p < 0.1 threshold and had a 43% participation rate; its authors read the findings as pointing to modifiable factors for which psychotherapy may be useful (Ambresin et al., 2023).

Two discrepancies remain open. Family history predicted chronicity in the systematic review and in the dysthymia cohorts but ran the other way in the Lausanne sample (Ambresin et al., 2023), and the review linked lower symptom severity to a chronic course (Hölzel et al., 2011) while the NIMH and outpatient cohorts found that greater severity slowed recovery (Keller et al., 1992). Neither discrepancy has been resolved by the studies reviewed here. Nearly every predictor described here comes from observational cohorts or cross-sectional comparisons rather than from designs that manipulate the factor; the systematic review, whose included studies were mostly cross-sectional, judged causal conclusions about risk factors difficult (Hölzel et al., 2011).

The CBASP Model of Chronic Depression

The Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is both a treatment and an implicit account of why depression becomes chronic. Most of the studies that test it recruited samples labelled chronic depression rather than persistent depressive disorder or dysthymia, and the label each study used is given below. The model's standing is contested: in a small stress-induction experiment, patients' empathy fell below that of controls only under stress, a pattern the authors took as support for the model (Guhn et al., 2022), whereas a small case-control study found no theory-of-mind deficit in early-onset patients, though their self-rated empathy was lower (Wilbertz et al., 2010).

McCullough's Account

McCullough presented CBASP as a psychotherapy built specifically for chronic depression, in a review that set out the therapy and illustrated it with a case (McCullough, 2003). Although its name acknowledges what it owes to cognitive behavioral therapy, the overview traces chronic depression to developmental causes and describes the patterns of psychopathology seen in chronically depressed adults, and it organises treatment around three named techniques: the Interpersonal Discrimination Exercise, Situational Analysis, and Behavioral Skill Training/Rehearsal (McCullough, 2003). The account's central claim is that people with chronic depression, early-onset cases in particular, reason in a preoperational way, a label McCullough borrows from Piaget (Wilbertz et al., 2010). As the construct is described, it covers two things: an egocentric view of oneself and of other people, and an inability to feel genuine empathy toward others in interpersonal exchanges (Wilbertz et al., 2010). Later experimental work treats preoperational thinking or functioning as the model's core and probes it through empathy and social-cognitive performance (Wilbertz et al., 2010; Guhn et al., 2022). These sources define the construct and look for its correlates; none of them tests how the preoperational pattern would keep the illness going, or shows that the three techniques work by changing it.

Beck's cognitive model is not tested as a model in chronic samples in the evidence gathered here. The closest tests are the comparisons, set out under The Cognitive-Vulnerability Account Applied to Chronicity, in which chronically depressed patients scored generally higher than nonchronic patients on cognitive-vulnerability measures, among them dysfunctional attitudes and maladaptive core beliefs (Riso et al., 2003), and on hopelessness and rumination (Wiersma et al., 2011). Both comparisons are cross-sectional (the second uses the baseline data of a cohort), so they show that these features accompany chronicity, not that they produce it.

Tests of the Model's Core Claims

The clearest support comes from a small experiment with patients diagnosed with persistent depressive disorders. Guhn and colleagues compared 22 patients with 21 controls on the Multifaceted Empathy Test, before and after a stress induction in which participants re-experienced negative autobiographical events (Guhn et al., 2022). Without stress the groups did not differ significantly; after the induction, patients showed less empathy than controls. Fifteen patients were retested after a 12-week inpatient CBASP programme, and their stress-induced empathy was higher than before treatment, with post-treatment empathy tracking clinical improvement. The authors read this as empirical support for the model, though only fifteen patients were retested (Guhn et al., 2022).

Tests of theory of mind, the ability to infer other people's mental states, have produced conflicting results. In a case-control study of 30 chronically depressed patients and 30 matched controls, patients performed markedly worse on two cartoon picture story tests and on neuropsychological tasks (Zobel et al., 2010). Once logical memory and working memory were taken into account, however, the theory-of-mind scores no longer distinguished patients from controls, and the authors suggested the deficit may be tied to general cognition. Wilbertz and colleagues, studying sixteen patients with early-onset chronic depression and sixteen matched controls, found no theory-of-mind deficit on the Movie for Assessment of Social Cognition, although patients rated their own empathy lower on the Interpersonal Reactivity Index (Wilbertz et al., 2010). Neither measure correlated significantly with therapists' structured ratings. The sample was small, and the controls were not rated by clinicians.

A third case-control study pointed to a narrower problem. Comparing 26 medication-free patients with chronic depression and 26 matched controls on a false-belief cartoon task, Mattern and colleagues found that patients were specifically slower on affective theory-of-mind items, alongside weaker general theory-of-mind performance (Mattern et al., 2015). The authors concluded that an affective mentalization deficit sits on top of a more general decline, which they thought likely to be cognitive, and they noted how scarce such data are.

Self-reported empathic responding also separates the groups, but not in the direction a simple deficit account would predict. In a cross-sectional study of 111 adults, empathic distress was highest in persistent depressive disorder, intermediate in episodic depression and lowest in healthy controls (Struck et al., 2021). Errors on the Mind in the Eyes Test did not differ across the three groups, and perspective taking in the persistent group did not differ significantly from controls. The authors proposed that the difficulty may be an overload of distress rather than a failure to decode others' states, a reading limited by the cross-sectional design, self-report measures and patients who were not drug-naïve (Struck et al., 2021).

The interpersonal side of the model has meta-analytic support. Across twelve studies, a hostile-submissive interpersonal style was more pronounced in chronic depression than in major depressive disorder: d = 0.93 against 0.63 for hostile-submissiveness, 0.86 against 0.40 for submissiveness, and 0.72 against 0.58 for hostility (Bird et al., 2018). The authors called this preliminary evidence only. Few of the studies concerned chronic depression, most were secondary analyses of trial baselines compared with normative data, quality scores were generally low and heterogeneity was high.

Mediator Evidence from the Therapy Trials

Two analyses of clinical-trial data asked whether change in interpersonal style carries the benefit of treatment. Pooling 259 chronically depressed patients from a trial's CBASP and combined conditions, Constantino and colleagues found that a decline in hostile-submissive impact messages, measured with the Impact Message Inventory, went with greater depression reduction and a higher chance of treatment response, with no difference between the two conditions (Constantino et al., 2012). They described the result as supporting CBASP theory, but only suggestively, and it rests on a subsample of that trial.

A later mediation analysis of 220 chronically depressed patients in CBASP or combined treatment traced a path from the early therapeutic alliance to reduced hostile-submissiveness, as rated by clinicians, and from there to lower final depression (Constantino et al., 2016). The bootstrapped indirect effect was small (B = -.02, 95% CI [-.07, -.001]), its interval only just excluding zero, and treatment condition did not moderate it. The section on how the psychological treatments work returns to these mediators.

The Cognitive-Vulnerability Account Applied to Chronicity

A cognitive-vulnerability account offers a different reading of persistence, one that places the problem in enduring negative thinking rather than in interpersonal immaturity. Riso and colleagues compared 42 outpatients with chronic depression, 27 with nonchronic major depressive disorder and 24 never-ill controls on measures that included dysfunctional attitudes and maladaptive core beliefs (Riso et al., 2003). Both depressed groups scored above the controls, and the chronic group scored above the nonchronic group, a difference that held after controlling for current mood and personality disorder symptoms. The study was cross-sectional, so it cannot show whether this vulnerability precedes chronicity or follows from it. A larger later comparison supported the account in part: in baseline data from a cohort of 1,002 adults with major depression, those whose depression was chronic reported more hopelessness and rumination than nonchronic patients, and rumination was among the traits still linked to chronicity in the multivariable analysis (Wiersma et al., 2011).

Standing of the Model

The CBASP model is contested. The empathy and interpersonal findings support parts of it: empathy that fails under stress and recovers after CBASP, and a hostile-submissive style that is stronger in chronic than in episodic depression and whose reduction tracks outcome. The theory-of-mind evidence does not line up. One case-control study found marked deficits, but once logical memory and working memory were controlled no theory-of-mind task predicted being a patient (Zobel et al., 2010), another found no group difference on a video-based theory of mind test (Wilbertz et al., 2010), and a third found a specific slowing on affective items alongside a general decline in theory-of-mind performance (Mattern et al., 2015). Most tests are small and cross-sectional, and the mediator analyses rest on subsamples of trial data. The most recent test supports the model but adds a new aspect, that empathy is impaired under stress rather than generally deficient, and it rests on 22 patients, only fifteen of them retested (Guhn et al., 2022). Whether preoperational functioning is a cause of chronic depression, rather than a feature of it, remains open.

Personality, Temperament and Persistence

A depression that lasts for years and begins early in life invites an old question: is it an illness of mood, or is it part of who the person is? The question has divided the field since the condition was first given a name, and the evidence now bears on both sides of it.

The Subaffective and Temperament Accounts

The mood-disorder side of the argument was developed most fully by Akiskal. In a theory paper laying out a nosologic framework, he divided the low-grade chronic depressions into three subtypes: late-onset primary depressions, chronic secondary dysphorias and early-onset characterologic depressions (Akiskal, 1983). The subtypes were said to differ in family history, in REM latency and in how they responded to medication, and the paper proposed operational criteria for a subaffective dysthymia, a form placed within the mood disorders rather than among the character-spectrum disorders (Akiskal, 1983). The framework is a classification argument, not a test, and its subtype differences were offered as the grounds for drawing the lines where it drew them. That account's standing is now contested, because a later narrative review judged the validity of the dysthymia diagnosis doubtful and argued that the DSM-5 category of persistent depressive disorder is likely to be heterogeneous as well (Rhebergen & Graham, 2014).

A decade later, a narrative review restated the case that dysthymia behaves like a subaffective mood disorder. Onset in childhood or adolescence was linked to familial mood disorders and to major depression later superimposed on the chronic state, and the review judged that the evidence supported the concept's usefulness (Akiskal, 1994). The same review acknowledged that dysthymia's validity had been questioned from opposite positions, with some placing it closer to major depressive illness and others to personality (neurotic) disorder, and that the condition may lack clinically observable signs of depression (Akiskal, 1994).

The temperament line reaches further back, to Kraepelin. A later narrative review argued that recent research backed Kraepelin's idea of temperamental dispositions underlying the affective illnesses, and that dysthymic and cyclothymic dispositions each predisposed people to major episodes (Akiskal, 2001). Its author concluded that Kraepelin's vision still guided thinking on aetiology and prevention, but two limits travel with the claim: Kraepelin's own observations came from hospitalised, severely ill patients, and the irritable and hyperthymic temperaments the review also described had no official diagnostic sanction (Akiskal, 2001). On this account a dysthymic temperament is a subthreshold affective condition, which is how it can be both lifelong and a mood disorder at once.

Depressive Personality and Personality Disorder

The trait side rests on the observation that a lifelong low mood can look like character. Schneider's depressive personality was tested in a validation study of 177 outpatients followed for 6 months (Klein, 1990). Applied through structured diagnostic interviews and family history interviews, the criteria reached moderate to good levels of interrater agreement, internal consistency and stability on retesting; dysthymia covered only part of the same ground, and the patient's current clinical state did not significantly change how the trait was rated (Klein, 1990). The author concluded that depressive personality was not wholly absorbed by the mood disorders, while describing the support for its validity as preliminary (Klein, 1990).

Personality disorder proper is also more common in the chronic form. In a cross-sectional interview study of 142 outpatients in two diagnostic groups, 60% of those with early-onset dysthymia met criteria for a DSM-III-R axis II disorder, against 18% of those with episodic major depression, and informant interviews gave similar results to the patients' own (Pepper et al., 1995). The authors left open what processes produced the association (Pepper et al., 1995).

One personality disorder in particular stands out in a more recent sample. Among 279 outpatients at a psychotherapy centre, whose diagnoses were labelled chronic depression rather than PDD or dysthymia, avoidant personality disorder was associated with chronic depression (OR = 2.20, P = .015), whereas the scales of the Childhood Trauma Questionnaire short form were not significant predictors on their own (Klein et al., 2015). Emotional abuse was associated with avoidant personality disorder, and the two interacted: among patients without the disorder, chronic depression was less frequent where more severe emotional abuse was reported (18.9% against 39.7%) (Klein et al., 2015). The analysis was retrospective and cross-sectional, the trauma reports were recalled, and the authors called the interaction tentative and asked for a prospective study (Klein et al., 2015). The wider literature on early adversity is taken up under Childhood Maltreatment and Early Adversity.

Traits That Predict Chronicity

Two large cohorts compared chronic with non-chronic depression on standard trait measures, and both labelled their groups chronic depression rather than PDD. In baseline data from the Netherlands Study of Depression and Anxiety, 312 of 1,002 adults with major depression aged 18 to 65 (31%) had been depressed for 24 months or more (Wiersma et al., 2011). Taken one at a time, many traits separated the groups: the chronic group scored higher on neuroticism (OR = 1.81), external locus of control (OR = 1.94), hopelessness and rumination, and lower on extraversion (OR = 0.57), agreeableness and conscientiousness (Wiersma et al., 2011). Entered together, only three held: low extraversion (OR = 0.73, P = .001), rumination (OR = 1.24, P = .04) and an external locus of control (OR = 1.48, P < .001), while neuroticism did not survive, and adjusting for severity, age of onset, comorbidity and treatment did not change the pattern (Wiersma et al., 2011). The authors suggested that the differentiating traits might point to more specific interventions (Wiersma et al., 2011). Rumination's wider role is discussed under Rumination, Cognitive Reactivity and Other Accounts.

The second cohort drew on 3618 adults in a Lausanne community sample, 563 with chronic and 1060 with non-chronic major depression, in a cross-sectional analysis of baseline data (Ambresin et al., 2023). On the Eysenck Personality Questionnaire the chronic group scored higher for neuroticism (OR 1.50, 1.33 to 1.70) and lower for extraversion (OR 0.77, 0.68 to 0.87), yet once depression-specific variables entered the fully adjusted model neither trait remained significant, and childhood trauma did not separate chronic from non-chronic cases (Ambresin et al., 2023). The study used a lenient p < 0.1 threshold and a 43% participation rate, and its authors framed the correlates as modifiable factors for which psychotherapy may be useful (Ambresin et al., 2023). Both cohorts found lower extraversion in chronic depression; in the Lausanne cohort, however, neither extraversion nor neuroticism remained significant once depression-specific variables were added to the fully adjusted model.

The dispute therefore has a partial outcome rather than a winner. Personality features, from depressive personality and avoidant personality disorder to low extraversion and an external locus of control, are repeatedly associated with chronicity, which supports the trait account; the familial and course findings behind the subaffective view support the mood-disorder account. Because nearly all of this evidence is cross-sectional or baseline data, it remains open whether personality is a cause of persistent depression, a consequence of years of low mood, or a shared vulnerability underlying both.

Childhood Maltreatment and Early Adversity

Childhood maltreatment is repeatedly linked, in the studies below, to a depression that does not lift. The evidence comes from samples defined in several ways, chronic major depression, chronic depression and early-onset dysthymia among them, and the labels are given below because they are not interchangeable.

Association with a Persistent Course

The broadest estimate is meta-analytic and concerns depression in general rather than persistent depressive disorder. Childhood maltreatment more than doubled the odds of a recurrent or persistent depression when 16 epidemiological studies covering 23,544 participants were pooled (odds ratio = 2.27, 95% CI = 1.80–2.87), and in 10 clinical trials covering 3,098 participants it went with a lower chance of response or remission (odds ratio 1.43; confidence interval 1.11 to 1.83) (Nanni et al., 2012). Neither association changed significantly with study quality, sample age or the outcome measure chosen, and publication bias was not significant; the authors concluded that maltreatment marks a worse course and a worse treatment outcome (Nanni et al., 2012).

Cohort data point the same way. At baseline in the Netherlands Study of Depression and Anxiety, 1230 patients with current major depressive disorder were classed as chronic when depressed for 24 months or more of the past four years (Wiersma et al., 2009). Childhood trauma was reported more often by the chronic patients, and at the top of the childhood trauma index the odds of chronicity were roughly tripled (OR 3.26, confidence interval 1.86–5.72); with anxiety, severity and age of onset controlled, the association remained (OR = 2.06, p = .02), while childhood life events bore no relation to chronicity (Wiersma et al., 2009). The design was cross-sectional, and the authors read multiple traumas as an independent determinant of a chronic course.

What seems to matter is how much maltreatment occurred rather than which kind. Among 349 chronically depressed patients in Germany, rates of self-reported emotional abuse (60.7%) and sexual abuse (25.2%) far exceeded those in a German general-population survey (15% and 12.6%), and 37% reported multiple trauma (Negele et al., 2015). Emotional and sexual abuse predicted Beck Depression Inventory (BDI-2) severity in a first model, but once multiplicity was entered it was the only predictor left; the multiple-trauma group scored higher (M = 34.88) than the other groups (29.51–31.43), although the predictors explained only 4–6% of the variance (Negele et al., 2015). The authors suggested that multiple trauma may contribute to a chronic course, while noting that the data were retrospective and cross-sectional and that longitudinal work is needed.

Early-onset dysthymia shows a similar pattern in an older case-control design. Interviews and self-reports from 97 outpatients with early-onset dysthymia, 45 with episodic major depression and 45 healthy controls were rated blind to diagnosis (Lizardi et al., 1995). The dysthymic group reported more physical and sexual abuse and poorer relationships with parents than controls, and lower-quality parenting than the episodic group; current mood, borderline or antisocial comorbidity and comorbid major depression did not explain these differences (Lizardi et al., 1995).

The type of adversity may instead shape which comorbidity develops. In an interview study of 76 women with major depression, 21 of whom also had dysthymia and 28 an anxiety disorder, severe physical abuse was linked to comorbid dysthymia, severe sexual and psychological abuse to comorbid anxiety, and parental indifference and antipathy to both (Harkness & Wildes, 2002). The sample was cross-sectional, made up of volunteers and confined to women, and the cognitive processes that might link each adversity to its comorbidity were left for future research.

Gene–Environment Interaction

One study tested whether the serotonin transporter polymorphism 5-HTTLPR changes the effect of maltreatment. Among carriers of the short allele, maltreatment was a stronger predictor of a chronic depressive episode, defined as one lasting 12 months or longer (risk difference 0.226; confidence interval 0.076 to 0.376; P = .0032), in a risk-enriched sample of 273 women of whom 220 were followed prospectively for 12 months (Brown et al., 2013). The interaction did not predict new onsets of depression, and severe life events showed no such interaction either. Maltreatment was assessed retrospectively with the Childhood Experience of Care and Abuse interview, and on that basis the authors concluded that the short variant specifically sensitises people to a chronic course after early abuse or neglect (Brown et al., 2013).

Maltreatment and Treatment Response

Whether maltreatment should guide the choice of treatment is less settled than its link with chronicity. A retrospective analysis of a randomised trial in 681 patients with chronic major depression compared 12 weeks of nefazodone, the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) and their combination (Nemeroff et al., 2003). Without a history of childhood trauma, the combination outperformed either treatment alone; with one, CBASP outperformed nefazodone alone, remission was more likely with CBASP than with the drug (odds ratio = 2.322), and the combination's further edge over CBASP was marginal and not significant (Nemeroff et al., 2003). Dropout did not differ by trauma history. The authors suggested that psychotherapy may be an essential element of treatment after childhood trauma, while cautioning that the trial tested one psychotherapy and one antidepressant and that the finding needs replication. The CBASP model itself, and its contested standing, are covered under The CBASP Model of Chronic Depression.

Adversity also predicted a poorer course in medication treatment. At baseline, among 808 patients with chronic major depression starting 12 weeks of open-label pharmacotherapy guided by an algorithm, those reporting childhood adversity had an earlier onset, an illness that had lasted longer and was more severe, and more self-criticism and dysfunctional attitudes (Klein et al., 2009). Among patients completing the trial, those with a clinically significant abuse history remitted less often (32% versus 44%), and paternal abuse, sexual abuse, maternal overcontrol and paternal indifference each predicted lower remission; the authors read adversity as a marker of chronic depression with a weaker response to medication (Klein et al., 2009).

A later trial did not confirm maltreatment as a general moderator. In follow-up at one and two years of 268 patients with chronic depression randomised to CBASP or supportive psychotherapy, a history of any childhood maltreatment did not moderate the long-term difference between the therapies, measured in well weeks on the Longitudinal Interval Follow-Up Evaluation interview (Bausch et al., 2020). Emotional abuse was the exception: it predicted worse outcomes than its absence (p = .015), and among emotionally abused patients CBASP did better than supportive therapy at one year; no other trauma subtype moderated the result (Bausch et al., 2020).

The current position is therefore split. The studies above link childhood maltreatment with a persistent, less treatment-responsive course in meta-analytic, cohort, case-control and trial data, although a systematic review of chronic against nonchronic depression found the results on childhood maltreatment inconsistent (Köhler et al., 2019). Whether maltreatment should steer patients toward psychotherapy remains open: the retrospective trial analysis favoured CBASP after childhood trauma (Nemeroff et al., 2003), while the later randomised follow-up, which compared CBASP with supportive psychotherapy rather than with medication, found no moderation by maltreatment overall and an advantage for CBASP only after emotional abuse (Bausch et al., 2020).

Limits of the Evidence

Much of this evidence rests on adults recalling their childhoods. The German cohort relied on retrospective self-report open to recall bias (Negele et al., 2015), the gene–environment study assessed maltreatment retrospectively (Brown et al., 2013), and the psychotherapy follow-up used retrospective self-assessment of maltreatment alone (Bausch et al., 2020). The German patient study and the Dutch baseline analysis were also cross-sectional (Negele et al., 2015; Wiersma et al., 2009), so these two establish associations but cannot show that maltreatment causes chronicity.

Social Cognition and Interpersonal Functioning

Research on how people with long-lasting depression perceive and respond to others is a small literature, and most of it recruited samples defined as chronic depression rather than as persistent depressive disorder or dysthymia. The studies below are labelled accordingly. The empathy and theory-of-mind tests that grew out of the interpersonal account of chronic depression are covered under The CBASP Model of Chronic Depression and are not repeated here.

Responses to Social Exclusion

Exclusion from a game of catch appears to affect people with chronic depression more than it affects others. The usual laboratory tool is Cyberball, a computerised ball-tossing game in which the participant is gradually left out by the other players. In one experiment, 21 patients with chronic depression and 21 matched healthy controls played the game while blood was drawn at 5, 15 and 40 minutes to measure oxytocin and cortisol (Jobst et al., 2015). The two groups began with similar oxytocin levels, but after exclusion the patients' oxytocin fell relative to the controls' (p = .035), whereas cortisol did not separate the groups at any point and declined over the session in both (Jobst et al., 2015). The patients also reported more anger and resentment, a stronger sense that their basic needs had been threatened, and greater sensitivity to exclusion that was ambiguous. The authors suggested, cautiously, that the drop in oxytocin may add to interpersonal dysfunction; with 21 people per group, the result is a small single-session finding.

A larger study compared four groups in the same paradigm: 29 patients with chronic depression, 20 with episodic depression, 28 with borderline personality disorder and 43 healthy controls, 120 participants in all (Seidl et al., 2020). Patients with chronic depression rated the ostracism as more intense and more aversive than patients with episodic depression did, and they more strongly wished to escape the situation. Across most rating categories the groups fell in a consistent order, with borderline personality disorder highest, then chronic depression, then episodic depression, then healthy controls; the borderline group differed most from controls (Seidl et al., 2020). The authors judged exclusion likely to be more aversive in chronic depression, while noting that they had no objective behavioural or biological measures and that the clinical subgroups were of moderate size.

Everyday loneliness shows a similar picture outside the laboratory. Wolf et al. used ecological momentary assessment, in which participants answer brief smartphone prompts several times a day, in the first and fifth weeks of a five-week study with 58 inpatients diagnosed with persistent depressive disorder and 42 healthy controls (Wolf et al., 2026). Compliance with the prompts was high in both groups (90.2% and 84.7%). Momentary loneliness was higher on average in the patients, their high-loneliness states lasted longer, and they were less likely to leave such a state once in it (hazard ratio 0.50, p = 0.018); they also reported more emotional and social isolation in the moment and more trait loneliness and early adversity (Wolf et al., 2026). Recalled emotional neglect was associated with momentary emotional isolation, whereas emotional abuse was not, and neither form of adversity was related to momentary loneliness itself. The authors proposed that early adversity may feed emotional isolation, but they described the analyses as exploratory: a secondary analysis that was not preregistered, comparing inpatients with community controls, with modest power, adversity recalled in retrospect and no formal test of mediation.

Emotion Recognition and Alexithymia

Difficulty identifying and describing one's own feelings, known as alexithymia, is the one social-cognitive domain in which a direct comparison found chronic depression to differ from episodic depression. Van Randenborgh et al. tested 30 chronically and 29 episodically depressed patients on alexithymia and on theory of mind, the ability to infer other people's mental states (van Randenborgh et al., 2012). The chronic group scored higher on alexithymia, but the two groups did not differ on theory of mind. In a mediation analysis, adverse relational experiences in childhood were linked to the type of depression by way of alexithymia (van Randenborgh et al., 2012). The authors concluded that how patients perceive their own emotions may be central to chronicity. The study had no healthy control group, and its childhood data were retrospective self-reports collected at a single time point, so the mediation cannot establish a causal sequence.

Avoidance

Patients with early-onset chronic depression report more avoidance than patients with episodic depression on several self-report measures. Brockmeyer et al. compared 30 patients with early-onset chronic depression, 30 with episodic depression and 30 never-depressed controls (Brockmeyer et al., 2015). The chronic group exceeded the healthy controls on every avoidance measure. It exceeded the episodic group in avoiding unwanted thoughts, in avoiding activities whether or not they involved other people, and in holding back emotional expression toward others, and that restriction of expression separated the two patient groups best (Brockmeyer et al., 2015). Within the chronic group, more general avoidance of emotion and more avoidance of social behaviour went with more severe depression. The authors argued that avoidance deserves to be a focus of treatment, while cautioning that all the data were self-reported and that a cross-sectional design cannot show whether avoidance precedes chronicity or results from it.

Social Networks

People with chronic depression probably have smaller social networks, although the evidence is limited. A systematic review searched six databases and three key journals and found nineteen articles covering 873 patients with chronic depression (Visentini et al., 2018). Networks were smaller than those of healthy people in six studies, smaller than those of people with non-chronic major depression in eight, and smaller than those of people with other mental disorders in three; four papers had no comparison group. The reviewers cautioned that the studies defined chronic depression in different ways, assessed networks with inconsistent methods, and in only three cases used objective measures (Visentini et al., 2018).

Taken together, three of the six sources here compared chronic with episodic or non-chronic depression directly (Seidl et al., van Randenborgh et al. and Brockmeyer et al.), and the systematic review drew eight of its studies from such comparisons; the other two studies compared patients only with healthy controls. Every individual study was small, and none followed patients over time beyond the five-week diary, so whether these social and interpersonal features cause persistence, result from it or merely accompany it remains open.

Rumination, Cognitive Reactivity and Other Accounts

Several accounts try to explain why some depressions persist when others remit. They differ in what they point to: a habit of thought, a vulnerability that a sad mood switches on, or a set of developmental and social conditions. The evidence for each is modest in size and mostly correlational, and few of the studies recruited people under the current diagnostic label. Most samples below were defined as chronic depression rather than as persistent depressive disorder or dysthymia, and the text says so study by study.

Rumination

Cognitive rumination, repetitive thinking that dwells on distress and its causes, is the most studied candidate. What it looks like from the inside was the subject of a preliminary phenomenological study of 22 people described as chronically depressed, not as meeting criteria for dysthymia or PDD (Pearson et al., 2008). Their ruminative episodes were not single-minded: each participant ruminated about at least two different topics, episodes varied in how long they lasted, and they carried mental imagery rather than words alone. Most participants attributed the end of an episode to distraction, with some evidence that stop rules were involved, although the authors presented the work as a first look (Pearson et al., 2008).

A treatment trial in primary care asked how response styles behave when symptoms are treated. Its 96 patients had minor depression or dysthymia and were randomised to problem-solving therapy, paroxetine or placebo (Schmaling et al., 2002). Rumination declined over the course of treatment, alongside symptoms, while the tendency to distract oneself showed no change. Both styles measured before treatment predicted higher symptom levels at the end. The distraction result is the awkward one: response style theory treats distraction as the helpful alternative to rumination, and the authors noted that their finding did not fit that expectation (Schmaling et al., 2002).

The largest dataset comes from the baseline wave of the Netherlands Study of Depression and Anxiety, which assessed 1,002 adults aged 18 to 65 with major depressive disorder (Wiersma et al., 2011). Here chronicity meant a depression lasting 24 months or more, which applied to 31% (n = 312); the sample was defined by MDD and duration, not by a dysthymia or PDD diagnosis. Chronic cases scored higher on rumination (OR = 1.55), and rumination remained associated with chronicity in the multivariable model, though more weakly (OR = 1.24; P = .04). Rumination was one of three characteristics that survived that model, with low extraversion and an external locus of control; the full set of personality findings is covered under Personality, Temperament and Persistence. Adding severity, age at onset, comorbidity and treatment did not change the pattern (Wiersma et al., 2011). Because these are baseline data, the analysis shows that rumination accompanies chronicity, not that it produces it.

Cognitive Reactivity

Cognitive reactivity is the degree to which a mild sad mood brings dysfunctional thoughts and feelings back to the surface. One laboratory study compared 15 patients with chronic depression with 15 healthy controls across two mood-induction experiments (Guhn et al., 2018). A general induction, using sad pictures and sad music, did not distinguish the groups on cognitive reactivity; if anything, the controls showed the larger drop in positive affect. An individualised induction, built from each participant's own autobiographical script, produced the opposite pattern: the patients showed greater affective reactivity and more dysfunctional cognitions than the controls. The authors read this as evidence that activating personal memories is central to the dysfunctional coping seen in chronic depression (Guhn et al., 2018).

The study's limits are substantial. The samples were very small, the order of the two inductions was not counterbalanced, the group-by-condition interaction for cognitive reactivity was significant only under the individualised induction, and no group with non-chronic depression was included, so the result cannot show that the effect is specific to chronicity (Guhn et al., 2018). The authors themselves warned against causal conclusions. The same construct appeared in the NESDA analysis, which measured it with the Leiden Index of Depression Sensitivity-Revised (Wiersma et al., 2011).

Psychosocial Maintenance Accounts

Two narrative reviews tried to organise the wider field. The earlier one grouped explanations of persistence into three major perspectives: cognitive theories, interpersonal theories and accounts centred on childhood adversity (Lara & Klein, 1999). In the cognitive view, low mood and negative processing feed each other in a downward spiral; in the interpersonal view, negative reactions from other people sustain the depression; in the developmental view, early adversity sets up a chronic course. The reviewers judged all three promising and suggested that they may interact, but support varied across them. They also found few clinical samples, few longitudinal studies, and confounds such as baseline severity, duration and comorbid psychopathology that were rarely handled well (Lara & Klein, 1999).

The later review weighed six putative determinants of chronicity and ranked them by evidence (Riso et al., 2002). Developmental factors had the strongest support. Chronic stressors and stress reactivity had some, while comorbidity, biological factors and cognitive factors had little. Chronic and acute depression did not appear to differ in kind, but chronic cases had more childhood adversity and greater stress reactivity, which the reviewers put forward as possible distinguishing features. They cautioned that much of the adversity evidence was collected retrospectively and is open to recall bias, that a parent's reaction to a child's subthreshold traits could confound it, and that the area needs stronger designs with longer prospective follow-up (Riso et al., 2002). The adversity evidence itself is set out under Childhood Maltreatment and Early Adversity.

Where the Accounts Stand

Some of these accounts have support, chiefly for developmental factors, chronic stressors and stress reactivity (Riso et al., 2002), but much of it comes from small laboratory samples, such as 15 patients against 15 controls (Guhn et al., 2018), or from baseline data of a cohort (Wiersma et al., 2011). None has yet been tested as a cause of chronicity, and whether rumination, cognitive reactivity or early adversity keeps depression going, rather than accompanying it, remains open. The designs that could settle the question are discussed under Testing Whether Cognition Is Cause or Consequence.

Executive Function and Other Cognitive Processes

Laboratory work on cognition in persistent depression is sparse, and it uses two kinds of comparison. Some studies set a chronic or dysthymic group against healthy controls, which shows whether a difference exists but not whether it belongs to chronicity. Others set chronic against episodic depression, which is the comparison that can say whether long duration carries its own cognitive profile. The samples are also labelled in different ways: several studies recruited people with dysthymia or dysthymic disorder, others people with chronic depression, a broader clinical grouping that is not the same thing as the current diagnosis of persistent depressive disorder. Each study below is described under the label its authors used. Whether these differences cause the persistence or follow from it is taken up in Testing Whether Cognition Is Cause or Consequence.

Executive Function

Two small cross-sectional studies bear on executive function, and neither isolates chronicity. In the earlier, 48 adults in three groups, people with major depression (n = 13), people with dysthymia (n = 17) and non-psychiatric comparison subjects (n = 18), completed the Wisconsin Card Sorting Test (Martin et al., 1991). How severe a person's symptoms were tracked their performance: greater severity went with more total errors, more perseverative responses and more failures to maintain a sorting set, and this association held independently of diagnosis, while diagnostic category itself, dysthymia versus major depression, related to card-sorting performance only marginally (Martin et al., 1991). On this evidence, executive difficulty scales with how depressed someone currently is rather than with which of the two diagnoses they carry.

The second study moved to brain activity in children. Using fMRI, it compared nineteen boys with dysthymic disorder with 16 typically developing boys, with mean ages of 11.2 and 10.5 years in the two groups (Vilgis et al., 2014). During a mental rotation task, the boys with dysthymic disorder showed less activation than controls in left frontal and in medial frontal regions; during a delay-match-to-sample task of spatial working memory, they showed more activation than controls in the right precuneus and posterior cingulate, regions among the cortical midline structures (Vilgis et al., 2014). The authors read the pattern as evidence that the pathophysiology of dysthymic disorder is continuous with that of major depression across the lifespan, while noting that the small sample and cross-sectional design limit how far the results generalise (Vilgis et al., 2014). The imaging side of this work is set in context in Brain Networks and Imaging.

Neither study compared a chronic group with an episodic one on executive tasks, so whether long-lasting depression carries an executive deficit beyond what current severity explains remains an open question.

Theory of Mind and Cognitive Deficits

Theory of mind, the capacity to infer other people's beliefs and feelings, is the domain where chronic samples have been tested most directly, and the results point in more than one direction. The interpersonal side of these findings is discussed in Social Cognition and Interpersonal Functioning; this subsection concerns the test performance and its overlap with general cognition.

In a case-control study, 30 chronically depressed patients and 30 matched healthy controls completed two cartoon picture story tests of theory of mind alongside a neuropsychological battery (Zobel et al., 2010). The patients performed markedly worse than controls on both the theory-of-mind tasks and the neuropsychological tasks (Zobel et al., 2010). Once logical memory and working memory were controlled, however, no theory-of-mind task predicted being a patient, and each theory-of-mind test correlated significantly with at least one other cognitive variable (Zobel et al., 2010). The authors concluded that the theory-of-mind deficit may be bound up with broader cognitive impairment rather than standing alone (Zobel et al., 2010).

A later case-control study tested 26 medication-free patients with chronic depression and 26 matched healthy controls on a false-belief cartoon task that separates affective from cognitive theory of mind, together with a visuospatial theory-of-mind task (Mattern et al., 2015). The patients were slower than controls specifically when the inference concerned another person's feelings, and they also performed below controls on theory-of-mind functions more generally (Mattern et al., 2015). The authors interpreted this as a deficit in affective mentalization sitting on top of a general decline, and they judged the general part likely to be cognitive in origin; they also noted that data on this question remain scarce (Mattern et al., 2015).

The two control-comparison studies therefore agree that chronically depressed patients do worse than healthy people on theory-of-mind tasks, and both trace much of the gap to general cognition. They differ on whether anything specific to mentalizing remains: in the first, nothing did once memory was controlled, while the second found a slowing confined to affective inferences. Neither design can say whether the deficit belongs to chronic depression rather than depression in general, because neither included an episodic group. The one study that did make that comparison, described next, found no chronic-episodic difference in theory of mind. Whether chronic depression carries a mentalizing deficit of its own, beyond general cognitive slowing and beyond what episodic depression shows, remains unresolved.

Socio-Emotional Information Processing

The chronic-versus-episodic comparison has been run for socio-emotional processing. A cross-sectional study compared 30 chronically depressed with 29 episodically depressed patients in two domains, theory of mind and alexithymia, the difficulty identifying and describing one's own emotions (van Randenborgh et al., 2012). The groups did not differ in theory of mind, but the chronically depressed patients reported more alexithymia (van Randenborgh et al., 2012). Alexithymia also mediated the link between adverse relational experiences in childhood and the type of depression, chronic or episodic (van Randenborgh et al., 2012). From this the authors suggested that perceiving one's own emotions, rather than reading other people's, may be the more central difficulty in chronic depression (van Randenborgh et al., 2012).

The evidence has clear limits. Childhood experience was reported retrospectively, the measures were self-report, and a cross-sectional mediation analysis cannot establish that alexithymia lies on a causal path from early adversity to chronicity (van Randenborgh et al., 2012). The wider evidence on early adversity is covered in Childhood Maltreatment and Early Adversity.

Cognitive Vulnerability

Cognitive vulnerability to depression refers to stable patterns of thinking held to make a person prone to depressive episodes. Here a three-group design allows both kinds of comparison. One cross-sectional study assessed 42 outpatients with chronic depression, 27 outpatients with nonchronic major depressive disorder and 24 controls who had never been psychiatrically ill (Riso et al., 2003). The measures covered two kinds of content: beliefs, in the form of dysfunctional attitudes and maladaptive core beliefs, and habitual styles of responding, in the form of how people explain events (attributional style) and whether they dwell on their distress (ruminative response style) (Riso et al., 2003).

Both depressed groups scored higher than the never-ill controls, and the chronic group generally scored higher than the nonchronic group on the cognitive measures (Riso et al., 2003). The chronic-nonchronic difference survived statistical control for current mood and for personality disorder symptoms, so it was not simply a product of the chronic patients feeling worse at the time of testing or having more personality pathology (Riso et al., 2003). Because the study was cross-sectional, it cannot show whether these thinking patterns came before the chronic course or developed during it (Riso et al., 2003). Rumination and cognitive reactivity are treated further in Rumination, Cognitive Reactivity and Other Accounts.

Attention and Memory

Two oxytocin trials give the closest look at attention to faces in chronic depression. In a double-blind trial, 43 chronically depressed patients received a single dose of oxytocin (n = 22) or placebo (n = 21) and then completed a facial dot probe task (Domes et al., 2016). The patients showed no overall threat bias. With longer primes, oxytocin reduced how quickly attention first went to angry faces and increased how long attention stayed on happy faces. It did not change the congruency effect, how long attention stayed on angry faces, how quickly it went to happy faces, or raw reaction times, and a three-way interaction of drug, valence and prime duration was only marginal (Domes et al., 2016). The authors describe these effects as small and in need of replication. They also note that the sample was heterogeneous, nearly all patients were medicated, only one dose was tested and no structured interview was used (Domes et al., 2016). An eye-tracking study of patients with chronic depression and healthy controls found that the patients, on placebo, looked less at the eye region of faces than controls did, but recognised facial emotions as accurately (Vehlen et al., 2023). A single dose of oxytocin increased the patients' gaze to the eyes without improving their emotion recognition, and the authors suggest that social attention may be altered in chronic depression and that this bias may respond to oxytocin (Vehlen et al., 2023).

Cognitive difficulties may also persist after mood improves. In a case-control comparison of men with unipolar or bipolar illness and healthy controls, the unipolar patients, tested in a euthymic phase after years of chronic illness, performed worse than controls on Trail Making Tests A and B, the Stroop Color/Word trial, the first CERAD learning trial and the WAIS Digit Symbol subtest (Paradiso et al., 1997). These tests cover executive function, processing speed, visual-motor sequencing and memory. The bipolar group did not differ significantly from controls. The authors take this to mean that men with chronic unipolar depression are at risk of impairment even when they are not symptomatic (Paradiso et al., 1997).

Memory specificity has been studied prospectively, but not in a chronic sample. Over a 16-month follow-up of 55 remitted adolescents with past major or minor depression, 10 (18.2%) had a new major depressive episode. Those who recalled fewer specific memories on the Autobiographical Memory Test were more likely to be among them (Sumner et al., 2011). This overgeneral memory predicted onset at high levels of chronic interpersonal stress, only marginally at medium levels and not at low levels. Interpersonal stress alone did not predict onset, and stress outside relationships did not interact with memory. The authors call the support preliminary. The authors raise the possibility that overgeneral memory stands in for wider problems in cognitive processing, cognitive inflexibility among them; only ten onsets occurred during the study (Sumner et al., 2011). Taken together, this evidence contains no direct comparison of chronic and episodic depression on memory bias or interpretation bias, so whether either distinguishes persistent depressive disorder remains an open question.

Testing Whether Cognition Is Cause or Consequence

Most of the cognitive differences described in the preceding sections were measured in people who were already chronically depressed, so they cannot say whether a way of thinking helped make the depression persistent or grew out of years of low mood. Three kinds of design could separate the two. Prospective cohorts measure a feature before the course unfolds. Experiments manipulate mood or stress and watch what follows. Treatment studies ask whether a change in a cognitive or interpersonal variable comes before, and carries, the change in symptoms. Each has been tried with chronic depression, and each has delivered part of an answer.

The starting point is descriptive. A systematic review of twenty-eight cohort and cross-sectional studies that set chronic against nonchronic major depression found that the chronic group had an earlier onset, more psychiatric comorbidity, more suicidality and, on some evidence, more submissive and hostile interpersonal styles, while symptom severity and most sociodemographic factors did not differ (Köhler et al., 2019). Findings on childhood maltreatment were inconsistent, and the authors concluded that the specific psychopathology of chronic depression still needs research (Köhler et al., 2019). The review concerns chronic depression defined against DSM-IV and DSM-5 criteria rather than persistent depressive disorder as such, and differences of this kind establish what accompanies chronicity, not what produces it.

Prospective Cohorts

The largest relevant cohort comes from the Netherlands Study of Depression and Anxiety. Among 1,002 adults aged 18 to 65 with major depressive disorder, 31% (n = 312) had a chronic course, defined as at least 24 months of depression within the previous four to five years (Wiersma et al., 2011). Compared with the nonchronic group, the chronic group scored higher on neuroticism (OR = 1.81), external locus of control (OR = 1.94), hopelessness (OR = 1.64) and rumination (OR = 1.55), and lower on extraversion (OR = 0.57) (Wiersma et al., 2011). When the traits were entered together, three remained: low extraversion (OR = 0.73), rumination (OR = 1.24) and an external locus of control (OR = 1.48); neuroticism did not survive the multivariable model, and adjusting for severity, age of onset, comorbidity and treatment left the pattern unchanged (Wiersma et al., 2011). The authors read these traits as pointers toward more specific interventions (Wiersma et al., 2011). Because the analysis used the cohort's baseline data, it identifies features that set the chronic group apart rather than features shown to precede the onset of chronicity.

Two smaller cohorts followed people with early-onset dysthymic disorder, the predecessor diagnosis, over long intervals. In 86 outpatients whose dysthymia began before age 21, assessed at 30 and 60 months, recovery was less likely with a comorbid anxiety disorder, cluster C or depressive personality features, and chronic stress, and more likely with a family history of bipolar disorder (Hayden & Klein, 2001). Neuroticism, chronic stress, childhood sexual abuse and poor relationships with parents predicted greater later depression, and the authors concluded that the course fits a multifactorial model spanning many domains (Hayden & Klein, 2001). A 10-year follow-up of 87 such outpatients, seen five times at 30-month intervals, found poorer outcomes with concurrent anxiety disorder, familial loading for chronic depression, a poor maternal relationship and childhood sexual abuse; the authors judged that several of these variables aid long-term prognosis (Klein et al., 2008). The predictors these cohorts reported were clinical, familial, personality and adversity variables, so they bear on the course of dysthymia without isolating a cognitive cause.

Experimental Inductions

Experiments can test whether a cognitive response appears when it is provoked, which a questionnaire cannot. In two mood-induction experiments with 15 chronically depressed patients and 15 healthy controls, a general induction using sad pictures and sad music lowered positive affect more in the controls than in the patients, and cognitive reactivity did not differ between groups (Guhn et al., 2018). Individualized autobiographical scripts produced the opposite pattern: affective reactivity and dysfunctional cognitions rose more in the patients than in the controls (Guhn et al., 2018). The authors proposed that activating personal memories is central to dysfunctional coping in chronic depression, while noting that the order of inductions was not counterbalanced, that causal conclusions are limited and that a comparison with nonchronic depression is still outstanding (Guhn et al., 2018).

A later experiment with twenty-two patients with persistent depressive disorder and 21 controls measured empathy with the Multifaceted Empathy Test after recalling a negative autobiographical event and, as a control, after a neutral event (Guhn et al., 2022). Without stress the groups did not differ; under stress the patients showed less empathy (Guhn et al., 2022). After a 12-week inpatient course of CBASP, stress-induced empathy was higher than before treatment, and post-treatment empathy was related to clinical improvement, but only fifteen patients were retested (Guhn et al., 2022). The authors took the result as empirical support for the CBASP model (Guhn et al., 2022), a model whose standing remains contested (see The CBASP Model of Chronic Depression). An uncontrolled pre-post comparison of this size cannot show that the empathy change caused the improvement.

Mediators and Moderators in Treatment Trials

Treatment trials offer a third test: if a change in some process carries the benefit of therapy, it should come first and account for part of the symptom change. In 220 chronically depressed patients receiving CBASP alone or combined with medication, a stronger early therapeutic alliance was followed by a fall in clinician-rated hostile-submissiveness, which in turn was linked to lower final depression (B = -.02, 95% CI: -.07, -.001), with no difference between the CBASP and combined conditions (Constantino et al., 2016). The indirect effect came from a subsample of a larger trial and its confidence interval lay close to zero, and the mediator was an interpersonal pattern rather than a belief (Constantino et al., 2016).

The one study here to track core beliefs directly found change only in step with symptoms. In a single-case series of 20 patients with chronic major depressive disorder in schema therapy, assessed weekly over up to 65 individual sessions, change in negative idiosyncratic core-beliefs moved with concurrent symptom change but did not predict later symptom change (Renner et al., 2018). With a small sample and no control group, the series could not establish that belief change led the way (Renner et al., 2018).

Cognition can also be tested as a moderator, a feature that changes who benefits. A secondary analysis of the REVAMP trial, which enrolled 808 chronically depressed adults at 8 sites, used the 40-item Dysfunctional Attitude Scale (Shankman et al., 2013). In the 12-week open-label antidepressant phase, patients with more dysfunctional attitudes started with higher depression scores and improved faster early on, the groups were level at the midpoint, and those with fewer dysfunctional attitudes improved more late in the phase (Shankman et al., 2013). In the second phase (N = 491), dysfunctional attitudes moderated response to medication alone but not to psychotherapy plus medication, and they did not distinguish CBASP from brief supportive psychotherapy (p = .71) (Shankman et al., 2013). The first phase was not randomized, the trial was not designed to test this question and the second-phase analyses were exploratory, so the authors called the relation complex and said replications are necessary (Shankman et al., 2013).

Taken together, these designs show that some cognitive and interpersonal features distinguish chronic from nonchronic depression, that they can be provoked in the laboratory and that they shift during treatment. None of the studies in this section has shown that a cognitive feature causes the transition from episodic to chronic depression, and that question remains open.

Validity of Laboratory and Daily-Life Measures

Much of what is known about cognition and social functioning in persistent depression comes from a few laboratory paradigms run on small groups, usually tested once. Four kinds of evidence bear on how far those measurements can be trusted: the paradigms and their samples, repeated sampling in everyday life, the agreement between a brief screener and a diagnostic interview, and the behaviour of placebo arms in drug trials.

Laboratory Paradigms and Their Samples

Social exclusion is most often staged with Cyberball, a virtual ball-tossing game in which the participant is gradually left out. In one such experiment, 21 patients described as having chronic depression and 21 matched healthy controls had plasma oxytocin and cortisol drawn at 5, 15 and 40 minutes after the game (Jobst et al., 2015). Resting oxytocin did not differ between the groups, but after exclusion it fell in the patients, and its change over the session was lower in them than in the controls (p = .035). Cortisol showed no group difference at any time point and declined across the session in both groups. The patients also reported more anger and resentment, more strongly threatened needs, and greater sensitivity to exclusion that was ambiguous. The authors suggested, cautiously, that the drop in oxytocin may contribute to interpersonal dysfunction (Jobst et al., 2015).

A larger cross-diagnostic Cyberball study compared 120 participants: 29 with chronic depression, 20 with episodic depression, 28 with borderline personality disorder and 43 healthy controls (Seidl et al., 2020). The chronic group rated the exclusion as more intense and more aversive than the episodic group did, and voiced a stronger wish to escape the situation. On most rating categories the groups were ordered borderline personality disorder, then chronic depression, then episodic depression, then controls, with the borderline group furthest from controls. The authors concluded that exclusion is likely more aversive for people with chronic depression, while noting that the study had no objective behavioural or biological measures and only moderate subgroup sizes (Seidl et al., 2020).

Mood induction has produced results that depend on the method. In two experiments with 15 patients with chronic depression and 15 healthy controls, a general induction using sad pictures and sad music lowered positive affect more in the controls than in the patients, and cognitive reactivity did not differ between groups (Guhn et al., 2018). Individualized autobiographical scripts reversed the pattern: the patients showed greater affective reactivity and more dysfunctional cognitions than controls. The authors took this to mean that activating personal memories is central to dysfunctional coping, but they acknowledged that the order of the two inductions was not counterbalanced, that causal inference is limited, and that a comparison with non-chronic depression is still needed (Guhn et al., 2018).

The same autobiographical approach has been applied to empathy. On the Multifaceted Empathy Test, 22 patients with persistent depressive disorder and 21 controls did not differ under neutral conditions, but the patients scored lower after recalling a negative personal event (Guhn et al., 2022). Fifteen patients were retested after a 12-week inpatient course of CBASP, and their empathy under stress had improved, in step with clinical improvement. The authors read the results as empirical support for the CBASP model, whose standing as a whole is contested (see The CBASP Model of Chronic Depression). Only the fifteen patients were retested (Guhn et al., 2022).

Theory-of-mind results conflict. Sixteen patients with early-onset chronic depression performed like sixteen matched controls on the Movie for Assessment of Social Cognition, yet rated their own empathy lower on the Interpersonal Reactivity Index; neither measure correlated significantly with therapists' structured ratings (Wilbertz et al., 2010). That study was small, and its controls were not rated by clinicians. In contrast, 30 chronically depressed patients performed markedly worse than 30 matched controls on two cartoon picture story tests and on neuropsychological tasks (Zobel et al., 2010). Once logical memory and working memory were taken into account, however, theory-of-mind scores no longer separated patients from controls, and the authors suggested that the deficit may be bound up with general cognitive performance (Zobel et al., 2010). Whether people with chronic depression have a specific theory-of-mind deficit therefore remains open. Most of these samples were labelled chronic depression rather than persistent depressive disorder or dysthymia; nearly all contain 15 to 30 patients per group and are cross-sectional, so a single null or positive result carries little weight on its own.

Daily-Life Measurement

Ecological momentary assessment prompts people repeatedly on a smartphone in everyday settings, which captures how states persist over time. Over five weeks, 58 inpatients with persistent depressive disorder and 42 healthy controls rated their loneliness on the movisensXS application, with adherence of 90.2% and 84.7% respectively (Wolf et al., 2026). The patients reported much higher mean state loneliness (44.3, SD = 17.4, against 10.9, SD = 13.0), stayed longer in high-loneliness states, and were about half as likely to leave such a state (HR = 0.50 [0.28, 0.89], p = 0.018). In the controls, momentary loneliness tracked trait loneliness on the UCLA Loneliness Scale (r = 0.47), whereas in the patients the association was weak and not significant (r = 0.21); the duration of emotional isolation related more closely to trait loneliness in patients than in controls. Recalled emotional neglect was associated with emotional isolation, while emotional abuse was not (Wolf et al., 2026).

The authors present these results as exploratory. The analysis was secondary and not preregistered, compared inpatients with community controls, relied on retrospective reports of adversity, had limited power and did not formally test mediation (Wolf et al., 2026). Daily-life data of this kind can check whether a pattern seen in a single laboratory session also appears in ordinary life.

Screening Against the Diagnostic Interview

Brief screening is a measurement question in its own right. Among 90 patients at a German depression clinic, 64% of whom met interview criteria for persistent depressive disorder, the persistent depression screener was checked against a structured clinical interview for DSM-5 (Brinkmann et al., 2019). It detected 85% of interview-confirmed cases, with a positive predictive value of 80%, but its specificity was only 63% and its negative predictive value 69%. Agreement with the interview was moderate (κ = .48, 95%-CI .28, .68), and agreement on retesting was similar (retest κ = .52; 80% retest agreement). Requiring more than 5 years of symptoms raised the Youden index from .48 to .56 but cut sensitivity to 59%. Its sensitivity was in line with that of typical screeners, but its specificity was below their usual range and below that of the PHQ-2 (78%). Because predictive values depend on prevalence, and the study used a single specialized clinic with a high proportion of cases, the authors judged the screener possibly useful only when a positive result is confirmed by interview (Brinkmann et al., 2019).

Placebo and Nocebo Rates as a Measurement Problem

Drug trials raise a measurement issue of their own, because the placebo arm sets the bar that the drug must clear. A meta-regression of twenty-three antidepressant trials in persistent depressive disorder pooled a placebo response rate of 31%, a placebo remission rate of 22%, adverse events in 57% of placebo-treated patients, and discontinuations attributed to them in 4% (Meister et al., 2017). These rates were comparable to those reported for episodic depression. Placebo response rose with the outcome in the medication arm, with trial size and with the share of early-onset patients, and fell as the chance of receiving placebo increased. The analyses were univariate only, and the number and quality of the trials limit them; the authors advised that such modifiers be taken into account when estimating unbiased drug effects (Meister et al., 2017).

The Biology of Persistent Depressive Disorder

Biological work on long-lasting depression is thin, and most of it predates the current category. The studies below recruited people their authors described as having chronic major depression, persistent depression or dysthymia, and each label is kept as the investigators used it, because none of these samples was diagnosed with persistent depressive disorder (PDD) as now defined. The subsections take the stress-hormone system, immune and endocrine markers, a neurotrophic factor and genetics in turn, then state where the evidence stands as a whole.

Stress Hormones

On the stress-hormone side of psychological stress biology, hypothalamic-pituitary-adrenal (HPA) axis function looked largely normal in people with long-standing depression. Two challenge tests, the combined dex/CRH test and the dexamethasone suppression test, were given in a case-control study to twenty-nine patients whose major depressive disorder was of the chronic subtype and to 28 matched controls (Watson et al., 2002). Cortisol responses did not differ significantly between the groups on either test. Abnormal dex/CRH responses were somewhat more frequent among patients, but only at trend level (P = 0.052), and the dex/CRH test was the more sensitive of the two procedures. No illness or demographic variable predicted which patients showed an enhanced response or how large it was (Watson et al., 2002). The sample was defined as chronic major depression rather than dysthymia or PDD, and it was small, so the result shows only that HPA abnormality was not a reliable feature of this group.

Immune and Endocrine Markers

Inflammatory signalling has one direct test in dysthymia. A clinical group comparison set people with typical major depression, atypical depression and dysthymia against healthy controls, measuring interleukin output from mitogen-stimulated lymphocytes together with plasma ACTH, cortisol and norepinephrine (Anisman et al., 1999). Interleukin-1beta was higher in the dysthymia group than in controls, whatever the patient's symptom profile. Interleukin-2 production, by contrast, was lower in every depressive group, with the smallest reduction among the atypical major depressives, and higher plasma norepinephrine went with greater interleukin-2 production. The atypical group also stood apart on the endocrine side, with more ACTH and less cortisol than controls (Anisman et al., 1999).

The link to chronicity is the tentative part. Interleukin-1beta correlated highly with age of onset and with illness duration, but the authors treated that connection as provisional, and neither depressed mood itself nor neurovegetative features accounted for the cytokine alterations (Anisman et al., 1999). Their conclusion was hedged accordingly: interleukins may play a part in certain subtypes of depression. No later study in this section's evidence repeats the dysthymia finding, so it stands as a single-sample result.

Neurotrophic Factor

Serum brain-derived neurotrophic factor (BDNF) offers the only longitudinal evidence here. A cohort of 1751 depressed and non-depressed individuals was followed for two years and sorted by course: incident depression (n=153), remitted depression (n=420), persistent depression (n=310) and controls (n=868) (Bus et al., 2015). Course group predicted the change in serum BDNF (P=0.007). Relative to controls, BDNF fell further in the persistent group (-1.33 ng ml(-1), P=0.001) and also in the remitted group (-0.97 ng ml(-1), P=0.011), while people with a new onset declined about as much as controls. Starting or stopping antidepressants did not significantly alter the change (P=0.72) (Bus et al., 2015).

Two cautions limit how far this reaches. The persistent group was a course category within the cohort, not a sample diagnosed with dysthymia or PDD, and the steeper decline was shared by people whose depression had remitted, so it does not single out persistence. The authors read the pattern as a relation between BDNF and depression that is possibly bidirectional, and they noted that only longitudinal designs can separate state from trait effects (Bus et al., 2015).

Genetics and Family Studies

The one genetic association specific to dysthymia comes from circadian clock genes. A population-based association study genotyped 5910 Finnish adults aged 30 and over (3283 women, 2627 men) at 48 SNPs in CRY1, CRY2 and TTC1, with diagnoses from the Munich-Composite International Diagnostic Interview; the analysis compared 136 dysthymia cases and 267 major depressive disorder cases against 3871 controls (Kovanen et al., 2013). After false discovery rate correction (q<0.05), carriers of risk alleles at several CRY2 variants had higher odds of dysthymia, with odds ratios near 1.7 (rs10838524, OR = 1.75, p = 0.000020). Under a dominant model the same variant gave OR = 3.27, and in women analysed separately it was associated with dysthymia under the additive model (OR = 1.97). CRY1 and TTC1 variants were not significantly associated with any phenotype, and CRY2 and TTC1 showed no significant interaction. The authors concluded that CRY2 probably plays a role in mood disorders (Kovanen et al., 2013).

Family data place dysthymia close to major depression without merging the two. Relying on direct and informant interviews plus medical records, a family study assessed 882 first-degree relatives drawn from three proband groups: 45 normal controls, 45 outpatients with episodic major depression, and 97 with early-onset dysthymia (Klein et al., 1995). Major depression was more common among relatives of dysthymic probands than among relatives of controls; against relatives of episodic major depression probands the difference was not significant. Dysthymia itself was more frequent in relatives of dysthymic probands than in either comparison family. Relatives of both patient groups had more personality disorders than control relatives, and the excess of any personality disorder and of cluster B disorders in dysthymic families over episodic families vanished once probands' own Axis II comorbidity was controlled. Whether a dysthymic proband also had a lifetime history of major depression made no difference to relatives' rates. The authors read this as a strong familial tie between the two conditions, with dysthymia somewhat distinct (Klein et al., 1995).

Genes may also act through the environment. In 273 risk-enriched women, the 5-HTTLPR variant moderated the link between childhood maltreatment and chronic depression, though not new onsets, and the short allele was proposed as possibly sensitizing (Brown et al., 2013). That study, with its retrospective measure of maltreatment, is covered under Childhood Maltreatment and Early Adversity.

Standing of the Biological Evidence

Each system above rests on a single study in this section's evidence, and several samples were defined as chronic major depression or persistent depression rather than dysthymia or PDD. Some of the results are negative or shared with other forms of depression: HPA function was largely normal in chronic major depression (Watson et al., 2002), the steeper BDNF decline also followed remission (Bus et al., 2015), and the familial loading of dysthymia overlaps with that of major depression (Klein et al., 1995). The associations most specific to dysthymia, for CRY2 variants (Kovanen et al., 2013) and for interleukin-1beta (Anisman et al., 1999), are not repeated by any other study cited here.

Sleep

Early researchers hoped disturbed sleep might give them a biological marker that could tell chronic low-grade depression apart from personality pathology. Almost all of the work used all-night electroencephalographic (EEG) recording, or polysomnography. It is old and small, and its samples were defined by DSM-III or earlier criteria under the labels dysthymia or characterological depression, not persistent depressive disorder. Its main measure is REM latency: the time from falling asleep to the first period of rapid eye movement (REM) sleep.

Sleep EEG in Dysthymia

The first claim was that sleep could split a mixed group. In a clinical and sleep EEG study, Akiskal and colleagues divided patients with characterological depression into two subtypes (Akiskal et al., 1980). In the subtype they called subaffective dysthymia, REM latency was shorter than normal. These patients also had more superimposed depressive episodes and responded better to tricyclic antidepressants or lithium. The other subtype, character spectrum disorders, had more alcohol and drug abuse and a worse outcome. The short REM latency was one of the features that set the subtype resembling a mood disorder apart from the characterological one (Akiskal et al., 1980).

The same group later used polysomnography within the atypical depressions. They compared 20 patients with primary dysthymia, 22 with anxious depression and 11 controls (Akiskal et al., 1984). On the first night, the anxious group showed a lower REM percentage and a longer REM latency than the dysthymic group, and lower sleep efficiency than both other groups. On the second night it had more awakenings. Clinical sleep complaints split the same way: 82% of the anxious patients had insomnia, while hypersomnia was more common among the dysthymic patients. Beck and MMPI depression scores did not differ significantly between the two patient groups, so the sleep measures separated groups that symptom scales did not. The authors concluded that the subtypes seemed distinguishable. The groups were small, and although differences tended to be minimized on the second night, the dysthymic patients still had the highest REM percentage and the shortest REM latency on both nights, despite clinical overlap in depressive symptoms (Akiskal et al., 1984). This study compared REM latency between the two patient groups, not between dysthymia and controls.

A 1997 review of clinical and polysomnographic studies extended the claim to subthreshold depression as a whole (Akiskal et al., 1997). It linked subthreshold depressions to shortened REM latency. It also reported that REM disturbance was a consistent feature of subthreshold affective conditions but not of personality or anxiety conditions without an affective basis. The same review found that characterological depression predicted later major affective episodes and a response to antidepressants and to sleep deprivation, and that neurotic depression predicted a later melancholic, psychotic or bipolar course (Akiskal et al., 1997).

Recordings by another group did not find the REM abnormality. Arriaga and colleagues ran a case-control study of patients with DSM-III dysthymia and normal controls, with all-night EEG after two weeks on placebo (Arriaga et al., 1990). The patients spent a larger share of the night in stage 1 sleep and had less slow-wave sleep, a lower stage 4 percentage and more of some EEG events. That profile is sleep that is fragmented and shallow, and REM sleep was no different from the controls'. The authors noted that the classification of minor depression was contested and discussed what their results meant for it (Arriaga et al., 1990).

A second case-control study added a comparison group with generalised anxiety disorder (Arriaga & Paiva, 1990). Primary dysthymia and generalised anxiety disorder both showed less slow-wave sleep than controls, and the two disorders did not differ in sleep architecture. The dysthymic patients showed no REM disturbance and matched controls on sleep duration and continuity. The anxious patients had more features of insomnia, and subjective sleep quality showed no relevant difference between the two patient groups. On conventional sleep parameters, the authors placed dysthymia closer to anxiety. They cautioned that the loss of slow-wave sleep may have different causes in the two disorders and that less conventional measures might separate them (Arriaga & Paiva, 1990).

Treatment and Sleep

Evidence on treatment and sleep comes from one small trial, and its sample was described as chronically depressed, not diagnosed with persistent depressive disorder or dysthymia. Twenty-five patients were randomly assigned to Mindfulness-based Cognitive Therapy (n = 9), the Cognitive Behavioral Analysis System of Psychotherapy (CBASP; n = 8) or treatment as usual (n = 8). Sleep was measured by cardiopulmonary coupling analysis (Schramm et al., 2016). After CBASP, patients had more stable sleep than with treatment as usual (p = 0.044), and less wake time than with treatment as usual (p = 0.004) or mindfulness-based therapy (p = 0.039). With eight or nine patients per arm, the result is preliminary. The therapy itself is described under The CBASP Model of Chronic Depression.

Returning to the EEG studies, the REM findings conflict, and the conflict remains open. Akiskal's group reported shortened REM latency in subaffective dysthymia and across subthreshold depressions. Arriaga's recordings found REM sleep unchanged in DSM-III dysthymia and a sleep profile closer to generalised anxiety disorder, with reduced slow-wave sleep the shared abnormality. The two programmes defined their samples differently: one sorted subaffective dysthymia from character spectrum disorders, the other used DSM-III dysthymia. Which pattern holds for persistent depressive disorder as it is now defined has not been settled.

Brain Networks and Imaging

Brain imaging of persistent depressive disorder rests on a small number of small studies. Each recruited a few dozen people at most, and the samples carry different labels: some were diagnosed with dysthymia or dysthymic disorder, others with chronic depression or chronic major depressive disorder. The far larger imaging literature on episodic major depression is covered on the major depressive disorder page and is not summarised here. What follows is limited to studies whose participants had dysthymia or chronic depression.

Resting-State Default Mode Connectivity

The most cited of these studies concerns the default mode network. Using resting-state functional-connectivity MRI, Posner and colleagues compared 41 adults with dysthymic disorder, aged 18 to 53 years, against 25 healthy controls, and found greater connectivity within this network in the patient group at baseline (Posner et al., 2013). The same patients then entered a 10-week randomised trial of duloxetine against placebo. Connectivity moved back toward the control pattern in the duloxetine arm, while no such normalisation appeared under placebo. The authors proposed, with a hedge, that default mode hyperconnectivity may underlie chronic depression. Two limits apply: the participants were volunteers, and only 32 of the 41 completed the trial. The trial itself is discussed under Medication.

Mood Induction Studies

A second design asked what happens in the brain when sadness is provoked rather than measured at rest. Ravindran and colleagues scanned 17 unmedicated patients with dysthymia and 17 matched control participants with fMRI while they viewed pictures from the International Affective Pictures System (Ravindran et al., 2009). Relative to controls, the patients showed weaker activation in the dorsolateral prefrontal cortex and stronger activation in the amygdala, the anterior cingulate and the insula, and these group differences were larger for negative images than for positive ones. The authors took the pattern as evidence that this circuitry is involved in dysthymia. The study combined early- and late-onset patients, imaged each person once, and its authors cautioned that the results may not generalise widely.

Renner and colleagues joined the two approaches, recording resting-state fMRI before and after a sad mood induction set to Adagio for Strings (Renner et al., 2017). Their 18 patients were diagnosed with chronic major depressive disorder, not dysthymia, and were compared with 18 matched controls. Before the induction, default mode connectivity was already higher in the patients. Compared with controls, patients showed stronger posterior cingulate coupling after it with three regions (the parahippocampal gyrus, the anterior inferior temporal cortex and the superior temporal gyrus) and weaker coupling with two others, the precuneus and the anterior prefrontal cortex. Self-rated mood fell in both groups, slightly more in controls, but that group difference was not significant (p = 0.057). The authors suggested that the altered coupling may reflect a failure of cognitive control. The caveats are substantial: the sample was small and mostly female, about half the patients were taking antidepressants, there was no clinical comparison group, the analysis applied no false discovery rate correction, cognitive reactivity was not measured, and the precuneus change in patients was only marginal.

Imaging Before and After Psychotherapy

One study imaged patients before and after psychotherapy. Klein and colleagues scanned ten patients with chronic depression, alongside healthy controls, before and after 12 weeks of the Cognitive Behavioral Analysis System of Psychotherapy (CBASP), using a task that presented emotional faces under both implicit and explicit processing conditions (Klein et al., 2014). Sixty per cent of the patients responded to treatment. During implicit processing, reactivity of the left amygdala was higher after treatment than at baseline, whereas the cingulum showed no significant change. With ten patients and no comparison treatment, the study cannot say whether the change was specific to CBASP; the therapy itself is described under The CBASP Model of Chronic Depression.

Imaging in Children

The one paediatric imaging study reviewed here scanned 19 boys with dysthymic disorder, mean age 11.2 years, and 16 typically developing boys, mean age 10.5 years, in a single cross-sectional fMRI session (Vilgis et al., 2014). During a mental rotation task the boys with dysthymic disorder activated left frontal and medial frontal regions less than controls did. During a delay-match-to-sample task, which loads spatial working memory, they activated the right precuneus and posterior cingulate more. The authors read the results as placing the pathophysiology of dysthymic disorder on a continuum with that of major depression across the lifespan, and they noted that the small, cross-sectional sample limits how far the findings generalise.

What the Imaging Shows

Taken together, these five studies report altered default mode connectivity and differences in prefrontal and limbic activity in dysthymia and chronic depression. Each is small, and whether these patterns cause persistence, accompany it or follow from it remains open.

Comorbidity

Persistent depression seldom arrives alone. The studies below concern co-occurring anxiety disorders, episodes of major depression layered on a chronic course, personality disorders, physical illness and late-life dementia, and most of them were run before DSM-5 merged dysthymia and chronic major depression into a single category. Each paragraph therefore names the label the original sample carried: dysthymia (or dysthymic disorder), chronic major depression, double depression, or persistent depressive disorder (PDD).

Anxiety and Other Psychiatric Disorders

Anxiety disorders are the companions that clinical interviews find most often. Additional Axis I diagnoses were common among 260 patients with depressive disorders who were assessed at a single time point with the Structured Clinical Interview for DSM-III-R, and the most frequent of them were anxiety disorders (Sanderson et al., 1990). The sample spanned depressive disorders in general, so the study describes the comorbidity of depression broadly rather than that of dysthymia in particular.

Early adversity may help explain which companion disorder appears. Harkness and Wildes interviewed 76 women with DSM-IV major depression, 28 of whom also had an anxiety disorder and 21 of whom also had dysthymia, and rated their childhood histories with a contextual interview system (Harkness & Wildes, 2002). Severe sexual abuse, the strongest predictor, and severe psychological abuse were linked to comorbid anxiety, whereas severe physical abuse was linked to comorbid dysthymia; indifference and antipathy were linked to both. The authors concluded that different forms of adversity may confer distinct vulnerabilities to particular comorbidity patterns. The design was cross-sectional, the volunteers were all women, and the cognitive processes that might connect each kind of adversity to each disorder were left for future research. The section Childhood Maltreatment and Early Adversity covers this literature in full.

Major Depression Within a Chronic Course

Dysthymia and major depression frequently co-occur, and they co-occur more strongly in the young. A community epidemiological survey of 1,710 adolescents and 2,060 adults put the lifetime odds ratio for having both disorders at 3.4 among adolescents and 1.6 among adults (Lewinsohn et al., 1991). Among participants with a depressive disorder, about 80% had major depression alone, 10% had dysthymia alone and 10% had both, the combination later called double depression. When both were present, dysthymia preceded the major depressive episode more often than it followed it, and an early depressive onset predicted that ordering. A history of depression predicted other psychiatric disorders, yet rates of those other disorders did not differ significantly among the major-depression-only, dysthymia-only and combined groups. The type of a first depressive disorder did not significantly predict the type of a second.

The national picture in the United States points the same way. In the National Epidemiologic Survey on Alcohol and Related Conditions, a cross-sectional survey of 43,093 adults interviewed in 2001 and 2002, chronic major depressive disorder was more prevalent than dysthymic disorder (1.5% against 0.5% over 12 months; 3.1% against 0.9% over the lifetime) and more often treated, but Axis I and Axis II comorbidity was nearly the same in the two, and they shared most of their sociodemographic correlates (Blanco et al., 2010). Dysthymic disorder stood out as especially undertreated.

A German study compared persistent and non-chronic major depression directly. Its population arm, 4,408 adults interviewed with the Composite International Diagnostic Interview, was paired with 45 PDD inpatients (Nübel et al., 2020). Among the population respondents with lifetime major depression, 36.5% had a chronic course. The PDD group showed only a trend towards more comorbid mental disorders than the non-chronic group (p = 0.071), short of significance. Taken together, these three studies do not show that a persistent course carries more psychiatric comorbidity than an episodic one: the German comparison of PDD with non-chronic major depression found only a trend, and the American survey compared two chronic subtypes with each other.

Personality Disorders

Personality disorders are the clearest point of difference. In a cross-sectional interview study of outpatients, 60% of the 97 patients with early-onset dysthymia met DSM-III-R criteria for at least one personality disorder, against 18% of the 45 with episodic major depression, and interviews with informants gave a similar result (Pepper et al., 1995). The authors could not say what processes produce the association.

One personality disorder has drawn particular attention. Among 279 outpatients at a psychotherapy centre, a sample defined by chronic depression rather than by PDD or dysthymia, avoidant personality disorder was associated with a chronic course (Klein et al., 2015). None of the Childhood Trauma Questionnaire short-form scales predicted chronicity significantly by itself. Emotional abuse, however, was associated with avoidant personality disorder, and the two interacted in predicting chronic depression. The authors called this interaction tentative, because the trauma reports were retrospective and a prospective study is still needed. The section Personality, Temperament and Persistence discusses these findings alongside the temperament research.

Physical Illness, Dementia and Mortality

Persistent depression also travels with bodily illness. In the German population sample, people with PDD were more likely than those with non-chronic major depression to report two or more somatic conditions (relative risk ratio 3.2, p = 0.004), although the two groups did not differ significantly on the physical component of the Short Form Health Survey-36 (Nübel et al., 2020). The authors noted that the design was cross-sectional, that many respondents left episode duration unanswered, and that some differences held only in unadjusted analyses.

Late-life dysthymia carries measurable risk over time. A retrospective cohort study drew on the Veterans Affairs records of 281,540 veterans aged 55 and older between 1997 and 2007, with diagnoses taken from ICD-9 codes (Byers et al., 2012). About 1% had dysthymia at baseline and 10% had depression. Compared with veterans who had neither, those with dysthymia were more likely to develop dementia (hazard ratio 1.96, 95% CI 1.71-2.25) and to die during follow-up (hazard ratio 1.41, 95% CI 1.31-1.53), figures close to those for depression (2.18 for dementia, 1.47 for death). Dementia developed in 10.2% of the dysthymia group, 11.2% of the depression group and 6.4% of those with neither. The authors judged that older adults with these conditions warrant close monitoring, but whether treatment changes the risk was not tested.

Sex Differences in Chronic and Double Depression

Sex shapes the presentation of chronic depression more in degree than in kind. At the baseline of a clinical trial, Kornstein and colleagues compared 235 men and 400 women outpatients with chronic major depression or double depression (Kornstein et al., 2000a). The women were less often married, had an earlier onset and a more frequent family history of affective disorder, and reported more sleep change, psychomotor retardation, and anxiety and somatization, with greater overall severity, more prior treatment and more marital impairment. The men reported more impairment at work. Symptom profiles were otherwise mostly alike, and the authors suggested that chronicity may weigh more heavily on women. Because the participants were trial enrollees, the trial's exclusion criteria may have shaped the differences observed.

Suicide and Self-Harm

Long-lasting depression carries a real risk of suicide, and the evidence on how large that risk is, compared with shorter-lived depression, is mixed. This section sets out what the studies found and where they disagree.

Chronic Compared with Nonchronic Depression

A review of the chronic forms of non-bipolar depression found that, set beside nonchronic depression, they differ in suicidality, comorbidity and impairment (Klein, 2010). The same review found the chronic forms differ little from one another and suggested they could possibly be merged into a single category, though it also noted that the evidence on subtyping is still growing (Klein, 2010). A large Canadian community survey of 36 984 people aged 15 and older pointed the same way: respondents whose major depressive disorder was chronic reported more suicidal ideation and more suicide attempts than those whose depression was nonchronic (Satyanarayana et al., 2009). That survey's group was labelled chronic major depression, not PDD or dysthymia, and its single time point cannot show which came first (Satyanarayana et al., 2009).

Dysthymia, Recurrent Depression and Suicide Risk

Studies that separate dysthymia from episodic depression do not agree. In a five-year prospective follow-up of outpatients with early-onset dysthymia or episodic major depression, suicide attempts were more frequent in the dysthymia group, as were hospitalisations (Klein et al., 2000). A cross-sectional study of 494 outpatients at one university clinic came to a different answer. A cluster analysis split the sample into a higher-risk and a lower-risk group, and only recurrent major depression predicted membership of the higher-risk cluster (OR = 3.54), while dysthymia (OR = 1.29, p = .50) and single-episode depression did not (Witte et al., 2009). In that sample people with dysthymia did not differ from non-depressed patients; double depression looked similar to recurrent depression, but the group was small and the confidence intervals wide, so the result was not significant (Witte et al., 2009). The authors noted that their sample carried relatively low suicide risk, that the cluster solution needs replication and that they had no data on suicide deaths (Witte et al., 2009).

The two designs differ: one followed patients for five years, the other measured current risk once in a lower-risk clinic sample. No study reviewed here settles the conflict, so whether dysthymia on its own raises suicide risk beyond episodic depression remains open.

Risk Factors for Suicide Attempts in Chronic Depression

One study examined which factors went with a history of suicide attempts among 368 chronically depressed adults seeking psychotherapy (Ernst et al., 2020). The sample was labelled chronic depression rather than PDD. Past attempts were more likely where depression was more severe and had lasted more years, and where a person reported sexual abuse, had a personality disorder, had interpersonal problems or had harmed themselves before; comorbid anxiety disorders and PTSD were not significant predictors (Ernst et al., 2020). The design was cross-sectional, some risk factors from earlier work did not replicate, and the authors suggested that risk factors might vary by diagnosis (Ernst et al., 2020).

Anyone who is thinking about suicide can get help now, for example from the 988 Suicide & Crisis Lifeline in the United States or a local emergency service; the Support Organizations section lists further services.

Psychological Treatments

Most controlled trials of talking treatment for long-lasting depression have tested one approach, the Cognitive Behavioral Analysis System of Psychotherapy (CBASP), whose account of chronic depression is set out in The CBASP Model of Chronic Depression. A smaller literature has tested interpersonal, cognitive-behavioural, psychoanalytic, problem-solving and supportive approaches, often in samples defined as dysthymia rather than as chronic major depression. Many of these trials predate the persistent depressive disorder category, so the label each one used is given below.

CBASP Against Medication and Combined Treatment

Combining CBASP with medication worked better than either treatment on its own in the largest early trial. Keller and colleagues randomised 681 adults with chronic nonpsychotic major depression, a sample defined as chronic major depression rather than dysthymia, to 12 weeks of nefazodone (up to 600 mg per day), 16 to 20 sessions of CBASP, or both (Keller et al., 2000). Overall response (remission or satisfactory response) reached 73 percent with the combination against 48 percent in each single-treatment arm (P<0.001), so the two monotherapies did equally well; among the 519 completers the figures were 85 percent for the combination, 55 percent for nefazodone and 52 percent for CBASP (Keller et al., 2000). Raters did not know which treatment a patient had received, and withdrawal rates were similar across the arms, although nefazodone brought side effects such as headache and somnolence (Keller et al., 2000).

Switching treatments helped patients whose depression had not responded. In a 12-week crossover study of 140 outpatients with chronic major depression at 12 centres, 61 moved to CBASP and 79 to nefazodone (Schatzberg et al., 2005). On an intention-to-treat basis, 57% of those switched to CBASP responded against 42% of those switched to the drug, but among completers neither response nor remission differed significantly; more of the nefazodone group left the study (22 against 8 dropouts), with adverse events accounting for more of the attrition there (Schatzberg et al., 2005). The authors judged that moving a medication non-responder to psychotherapy appears useful, and noted that no controlled switch trial had been run before (Schatzberg et al., 2005).

Adding psychotherapy to medication did not help in the trial the field calls REVAMP (Kocsis et al., 2009). Of 808 people with chronic depression who began 12 weeks of medication across 8 sites, 491 who had not responded or had only partly responded went on to a second 12-week phase, randomised in a 2:2:1 ratio to medication plus CBASP (200), medication plus brief supportive psychotherapy (195) or continued medication alone (96) (Kocsis et al., 2009). Remission and response did not differ among the three arms, and medication plus either psychotherapy did no better than medication alone on the categorical outcomes (P = .39) (Kocsis et al., 2009). The authors called the findings essentially negative and listed possible reasons: an academic-centre sample, a design that may have weakened motivation for psychotherapy, and a course that may have been too short (Kocsis et al., 2009).

Pooled individual-patient data later backed the combination. A network meta-regression of 1,036 participants from 3 randomised trials of persistent depressive disorder found that CBASP plus medication beat either treatment alone on both efficacy and acceptability, while CBASP and medication alone came out essentially similar (Furukawa et al., 2018). Baseline features such as severity, anxiety, prior medication and age changed how the options compared, which the authors took as a basis for individual treatment recommendations, delivered through an interactive web app; the analysis rested on only three studies (Furukawa et al., 2018).

What the combined-treatment advantage means in practice

Choose the sample and set how many patients are treated to see the response rates and the extra responses the combination would add.

Nefazodone48%CBASP48%Combination73%
Combination minus the better single treatment25 percentage points
Number needed to treat for one more responseabout 4.0
Extra responses among 100 patientsabout 25
Response rates from Keller et al. (2000), a 12-week trial in adults with chronic major depression; the differences, numbers needed to treat and counts are arithmetic on the reported rates, not reported figures.

CBASP Against Other Psychotherapies

The best test of whether CBASP does more than general therapeutic support gave it a modest edge that did not last. A multicentre, evaluator-blinded trial randomised 268 outpatients with early-onset chronic depression who were taking no antidepressant to CBASP (137) or supportive psychotherapy (131), with 24 sessions over 20 weeks and 8 continuation sessions over the next 28 weeks (Schramm et al., 2017). On the 24-item Hamilton scale, CBASP patients scored 2.51 points lower at 20 weeks (Cohen d of 0.31, P = .003) and 3.13 points lower at 48 weeks (d = 0.39, P = .001); response was 38.7% against 24.3% and remission 21.8% against 12.6%, though some secondary outcomes did not differ (Schramm et al., 2017). By the two-year mark, when 207 participants (77%) were followed up, neither remission nor well weeks (rate ratio 1.26; confidence interval 0.99 to 1.59; p = 0.057) separated the groups significantly (Schramm et al., 2019). CBASP's lead held at one year, significantly so for well weeks, self-rated depressive symptoms and quality of life related to depression, while the remission gap (40% against 28.9%) fell short of significance; in the authors' reading, its advantage was gone by some point between year one and year two (Schramm et al., 2019).

A pilot comparison with interpersonal psychotherapy pointed the same way but was too small to settle anything. Thirty patients with early-onset chronic depression received 22 sessions over 16 weeks; the primary Hamilton outcome did not differ, but remission was 57% with CBASP against 20% with IPT and self-rated depression on the Beck Depression Inventory favoured CBASP after treatment, a difference that had gone by one year (Schramm et al., 2011). The authors called this preliminary evidence, citing the small sample and the lack of a placebo condition (Schramm et al., 2011).

Against care as usual, the CBASP advantage was slow and borderline. In a Dutch trial at 3 outpatient clinics, 139 people with chronic depression, whose diagnoses included both dysthymic disorder and major depressive disorder, received CBASP or usual care, with algorithm-based medication in both arms (Wiersma et al., 2014). Self-rated symptoms did not differ at weeks 8, 16 or 32, and CBASP pulled ahead only at week 52 (t = -2.00, p = 0.05), which led the authors to suggest it is at least as good as standard care and may pay off in the long run (Wiersma et al., 2014). A German two-centre trial added either CBASP or mindfulness-based cognitive therapy (MBCT) to treatment as usual for 106 patients whose symptoms had lasted more than 2 years (Michalak et al., 2015). After 8 weeks CBASP reduced symptoms more than treatment as usual at both sites, whereas MBCT showed no overall benefit and helped at only one of the two sites; both added treatments improved social functioning, with small to medium effects (Michalak et al., 2015). The authors suggested that the interpersonal focus of CBASP may explain its edge (Michalak et al., 2015).

A meta-analysis of 6 randomised trials covering 1,510 chronically depressed patients found that CBASP outperformed its comparison conditions with a small pooled effect (Hedges' g about 0.34 to 0.44) (Negt et al., 2016). It matched antidepressant medication, gained when added to medication, and did not differ from MBCT; the pooled effect was smaller than those reported for CBT and IPT, and higher treatment dosage looked like it might increase the benefit (Negt et al., 2016). The review was limited by few trials, varied designs, possible publication bias and only one study with follow-up, but its authors still read the results as support for CBASP in chronic depression (Negt et al., 2016).

Other Psychotherapies in Dysthymia and Chronic Depression

Across psychotherapy more broadly, the benefit in chronic depression and dysthymia is real but small. In a meta-analysis of 16 randomised trials, psychotherapy beat control conditions (d = 0.23) but trailed pharmacotherapy in direct comparisons (d = -0.31), a gap wholly attributable to the dysthymic patients; combined treatment beat medication alone (d = 0.23) and psychotherapy alone (d = 0.45) (Cuijpers et al., 2010). Effects grew with session number, at least 18 sessions apparently being needed; the authors judged psychotherapy effective but probably less so than SSRIs, cautioning that the dysthymia trials were the same ones that tested SSRIs and that dysthymic samples confounded the combined-versus-psychotherapy contrast (Cuijpers et al., 2010).

Most head-to-head trials of interpersonal psychotherapy favoured medication. In 94 patients with early-onset dysthymic disorder treated for 16 weeks, response was 58% with sertraline, 57% with sertraline plus IPT, 35% with IPT and 31% with brief supportive psychotherapy, putting the sertraline arms ahead, though the trial was underpowered and lacked follow-up data (Markowitz et al., 2005). In Ontario primary care, a single-blind trial with naturalistic follow-up assigned 707 adults with dysthymia to sertraline, to 10 IPT sessions or to the two together, and 586 of the 707 were assessed at 6 months; the sertraline and combined arms outperformed IPT alone on response at 6 months and on symptoms at 2 years (P = 0.03), and while pairing IPT with sertraline added no symptom benefit, it trimmed the 2-year bill for health and social services by $480 per person (Browne et al., 2002). The exception came from 45 inpatients with chronic major depression: over 5 weeks, intensive IPT plus medication beat clinical management plus medication, with completer remission of 67% against 32%, and 12-month relapse of 7% among initial IPT responders against 25% of the clinical-management patients, though attention was unequal and the result may not carry over to outpatients (Schramm et al., 2008).

Cognitive-behavioural and problem-solving formats show the same pattern. In a 12-week double-blind trial of 97 patients with primary dysthymia, sertraline beat placebo on symptoms and functioning, group cognitive behaviour therapy alone did not significantly beat placebo on depression scores, and adding it to sertraline mostly matched sertraline alone on functional impairment, with an advantage on some functional measures (Ravindran et al., 1999). Among 415 older primary-care patients (mean age 71 years), 211 with dysthymia, paroxetine beat placebo on symptom resolution, while problem-solving treatment did not differ significantly from placebo overall despite faster late-week improvement (Williams et al., 2000). In dysthymia, paroxetine improved mental health functioning at high or intermediate baseline functioning and problem-solving treatment did not, its results also varying by site (Williams et al., 2000).

Longer treatment and support outside formal therapy have also been tested. In 252 chronically depressed adults allocated by preference or at random, long-term psychoanalytic therapy and CBT did not differ, nor did the two allocation methods (Leuzinger-Bohleber et al., 2019). Scores on the Beck Depression Inventory dropped by 12.1 points in year one and by 17.2 points across 3 years, while remission by that measure climbed from 34% to 45%; the d values of 1.17 and 1.83 index change since baseline rather than any gap between the two therapies (Leuzinger-Bohleber et al., 2019). The ProCEED trial randomised 558 patients with chronic depression or dysthymia at 42 UK general practices to proactive practice-nurse care or usual care for 2 years (Buszewicz et al., 2016). Social and work functioning improved by 2.5 points (P = 0.010), but the 1.2-point BDI-II symptom gain (P = 0.125) was not significant; more sessions attended went with larger symptom reduction, and only 65% completed follow-up (Buszewicz et al., 2016). Against a waiting list, befriending raised one-year remission among women with chronic depression in inner London; given restricted intake conditions, the authors called it not unpromising and asked for further trials (Harris et al., 1999).

Guidance

A guidance paper built on a systematic search and expert consensus recommended combined psychotherapy and medication as the first-line treatment for chronic depression, noting that chronic depression responds less well to psychotherapy than episodic depression (Jobst et al., 2016). Its authors also noted that ICD-10 has no category for chronic depression, that longer-term research is needed and that which patients benefit from which treatment is still unclear (Jobst et al., 2016).

On the question of psychotherapy against medication, the evidence has reached a qualified position. A random-effects meta-analysis of twenty-eight studies (n=3,381), most of them in unipolar depression in general, found the two treatments equivalent at the end of treatment and found psychotherapy ahead at follow-up, with a small advantage for medication in dysthymia drawn from few studies (Imel et al., 2008). The meta-analysis of chronic depression and dysthymia likewise put psychotherapy alone behind pharmacotherapy, a gap it attributed wholly to the dysthymic patients (Cuijpers et al., 2010). Taken together, medication has had a small edge over psychotherapy alone in dysthymia (Imel et al., 2008; Cuijpers et al., 2010), while in pooled data from three trials of persistent depressive disorder combining CBASP with medication did better than either alone and the two monotherapies came out essentially similar (Furukawa et al., 2018).

How the Psychological Treatments Work

Knowing that a therapy helps is not the same as knowing why. The studies below ask which processes change alongside improvement and which patient characteristics change who benefits from which treatment. Almost all of them are secondary analyses of trials designed for another purpose, and almost all recruited patients described as chronically depressed or as having chronic major depression rather than diagnosed with persistent depressive disorder or dysthymia. The treatments themselves, and the trials that compared them, are covered in Psychological Treatments; the model behind the cognitive behavioral analysis system of psychotherapy (CBASP) is set out in The CBASP Model of Chronic Depression.

The Therapeutic Alliance

The working relationship between patient and therapist, the therapeutic alliance, is the best-studied candidate process. A secondary analysis of a randomized trial in 395 chronically depressed adults had alliance ratings for 224 of them, collected on the Working Alliance Inventory-Short Form at week 2 or week 4 of 16 to 20 sessions of psychotherapy added to continued medication after a 12-week pharmacotherapy phase (Arnow et al., 2013). Mixed models showed that patients who reported a stronger alliance early on had lower Hamilton Rating Scale for Depression scores later, in both CBASP and brief supportive psychotherapy (F(1, 1236) = 62.48, p < .001). The link was stronger in CBASP than in the supportive condition (F(1, 1234) = 8.31, p = .004), the reverse of what the authors had expected, and they read the result as evidence that alliance predicts outcome across quite different therapies (Arnow et al., 2013). The sample was 57% female, with a mean age of 46, and 91% Caucasian, which limits how far the pattern can be generalised.

Interpersonal Change

CBASP aims to change how patients come across to other people, so its trials have measured the impact a patient makes on others. In 259 chronically depressed patients from a clinical trial, those whose hostile-submissive impact on others, rated with the Impact Message Inventory, declined during treatment showed larger falls in depression (γ = 0.27, 95% CI [0.11, 0.43]) and were more likely to respond (Constantino et al., 2012). The analysis pooled the CBASP and combined-treatment conditions, which did not differ, so it says nothing about the supportive or medication-only arms. The authors described the result as consistent with CBASP theory but only suggestive.

A later analysis of 220 patients from the same two conditions joined the alliance and interpersonal findings into one pathway (Constantino et al., 2016). A stronger early alliance was followed by a larger decrease in clinician-rated hostile-submissiveness, and that decrease was in turn associated with lower depression at the end of treatment. The bootstrapped indirect effect was small, and its confidence interval stopped just short of zero (B = -.02, 95% CI: -.07, -.001); treatment condition did not moderate it. Like the earlier study, it drew on a subsample of a larger trial.

Core Beliefs in Schema Therapy

Schema therapy targets long-standing negative beliefs about the self. A single-case series of 20 patients with chronic major depressive disorder tracked idiosyncratic core beliefs and symptoms with repeated weekly assessments and mixed regression (Renner et al., 2018). Weeks in which core beliefs improved were weeks in which symptoms improved too, but belief change did not predict symptom change in the weeks that followed. Agreement between patient and therapist on goals and tasks was partly related to concurrent symptoms. Because the change was simultaneous rather than leading, the series cannot say whether shifting beliefs drives improvement or accompanies it, and the sample was small and had no control group.

Who Responds to Which Treatment

A second line of work asks which baseline characteristics change the relative benefit of psychotherapy and medication. A retrospective analysis of a randomized trial in 681 patients with chronic major depression compared CBASP, the antidepressant nefazodone and their combination over 12 weeks (Nemeroff et al., 2003). In patients without childhood trauma, the combination did better than either treatment alone, which did not differ from each other. In patients reporting early trauma the pattern changed: CBASP alone outperformed nefazodone alone, remission was more likely with CBASP than with the drug (odds ratio = 2.322, 95% CI = 1.225-4.066), and the further advantage of adding the drug to CBASP was marginal and not significant. When specific forms of adversity were examined separately, parental loss and other types of trauma also interacted with treatment in the same direction, and trauma did not affect dropout. The authors suggested that psychotherapy may be essential for this group, while noting that the trial tested one psychotherapy and one antidepressant and that the finding needs testing in further studies.

When the comparison was between two psychotherapies, childhood maltreatment did not sort patients in the same way. Following 268 chronic depression patients one and two years after a trial of CBASP against supportive psychotherapy, the presence of any maltreatment did not significantly moderate long-term outcome, measured as well weeks on the Longitudinal Interval Follow-Up Evaluation Interview (Bausch et al., 2020). One subtype did: patients who reported emotional abuse fared worse overall than those who did not (p = .015), and among them CBASP did better than supportive psychotherapy at one year. Other trauma subtypes showed no significant effects, and maltreatment was assessed only by retrospective self-report.

Cognitive style has also been examined as a moderator. In a secondary analysis of the two-phase REVAMP trial, 808 chronically depressed adults at 8 sites completed the 40-item Dysfunctional Attitude Scale before a 12-week open-label antidepressant phase (Shankman et al., 2013). Higher dysfunctional attitudes went with higher depression scores. Patients high in such attitudes improved faster early in the first phase, the two groups were level by its midpoint, and low scorers improved more later. In the second phase, attitudes moderated response to continued medication alone but not to medication combined with CBASP or with brief supportive psychotherapy, and they did not distinguish the two psychotherapies (p = .71). The authors called the moderation complex and tentative: the first phase was not randomized, the trial was not designed to test this question, the second-phase analyses were exploratory, and replication is needed.

Personalising the Choice of Treatment

These moderator findings point towards matching patients to treatments, and one analysis has tried to do so formally for persistent depressive disorder. An individual-participant-data network meta-regression pooled 3 randomized trials with 1,036 participants (Furukawa et al., 2018). Combining CBASP with medication was better than either alone on both efficacy and acceptability, and CBASP and medication alone were essentially similar. Which option suited a given patient best depended on how severe the depression was at baseline, on anxiety and on other baseline characteristics, and the authors built an interactive web app that turns a patient's profile into an individual estimate. They concluded that the approach permits individualised recommendations, though it rests on only three studies.

None of these processes has been shown to cause improvement. The alliance, interpersonal and core-belief findings are associations measured within trials, the moderator results come largely from secondary or retrospective analyses, and no study here manipulated a candidate mediator to test whether changing it changes outcome. Which mechanism, if any, carries the benefit of psychological treatment for persistent depression remains open.

Medication

Antidepressant medication is the most tested treatment for long-standing depression. Most of the trials were run before persistent depressive disorder (PDD) became a diagnostic category, so their samples were labelled dysthymia, chronic major depression, double depression or chronic depression, and the label each study used is kept below. Psychological treatments are covered under Psychological Treatments, and approaches with thinner evidence under Emerging and Less-Tested Approaches.

Acute Treatment

The first large placebo-controlled test in early-onset dysthymia found both a selective serotonin reuptake inhibitor (SSRI) and a tricyclic antidepressant (TCA) effective. In a 12-week multicentre double-blind trial of 416 outpatients aged 25 to 65, 59% responded to sertraline and 64% to imipramine, against 44% on placebo, and both drugs also lowered scores on the Hamilton and Montgomery-Asberg depression scales (Thase et al., 1996). Imipramine cost more in side effects: more patients left that arm because of adverse events than left either the sertraline or the placebo arm. The authors judged sertraline the better tolerated of the two and noted that a condition this chronic may need prolonged treatment. A second report from the same 416 patients turned to everyday life (Kocsis et al., 1997). Both drugs beat placebo on psychosocial functioning and quality of life, measured with instruments such as the Social Adjustment Scale and the Quality of Life Enjoyment and Satisfaction Questionnaire, and adverse events led to dropout in 6.0% of the sertraline group against 18.4% of the imipramine group. The authors concluded that medication helps even when dysthymia is long-standing, though the trial covered the acute phase only.

The same two drugs were then compared head to head in chronic major and double depression. A 12-week double-blind trial of 635 outpatients at 12 sites found that 52% achieved a satisfactory response to either sertraline or imipramine (Keller et al., 1998a). Sertraline produced fewer adverse events, and 6.3% of its patients discontinued against 12.0% on imipramine. The authors noted that this population was poorly studied, that comorbidity was high, and that response came more slowly in the most chronic cases. Functioning was impaired severely at the start of the acute trial and had improved significantly by week 4 (Miller et al., 1998). By week 12 the sample as a whole still fell short of community norms, but patients whose symptoms fully remitted came close to community levels in most areas, which led the authors to argue that successful treatment can ease the impairment that accompanies chronic depression.

Sex appears to change which drug works better. In the 235 men and 400 women of the same chronic-depression trial, women responded better to sertraline and men to imipramine, and each group was more likely to drop out of the drug that suited it less (Kornstein et al., 2000b). Women on imipramine also took longer to respond than men did. The advantage of sertraline for women held among premenopausal women but not after menopause, and the authors proposed, as a possibility rather than a finding, that female hormones may enhance the response to SSRIs and hinder the response to tricyclics.

Newer drugs have been tested in smaller samples. In a 10-week double-blind trial of the serotonin-norepinephrine reuptake inhibitor duloxetine in chronic nonmajor depression (dysthymic disorder), 65 outpatients were enrolled and 57 began medication (Hellerstein et al., 2012). Duloxetine beat placebo on the 24-item Hamilton scale, with response rates of 65.5% against 25.0% and remission rates of 55.2% against 14.3%. Gains on other outcomes did not follow: the Beck Depression Inventory, the Global Assessment of Functioning and the Social Adjustment Scale showed no difference from placebo. The authors described duloxetine as apparently effective for acute treatment.

Pooled Evidence and Tolerability

Pooled analyses agree that the drugs work in this population. A meta-analysis of 194 randomised trials, 17 of them in dysthymic disorder, found that patients with dysthymia were 1.75 times as likely to respond to an antidepressant as to placebo (95% CI 1.49 to 2.04) (Levkovitz et al., 2011). Placebo response was lower in the dysthymia trials than in the major depression trials (29.9% against 37.9%), and meta-regression found a larger drug advantage in dysthymia; the authors called for longer-term data. A meta-analysis of 20 trials in chronic depression, most of them in dysthymic samples, found SSRIs (benefit ratio 1.49) and TCAs (benefit ratio 1.74) both more effective than placebo and no different from each other (von Wolff et al., 2013). SSRIs led to fewer dropouts than TCAs. The methodological quality of many of the trials was unclear, and the authors said more evidence was needed for the other forms of chronic depression.

The network meta-analysis of Kriston and colleagues compared treatments for PDD directly. Across 45 drug trials (28 drugs, 5,806 patients for efficacy), several agents beat placebo, among them sertraline (odds ratio 4.47), imipramine (4.53) and moclobemide (6.98) (Kriston et al., 2014). Moclobemide and amisulpride were more effective than fluoxetine, and sertraline and amisulpride led to fewer dropouts than imipramine. The 15 psychotherapy trials gave a mixed picture: interpersonal psychotherapy (IPT) was less effective than medication and than the cognitive behavioral analysis system of psychotherapy (CBASP), and adding IPT to medication helped in chronic major depression but not in dysthymia. The authors concluded that several evidence-based treatments exist and that they differ significantly in effect. They noted that several treatments rested on single studies and that the CBASP evidence was partly inconclusive.

Whether medication or psychotherapy should come first has no settled answer. A random-effects meta-analysis of 28 studies (39 effects, 3,381 patients with unipolar depression) found no significant difference between the two at the end of treatment overall, although effect sizes were not consistent (Imel et al., 2008). In the dysthymia studies, however, medication held a small advantage. Psychotherapy did better at follow-up, which the authors read as a possible protective effect. Few of the included studies concerned dysthymia or severe chronic depression, and only a minority reported follow-up. The authors judged both treatments viable, and the network analysis above found that treatments differ without naming a single best one, so the question remains open.

Tolerability differs between drug classes. A network meta-analysis of 34 randomised trials in 4,769 adults with PDD found TCAs the hardest to tolerate, with discontinuation odds 3.98 times those of placebo and twice those of SSRIs (Meister et al., 2016). SSRIs did not differ from placebo in the rate of any adverse event, whereas SNRIs and TCAs did. Acetyl-l-carnitine caused fewer adverse events than placebo and the lowest discontinuation of any class. The trials were mostly of low or unclear quality and underpowered for adverse events, the confidence intervals were broad, and too few studies existed to compare PDD subtypes. The same review cautioned that PDD is a heterogeneous grouping whose validity as a category has been questioned (Meister et al., 2016).

Second-generation antipsychotics have been studied mainly in major depression. A Cochrane review of 28 trials (8,487 participants with major depressive disorder or dysthymia) found modest benefit as monotherapy or augmentation and poorer tolerability than placebo (Komossa et al., 2010). For dysthymia specifically, the evidence concerned low-dose amisulpride, which beat placebo. The authors described the data as very limited and quetiapine as the best supported agent. Most trials were short and 21 of the 28 were sponsored by manufacturers.

A recent narrative review of dysthymia studies, defined by DSM-III to DSM-IV-TR criteria, found several drugs more effective than placebo, and psychotherapy matching drugs in some studies but not beating placebo in others (Mathias et al., 2024). It judged the findings inconclusive because the studies were few and small, some lacked placebo arms or blinding, and many had substantial methodological limits.

Continuation and Maintenance

Because PDD is chronic, the question that matters most is whether continuing a drug prevents relapse. In an early test, 129 outpatients with chronic depression received open-label desipramine, and those who remitted were then randomly assigned to continue it or taper to placebo (Kocsis et al., 1996). Relapse was far more common on placebo (52%) than on desipramine (11%; χ² = 8.1, P = .004). The protection held for pure dysthymia and for double depression and was clearest in patients who had fully remitted. Subtype did not predict acute response, and most relapses came within the first six months.

A larger trial tested sertraline over 76 weeks in 161 outpatients with chronic major or double depression (Keller et al., 1998b). Recurrence struck 6% of the 77 patients kept on sertraline against 23% of the 84 switched to placebo (P = .002), and symptoms re-emerged in 26% against 50% (P = .001). After adjustment for site and depression type, the placebo group's hazard of recurrence was 4.07 times higher (95% CI 1.51 to 10.95). The authors judged sertraline maintenance effective and well tolerated.

Duloxetine has follow-up data only from an open-label extension of its acute trial. Fifty outpatients with dysthymia entered it: 19 duloxetine responders continued the drug and 24 placebo patients started it (Hellerstein et al., 2017). By week 22, 84% of continuers were responders and 63% remitters, and the placebo-first group reached similar rates (83% and 62%). Social and cognitive functioning improved modestly, but 66.7% remained impaired on the Social Adjustment Scale, and remission did not predict normal functioning. The authors read duloxetine as apparently effective while noting that most patients were still impaired. The design was observational and uncontrolled.

The pooled evidence on maintenance is more cautious than these trials. A Cochrane review of 10 studies (seven randomised, three non-randomised) in 840 adults with PDD found, in the four studies (383 participants) comparing an antidepressant with placebo, relapse or recurrence in 13.9% of those continuing the drug against 33.8% on placebo (risk ratio 0.41, 95% CI 0.21 to 0.79), on moderate-quality evidence (Machmutow et al., 2019). Dropout did not differ, on low-quality evidence, and when the analysis was limited to studies at low risk of bias the relapse difference disappeared. Most studies carried moderate or high risk of bias, many were sponsored by drug makers, and none compared treatment with usual care. The review therefore judged the benefit of continued medication uncertain; the trials above show protection, but whether it survives stricter study designs remains open.

Long-term naturalistic data come from a private mood clinic. Haykal and Akiskal followed 42 consecutive patients with primary dysthymia, defined by DSM-III-R, for a mean of five years and compared their clinical features with those of 42 patients with episodic major depression (Haykal & Akiskal, 1999). The dysthymic patients had become ill far earlier (mean onset age 12.6 against 34 years) and carried more psychiatric comorbidity and family loading for mood disorder. With sustained pharmacotherapy, 76% responded, and 85% of women on fluoxetine did. Fluoxetine brought higher adaptive functioning than TCAs, and 39% of TCA-treated patients had intolerable side effects, against agitation in 11% of those on fluoxetine. Some men with a bipolar family history switched into a hyperthymic state. The authors concluded that SSRIs appear broadly efficacious, but treatment was open and uncontrolled.

Augmentation, Brain Stimulation and Rapid-Acting Treatments

None of the studies below enrolled people defined as having persistent depressive disorder or dysthymia. Their evidence comes from treatment-resistant depression (TRD), a category based on how many antidepressant trials have failed, not on how long the illness has lasted. Many people with chronic depression have also tried several drugs without benefit, so the two groups overlap, but they are not the same. What these studies show is how treatment-resistant patients respond, not how chronic depression in general responds.

There is no agreed definition of treatment resistance. Many have been proposed, and a common threshold is failure to respond to at least two antidepressants (McIntyre et al., 2023). The same review separates true resistance from pseudo-resistance and from partial response. It finds mixed evidence on whether to extend the current drug, switch to another or combine drugs. It also notes that few factors reliably predict non-response to any treatment, and that only olanzapine-fluoxetine has been tested in TRD as the FDA defines it (McIntyre et al., 2023). On psychotherapy, the review concludes that psychotherapy alone is not established for TRD, while adding it to an antidepressant improved symptom relief (McIntyre et al., 2023).

Augmentation means adding a second agent to an antidepressant that has not worked. Lithium is the oldest example. A meta-analysis of nine double-blind, placebo-controlled studies of refractory depression found that lithium raised response rates over placebo. Only three studies, with 110 patients, met its criteria for an adequate dose (at least 800 mg a day, serum levels of 0.5 mEq/L or more, for at least two weeks). In those three studies the odds ratio was 3.31 (95% CI 1.46-7.53), the absolute gain in response was 27% and the number needed to treat was 3.7 (Bauer & Döpfmer, 1999). The authors treated lithium as a first-choice option once antidepressant monotherapy fails, though the small number of qualifying trials limits that conclusion (Bauer & Döpfmer, 1999). A later network meta-analysis pooled 65 randomised trials (N = 12,415 adults with TRD) covering 19 augmenting agents, followed for up to 24 weeks. Thyroid hormone (T4) and several antipsychotics produced higher remission rates than placebo, while some agents, including ziprasidone and mirtazapine, led to more dropouts than placebo (Nuñez et al., 2022). Only about a quarter of the trials were at low risk of bias. Definitions of TRD varied, and most comparisons rested on few trials, so the authors called for head-to-head studies (Nuñez et al., 2022).

Repetitive transcranial magnetic stimulation (rTMS) uses magnetic pulses applied to the scalp. A meta-analysis of 18 sham-controlled trials in adults who had failed two or more antidepressants found that rTMS lowered Hamilton scores by 4.53 points more than sham. Response was 29% against 8% and remission 30% against 6%; the evidence was rated high for severity and response and moderate for remission (Gaynes et al., 2014). The authors judged rTMS a reasonable option at this stage (Gaynes et al., 2014). Their caveats were substantial: the trials were small and heterogeneous, stimulation settings varied, early sham conditions may have been inadequate, and no trial followed patients for more than a week. Effects were also smaller in more recently published trials (Gaynes et al., 2014).

Ketamine and its nasal-spray form, esketamine, are described as rapid-acting. In a phase 3 trial, 227 adults with TRD were randomised to esketamine (56 or 84 mg twice weekly) or placebo, each added to an antidepressant. By day 28, Montgomery-Åsberg scores had fallen 4.0 points more in the esketamine group (Popova et al., 2019). The esketamine group also had more adverse events, mainly dissociation, nausea and vertigo, which passed within about 1.5 hours. Seven percent stopped because of them, against 0.9% on placebo (Popova et al., 2019). An expert review agreed that short-term efficacy is established. However, it warned that functional unblinding and expectancy may inflate the apparent efficacy of ketamine; that evidence on the long-term safety of maintenance intravenous ketamine is insufficient; and that no adequately designed head-to-head trial has compared ketamine with esketamine (McIntyre et al., 2021). Electroconvulsive therapy (ECT) has also been compared with ketamine. An open-label trial of 403 patients with nonpsychotic TRD at five sites found ketamine noninferior to ECT, with response rates of 55.4% against 41.2%. Quality of life was similar in the two groups (Anand et al., 2023). Delayed recall scores fell far less with ketamine (-0.9 against -9.7 for ECT), though the memory loss after ECT recovered gradually. ECT caused more musculoskeletal side effects and ketamine more dissociation (Anand et al., 2023).

Two sources speak to whether more resistant illness changes the response. An expert review noted that some studies, though not all, raise the possibility that ketamine works less well when treatment resistance is greater, and that whether this holds for esketamine is not known (McIntyre et al., 2021). In a secondary subgroup analysis, esketamine did not separate significantly from placebo in some subgroups, such as patients with fewer than three previous antidepressant failures, and no biomarker has yet been shown to forecast ketamine response reliably (McIntyre et al., 2021). In the rTMS meta-analysis, an informal comparison of the three studies that required resistance within the current episode suggested no difference in effect, though too few studies existed for a formal test (Gaynes et al., 2014). No study here examined duration of illness as such. Whether these results apply to persistent depressive disorder in particular has not been tested.

Emerging and Less-Tested Approaches

Several psychological treatments have been adapted for long-lasting depression but tested only in small, early studies. Four of them illustrate the range: two draw on mindfulness or meditation practice, one extends a personality-focused therapy, and one combines cognitive work with mindfulness in a group. None has yet been compared with an established active treatment, and only one of the four recruited a sample defined by the diagnosis of persistent depressive disorder; the others enrolled people described as having chronic or chronic-recurrent depression.

Mindfulness-based cognitive therapy (MBCT), delivered as eight weekly classes, was tested in a pilot randomised trial with blind assessors that added it to treatment as usual and compared the combination with treatment as usual alone (Barnhofer et al., 2009). The sample was described as chronic-recurrent depression rather than as dysthymia or persistent depressive disorder. Of 31 people randomised, 28 completed. Self-reported symptoms on the Beck Depression Inventory-II fell further with MBCT (partial η2 = 0.17), and 37% of the MBCT group met the response criterion against 6% of the comparison group. Seven of 10 patients after MBCT, against 2 of 11 after treatment as usual, no longer met criteria for major depression. Change in suicidal ideation did not differ significantly between the arms. The authors read the results as preliminary evidence that MBCT may reduce symptoms, and the trial was small and underpowered, measured symptoms by self-report, followed no one beyond the end of treatment and had groups that were unequal at the start: more of the treatment-as-usual group were in a full chronic episode (85% against 50%).

Metta-based therapy, built around loving-kindness meditation, was the one approach tested in a sample diagnosed with persistent depressive disorder. In a randomised trial of 48 adults, the therapy (an 8-session meditation group followed by 8 sessions of individual therapy) outperformed a wait list on clinician-rated depression (d = 0.93) and on the self-rated Beck Depression Inventory-II (d = 1.46), with response (37.5%) and remission (25%) rates that the authors described as on a low level (Stangier et al., 2021). Treated patients also improved more in behavioural activation, mindfulness and rumination, but not in compassion, and rates of clinical deterioration did not differ between the arms. Change in mindfulness acted as a mediator of change in depression, and the benefit was smaller among patients taking antidepressants; childhood trauma did not predict outcome. The effects are large, but a wait list is a weak comparison, participants knew their allocation, the components ran in a fixed order without formal fidelity checks, and a 6-month follow-up was judged too short. The authors described their results as preliminary support for the therapy.

Schema therapy has been examined without any control group. A multiple-baseline case series followed 25 patients with chronic major depression through a no-treatment baseline of 6 to 24 weeks and then up to 65 sessions of therapy, with about 100 repeated assessments each (Renner et al., 2016). Symptoms improved relative to baseline by large margins on both the Beck Depression Inventory II (d = 1.30) and the Quick Inventory of Depressive Symptomatology (d = 1.22), and secondary outcomes moved by moderate to large amounts. Given the small sample and the absence of a control group, the authors concluded only that schema therapy is possibly effective for chronic depression.

Person-based cognitive therapy, run in groups, was tested in a pilot randomised trial of twenty-eight adults with chronic depression, again added to treatment as usual (Strauss et al., 2012). Over time the combination reduced depression and raised scores on the Southampton Mindfulness Questionnaire more than treatment as usual did, and 64% of those who received the therapy showed reliable improvement, against none in the comparison arm. Because it was a pilot, the authors called the approach promising and argued that a full trial is needed.

Taken together, these four approaches stand at an early stage. Each rests on a pilot trial, a wait-list comparison or an uncontrolled case series, and each set of authors framed its findings as preliminary, possible or promising. Whether any of them matches the established therapies described under Psychological Treatments remains untested.

Digital and Psychedelic-Assisted Treatments

Web-based self-help has been tested in a trial that took dysthymia in alongside other depression. The trial recruited 347 adults online, all with mild to moderate depression or dysthymia; 42 of those with dysthymia went to the guided iFightDepression tool and 41 to a progressive muscle relaxation control. The trial's main test, depressive symptoms at the end of the 6-week programme, found no difference between the arms (Oehler et al., 2020). A small advantage for the web programme did appear at 3 months (d = 0.281), and across the whole follow-up it showed greater symptom reduction (P = .01), better quality of life (P < .001) and higher user satisfaction. The gap was not significant at 6 or 12 months, however, so the benefit was both delayed and short-lived. The authors read the trial as support for web tools, while noting that the effect against an active control may be smaller than wait-list trials suggest. Participants were mostly treatment-experienced, highly educated and comfortable online, and use of the relaxation control could not be tracked (Oehler et al., 2020).

Psilocybin given with psychological support is at an earlier stage still. In an open-label feasibility study, 12 patients with treatment-resistant unipolar depression took a 10-mg dose and then, seven days later, a 25-mg dose. Their Quick Inventory of Depressive Symptoms scores were lower than at baseline both one week and three months after the higher dose (Carhart-Harris et al., 2016). With no control group and open-label dosing, the authors offered this only as preliminary support and called for more rigorous trials. Transient confusion (nine patients), nausea and headache were reported. A phase 2 double-blind trial followed, randomising 233 adults with treatment-resistant depression to one dose of 25 mg, 10 mg or 1 mg (Goodwin et al., 2022). On the Montgomery-Åsberg Depression Rating Scale at week 3, the 25-mg group improved more than the 1-mg group (difference -6.6, P < 0.001). The 10-mg group did not differ from 1 mg (P = 0.18). The evidence did not support a response lasting to 12 weeks, suicidal ideation or behaviour was reported in every dose group, and headache, nausea and dizziness were among the adverse effects. The authors concluded that larger and longer trials are needed (Goodwin et al., 2022).

Neither psilocybin trial studied persistent depressive disorder. Both recruited treatment-resistant depression, so their results cannot simply be carried over to chronic low-grade depression (Carhart-Harris et al., 2016; Goodwin et al., 2022). The web-based trial did include people with dysthymia, but within a mixed sample with a null primary outcome (Oehler et al., 2020). For persistent depressive disorder, both lines of work remain early-stage, and neither can yet be counted as an established treatment.

Culture and Social Context

Culture and Country

How common long-lasting low mood appears to be depends partly on where it is counted. A narrative review of dysthymia across cultures reported that prevalence may be higher in high-income countries than in low- and middle-income ones, while the disability attached to the disorder looked comparable from one country to the next (Gureje, 2011). The same review cautioned that dysthymia remains less studied than major depression and that studies testing whether the diagnosis is valid across cultures were still awaited (Gureje, 2011).

Within one country, social position also tracks risk. A survey of adults in five U.S. communities estimated the rate of dysthymia at approximately 3% (Weissman et al., 1988). Women under 65 carried more risk than men, unmarried adults more than married ones, and young people on low incomes more than others; people with dysthymia also used health services and psychotropic drugs more than those without it (Weissman et al., 1988). These are associations from a cross-sectional survey, not tests of cause.

Race, Ethnicity and Access to Treatment

Who receives adequate treatment differs by race and ethnicity, at least in one large health system. A retrospective chart review of 62,095 veterans with chronic depression in the U.S. Department of Veterans Affairs (VA) found that only 51% received adequate antidepressant care, 13% attended six psychotherapy sessions, and 57% received guideline-concordant care (Quiñones et al., 2014). The sample was labelled chronic depression rather than PDD or dysthymia. Every minority group studied was less likely than white veterans to receive adequate antidepressant therapy (adjusted odds ratios between .53 and .82), with the lowest odds among black veterans (OR = .53), followed by Hispanic (OR = .65), American Indian or Alaska Native (OR = .80) and Asian veterans (OR = .82). Black veterans were also less likely to receive guideline-concordant care (OR = .59), whereas Asian veterans did not differ from white veterans on that measure (Quiñones et al., 2014).

Psychotherapy ran in the other direction before adjustment: minority veterans were more likely than white veterans to receive it, black veterans with an unadjusted OR of 1.52. Once distance to a VA facility was taken into account, the black-white gap was no longer significant, Hispanic and American Indian or Alaska Native veterans did not differ significantly from white veterans, and Asian veterans remained more likely to receive psychotherapy (OR = 1.26) (Quiñones et al., 2014). The authors judged the cause of the antidepressant disparity unclear and named patient preferences, one side of help-seeking behavior, as a possible factor (Quiñones et al., 2014). The records could not show which veterans refused treatment; the study also lacked depression severity, counted only VA encounters, and grouped broad and heterogeneous racial and ethnic categories (Quiñones et al., 2014).

Social Networks and Social Interventions

People with chronic depression probably have smaller social networks, though the evidence is limited. A systematic review of nineteen articles covering 873 patients found smaller networks in chronic depression than in healthy people, in non-chronic major depression and in other mental disorders (Visentini et al., 2018). The authors flagged that the included studies defined chronic depression in different ways, assessed networks with inconsistent methods, and in only three cases used objective measures (Visentini et al., 2018).

Social contact has also been tested as treatment. In a randomised trial with a waiting-list control, women with chronic depression in inner London who were offered befriending were more likely to remit over one year than those waiting, with remission judged on the Present State Examination (Harris et al., 1999). Other treatments the women received, the duration of the initial episode and comorbidity did not predict remission, while initial Present State Examination score was associated with it. The authors called the result not unpromising and asked for more trials, noting restricted intake conditions and that other treatments were only monitored naturalistically (Harris et al., 1999).

The social cost reaches those close to the person. Interviews with thirteen partners of chronically depressed people, analysed thematically, described stigma, shifts in roles within the relationship and persistent uncertainty, framing chronic depression as a condition borne by the couple (Priestley et al., 2018). Family, Partners and Support takes up partners and relatives in more detail.

Family, Partners and Support

A long-lasting depression is rarely carried by one person alone. The research on the people around a patient is small and mostly qualitative, and several of its samples were defined as chronic depression rather than as persistent depressive disorder (PDD) or dysthymia, a difference this section marks study by study.

Partners and Caregivers

Partners describe a relationship reorganised around the illness. In interviews with thirteen partners of people with chronic depression, analysed thematically, the partners reported stigma, a shift in the roles they held within the couple, and persistent uncertainty about what lay ahead (Priestley et al., 2018). The study framed depression as a couples disease, an illness whose effects reach the partner's own sense of identity and not only the patient's mood. Its sample was labelled chronic depression, and a group of thirteen permits description of shared experience, not estimates of how common each concern is.

A Dutch study of PDD itself set caregivers beside patients. Semi-structured interviews with 28 patients and 9 informal caregivers, analysed with Grounded Theory, found a high burden on both sides (Solis et al., 2025). The two groups' themes overlapped substantially: nine main themes emerged from the patients and eleven from the caregivers, and nine of these were common to both. Shame and stigma and a sense of powerlessness were among the constructs the analysis traced. The groups also differed. Caregivers held more positive attitudes towards self-management than patients did; patients reported more problems in social life and at work; caregivers wanted psychoeducation covering a wider range of topics; and caregivers voiced more concern about the risk of suicide. The authors recommended that self-management support begin early and that caregivers receive help in dealing with suicide risk. The study was conducted in connection with PPEP4All-PDD, a nine-session programme, and its limits are specific: the patients were mainly Dutch and highly educated, the caregiver sample was small and outnumbered by patients, some interviews took place only by telephone, and three participants were interviewed after the programme had begun (Solis et al., 2025).

Social Networks and Befriending

Smaller social worlds appear to accompany chronic depression, although the evidence is thin. A systematic review of nineteen articles, covering 873 patients and drawn from six databases and three key journals, compared network size across groups (Visentini et al., 2018). People with chronic depression had smaller networks than healthy comparison groups (six studies), than people with non-chronic major depression (eight studies) and than people with other mental disorders (three studies); four papers had no comparison group. The authors concluded that networks are probably smaller and that the evidence is limited. Three problems restrict the conclusion: the studies used different concepts of chronic depression, they assessed networks with inconsistent methods, and only three used objective measures. The review therefore describes an association with reduced network size; it does not establish whether a shrinking network precedes the depression or follows from it, nor does it equate a small network with social isolation as a felt state.

Befriending is the one social-support intervention with a controlled trial in this group. In an inner-London randomised trial, women with chronic depression were assigned either to befriending or to a waiting list, and after one year remission was significantly more frequent with befriending (Harris et al., 1999). The trial used the Present State Examination. Other treatments the women received did not predict remission, and neither did the duration of the initial episode or comorbidity, while the initial Present State Examination score was associated with the outcome. The authors judged the approach not unpromising and called for more trials. Two caveats limit the result: entry to the trial was restricted by its intake conditions, and the other treatments were monitored naturalistically rather than controlled. The sample was women only and was described as chronically depressed rather than diagnosed with dysthymia. Whether befriending helps beyond that population remains open on this evidence.

Clinicians and Long-Term Care

The professionals who treat chronic depression report their own strain. A Delphi study conducted in 2006–2007 asked eight experts in chronic depression to identify problems in long-term care in a focus group, validate the resulting list and then score it twice on a 7-point Likert scale over four rounds (Koekkoek et al., 2008). The panel identified 35 problems, grouped by thematic analysis into five areas. Relapse, pessimism among professionals and demoralisation ranked as major problems. The panel scored each problem for urgency and changeability, and the problems were ranked into a hierarchy. The panel was small and the authors noted that little was known about this patient group; the study records expert consensus, not measured outcomes of care.

Persistent depressive disorder borders several other conditions, and much of the evidence about where those borders lie comes from samples defined by duration rather than by the current manual's category. Studies labelled their groups chronic depression, dysthymia or dysthymic disorder according to the criteria of their time, and the subsections below keep those labels as each study used them.

Episodic Major Depression

The most consequential boundary is the one with major depression that remits within its episodes. A review that drew on samples described as chronic and nonchronic depression found that the chronic groups carried more comorbidity, more functional impairment, more suicidality, more childhood maltreatment and more psychopathology among relatives (Klein, 2010). The same review found that the chronic subtypes then recognised differed little from one another, offered little support for keeping them apart, and suggested that they could possibly be merged into one category, while noting that the evidence on subtyping was still accumulating (Klein, 2010).

A later systematic review of twenty-eight cohort and cross-sectional studies, which compared chronic depression with nonchronic major depressive disorder under DSM-IV and DSM-5 definitions, confirmed most of that picture (Köhler et al., 2019). Chronic depression began earlier, came with more psychiatric comorbidity and more suicidality, and was marked by more submissive and more hostile interpersonal styles. The two groups did not differ in symptom severity, nor on most sociodemographic factors, so chronicity was not simply a matter of a more intense depression. On childhood maltreatment the studies were inconsistent, and the authors treated the group differences as verified while calling for more work on the specific psychopathology of chronic forms (Köhler et al., 2019). Whether maltreatment reliably separates chronic from episodic depression therefore remains open: the earlier review reported a difference, and the later and larger synthesis found the evidence mixed.

An Australian national household survey of 8841 households, interviewed with the WMH-CIDI 3.0, examined a proposed DSM-5 category that merged DSM-IV dysthymic disorder with chronic major depressive disorder, defined by two years' duration (Murphy & Byrne, 2012). Chronic cases were older, had an earlier age of onset, more frequent episodes and more psychiatric comorbidity than non-chronic cases, and the authors judged that separating chronic from non-chronic depression seemed warranted, a judgement made on the draft proposal rather than the final text (Murphy & Byrne, 2012). The category the manual eventually adopted is named persistent depressive disorder (American Psychiatric Association, 2022). Taken together, the reviews converge on a distinction between chronic and episodic depression and on little distinction among the chronic forms themselves.

Minor and Subsyndromal Depression

Below the threshold for a full disorder lie minor depression and subsyndromal symptomatic depression. In a Stockholm County cohort of 8,622 adults aged 20 to 64, assessed by mailed questionnaire with the Major Depression Inventory and followed for three years, major depression and dysthymic disorder were analysed as one group, and that group proved the most stable (Forsell, 2007). At follow-up, 35.9% of that group reported one symptom or fewer, against 58.9% of those with minor depression and 56.5% of those with subsyndromal depression, two milder groups that behaved alike. Baseline major depression or dysthymia raised the risk of the same diagnosis three years later (RR = 22.4), but minor depression (RR = 4.8) and subsyndromal depression (RR = 5.0) raised it too. Forsell concluded that depression is better seen as dimensional, with people moving between subtypes over time (Forsell, 2007). Because dysthymia was not separated from major depression in that analysis, the cohort shows the stability of the more severe end of the spectrum rather than of dysthymia alone.

Dysthymia and minor depression also responded differently to treatment. A placebo-controlled trial in four primary care practices randomised 415 older patients (mean age, 71 years), 211 with dysthymia and 204 with minor depression, to paroxetine, placebo or problem-solving treatment-primary care (PST-PC) (Williams et al., 2000). Paroxetine resolved symptoms better than placebo, whereas PST-PC did not differ significantly from placebo overall, although it improved faster in the later weeks and varied more between sites. Among patients with dysthymia, paroxetine improved mental health functioning for those with high and intermediate baseline functioning and PST-PC did not; among patients with minor depression, both treatments helped only those in the lowest tertile of baseline functioning. The authors judged the benefit of paroxetine for dysthymia moderate (Williams et al., 2000).

Subthreshold, Residual and Masked Forms

A review of clinical and polysomnographic studies linked subthreshold depressions, dysthymic disorder among them, to shortened REM latency (Akiskal et al., 1997). REM disturbance was more consistent in subthreshold affective conditions than in nonaffective personality or anxiety conditions. In the same review, neurotic depression was followed by later melancholic, psychotic or bipolar courses, and characterological depression was followed by later major affective episodes and responded to antidepressants and to sleep deprivation (Akiskal et al., 1997).

Cyclothymia and the Bipolar Spectrum

Dysthymia and cyclothymia share a history. A historical review traced both terms to Greek roots and to nineteenth-century psychiatry, where Kahlbaum developed them alongside hyperthymia, before both terms faded or blurred under Kraepelin's rubric of manic-depressive insanity (Brieger & Marneros, 1997). The review found the term cyclothymia ill defined, used in three senses that partly contradict one another, and cyclothymic disorder comparatively neglected; it concluded that cyclothymia is likely a precursor of bipolar II disorder, which places it on the side of bipolar disorder rather than with persistent depression (Brieger & Marneros, 1997).

A narrative review of temperament argued that recent research supports Kraepelin's affective dispositions, with both dysthymic and cyclothymic temperaments preceding major episodes (Akiskal, 2001). It noted that Kraepelin had observed hospitalised, severely ill patients and that the irritable and hyperthymic temperaments have no official diagnostic standing, and it held that the Kraepelinian view continues to guide work on causes and prevention (Akiskal, 2001).

Depressive Personality

Depressive personality, the trait construct associated with Schneider, raises the question of whether lifelong gloom is a mood disorder or a personality style. In a study of 177 outpatients assessed with structured diagnostic and family history interviews and followed for six months, depressive personality could be rated reliably and showed preliminary evidence of validity (Klein, 1990). It overlapped only partly with dysthymia, and the trait ratings were not significantly influenced by the patient's current clinical state. Klein concluded that the construct is not wholly absorbed by the mood disorders (Klein, 1990). Because the support was described as preliminary, whether depressive personality is a separate entity or a variant of persistent depression remains open on this evidence.

Demoralisation

Demoralisation appears in this literature as a clinical problem rather than as a rival diagnosis. In a Delphi study, eight experts in chronic depression scored 35 problems of long-term care on a 7-point Likert scale in a four-round process that began with a focus group, and they ranked relapse, pessimism among professionals and demoralisation among the major ones (Koekkoek et al., 2008). The authors noted how little was known about these patients.

Grief and Bereavement

The link to grief in the available evidence concerns onset. In the Australian household survey, bereavement before the first episode was more common in chronic than in non-chronic depression and was associated with a chronic course (Murphy & Byrne, 2012). That finding ties loss to chronicity but does not compare persistent depressive disorder with grief itself.

Worked Example

The largest trial of combined treatment shows how a pair of response rates turns into a clinical decision. Keller and colleagues randomised 681 adults with chronic nonpsychotic major depression to nefazodone, to the cognitive behavioral-analysis system of psychotherapy (CBASP), or to both, for 12 weeks, with raters who did not know the assignment (Keller et al., 2000). The sample was defined as chronic major depression, not as persistent depressive disorder or dysthymia, so the figures describe the chronic end of the spectrum the later category absorbed. A response (remission or satisfactory response) was reached by 48 percent of the nefazodone group, 48 percent of the CBASP group and 73 percent of the combination group; the two single treatments did not differ, the combination exceeded each of them (P<0.001), and withdrawal was similar across the three arms (Keller et al., 2000).

The steps below are illustrative arithmetic on those reported rates; they are not figures the trial itself published. First, the absolute difference: 73 minus 48 gives 25 percentage points between the combination and either single treatment. Second, the number needed to treat, the count of patients who must receive the combination instead of one treatment for one additional response, is the reciprocal of that difference, 1 / 0.25 = 4. Third, in a group of 100 patients, about 73 would be expected to respond to the combination and about 48 to either treatment alone, so roughly 25 more people respond for every 100 treated.

The same steps applied to the 519 completers give a larger gap. Among those who finished the 12 weeks, response reached 85 percent with the combination, 55 percent with nefazodone and 52 percent with CBASP (Keller et al., 2000). Again as arithmetic on the reported rates, the combination exceeds nefazodone by 30 points (a number needed to treat of 1 / 0.30, about 3.3) and CBASP by 33 points (1 / 0.33, about 3.0).

Figure 1

Response Rates After 12 Weeks in the Nefazodone, CBASP and Combination Trial

Bar chart of response rates: 48 percent with nefazodone, 48 percent with CBASP and 73 percent with the combination. 0% 50% 100% 48% 48% 73% Nefazodone CBASP Combination Treatment arm (12 weeks)
Note. Response rates reported by Keller et al. (2000) for 681 adults with chronic major depression. Original schematic.

A number needed to treat of 4 holds only for patients like those in the trial, starting both treatments at once. A later two-phase trial at eight sites asked a different question: whether psychotherapy helps people with chronic depression who had not responded, or had responded only partly, during a first 12-week phase (Kocsis et al., 2009). Of the 808 who entered, 491 went on to a second 12-week phase in which CBASP plus medication, brief supportive psychotherapy plus medication, or medication alone were compared. Remission and response did not differ significantly across the three arms, and adding either psychotherapy did not improve depression scores over medication alone (P =.39); CBASP ended 1.59 Hamilton points lower than supportive therapy (P =.04), but the categorical outcomes did not separate (P =.06). The authors described the findings as essentially negative and noted that the patients came only from academic centres, that the design may have dampened motivation for psychotherapy and that the therapy may have been too brief (Kocsis et al., 2009).

Pooled evidence does not yet settle the matter either. An individual-participant network meta-regression of randomised trials in persistent depressive disorder found the combination of CBASP and medication ahead of either treatment alone in both efficacy and acceptability, with the two single treatments broadly similar, and it identified moderators such as baseline severity, anxiety, prior medication and age (Furukawa et al., 2018). It rested on only 3 studies and 1,036 participants, however, and the trial above shows that an advantage when both treatments begin together need not carry over to adding psychotherapy after medication has failed. Whether combined treatment helps that second group remains open. The demonstration earlier on this page can be used to revisit the same kind of comparison between response rates.

Current Directions

Recent work on persistent depressive disorder asks less whether treatments help on average and more which person should receive which treatment, how the disorder unfolds from day to day, and how large its burden is in groups that earlier research neglected. Several of these lines are young, and most of their findings still await replication.

Personalising Treatment

The search for individual treatment rules is the most direct attempt to move beyond average effects. An individual-participant-data network meta-regression of the randomised trials comparing the Cognitive-Behavioral Analysis System of Psychotherapy (CBASP), medication and the two together found that combined treatment beat either one alone on both efficacy and acceptability, while CBASP and medication on their own performed much the same (Furukawa et al., 2018). The authors' main interest lay in moderators. Characteristics measured at baseline, among them initial severity, anxiety and previous medication, shifted which option was likely to do best, and the team built an interactive web app that converts a patient's profile into a tailored recommendation. The model drew on only three trials with 1,036 participants, so its individual predictions rest on a narrow base. Psychotherapy and medication are compared in full under Psychological Treatments and Medication.

The older dysthymia literature shows why such rules are needed and how far it remains from supplying them. A narrative review of dysthymia trials run under DSM-III to DSM-IV-TR criteria found that several drugs, including imipramine, sertraline and amisulpride, outperformed placebo (Mathias et al., 2024). Psychotherapy matched medication in some of the studies it covered and did not beat placebo in others. The authors judged the evidence inconclusive: the studies were few and small, and many lacked blinding or a placebo arm. Whether psychotherapy or medication should come first for dysthymia therefore remains open.

Measuring Persistent Depression in Daily Life

Ecological momentary assessment (EMA), in which participants answer brief prompts repeatedly as they go about their day, lets researchers ask how long a feeling lasts, not only how strong it is. In a five-week EMA study with a mobile application, 58 inpatients with persistent depressive disorder reported more state loneliness than 42 healthy controls (Wolf et al., 2026). Their high-loneliness episodes also lasted longer, spanning on average 3.5 consecutive prompts against 0.8, and the chance of leaving such an episode was about half that of controls (HR = 0.50). Emotional isolation, the sense of lacking close attachment, tracked trait loneliness on the UCLA Loneliness Scale, and the duration of emotional isolation was more closely tied to trait loneliness in the patient group (r = 0.60 against 0.20 in controls). Recalled emotional neglect went with greater emotional isolation; recalled emotional abuse did not. The authors suggested, cautiously, that early adversity may feed a lasting sense of emotional isolation. The study was exploratory and not preregistered, it compared inpatients with community controls, childhood adversity was recalled rather than recorded at the time, mediation was not formally tested, and the duration associations lost significance once mean loneliness was controlled.

New Psychological Treatments

Meditation-based therapies are being adapted for persistent depression. In a randomised trial with 48 adults with persistent depressive disorder, metta-based therapy, eight group meditation sessions built on loving-kindness meditation followed by eight sessions of individual therapy, reduced depression relative to a wait list, with large effects on clinician-rated symptoms (d = 0.93) and on the self-rated Beck Depression Inventory-II (d = 1.46) (Stangier et al., 2021). Response and remission were more common after treatment, and behavioural activation, mindfulness and rumination improved, but compassion itself did not differ significantly between groups. Gains in mindfulness went with gains in mood, and the benefit was larger in participants not taking antidepressants. The authors described the support as preliminary. The only comparison was a wait list, participants knew their allocation, the components ran in a fixed order, therapist allegiance cannot be excluded and the six-month follow-up was short.

Course in Young People

Which young people go on to a chronic course is a second open front. The evidence here concerns depression in general among people aged 10 to 25, not persistent depressive disorder specifically. A meta-analysis of 46 studies covering 7,488 young people found that female sex, greater symptom severity, poorer global functioning, suicidal thoughts and behaviours, and longer sleep-onset latency (by about 6.96 minutes) were each associated with relapse, recurrence or chronicity, though the certainty of the evidence was very low to moderate (Tagliaferri et al., 2026). The suicidality estimate was only borderline significant (p = .045). Relationships with friends and family looked promising but could not be pooled. Most reports carried a high risk of bias and the certainty of evidence ranged from very low to moderate, so the authors credited these factors with some prognostic value and left the relational ones unconfirmed.

Later Life

Late-life persistent depression has received its first pooled estimates. A systematic review of 38 studies of adults aged 60 and over, 20 articles of which were pooled, whose samples were labelled chronic depression rather than persistent depressive disorder alone, put prevalence at about 4% (4.02%) (Stratmann et al., 2025). The figure depended on method: 2.30% under DSM-IV or DSM-III-R criteria, 7.12% under DSM-III or ICD-10, and 5.52% with rating scales. Prevalence was higher in women (6.05%) than in men (4.24%) and lower in North America than in Europe. Lower physical activity and impairment in daily life were linked to chronic depression, whereas socioeconomic and marital status were not. The authors cautioned that pooling across classification systems is debatable, that heterogeneity was large and that institutionalised and impaired older people were underrepresented.

Population trends point the same way, though at a broader level. A secondary analysis of the Global Burden of Disease Study 2021, which covered major depressive disorder and dysthymia together in adults aged 55 and over, found the burden of late-life depression rising between 1990 and 2021 (Liu et al., 2025). Women exceeded men in incidence at every age band, the steepest rise in incidence came in medium Socio-demographic Index regions (AAPC = 0.5), and low-index regions kept high incidence with no decline. These estimates describe depressive disorders in later life, not persistent depressive disorder as a separate category.

Patients and Caregivers

Qualitative research is turning to what people with the disorder and those close to them need from care. Interviews analysed with Grounded Theory, with 28 patients with persistent depressive disorder and 9 informal caregivers, found a heavy burden on both groups, with shame, stigma and powerlessness among the recurring themes (Solis et al., 2025). Caregivers held more positive views of self-management than patients, wanted broader psychoeducation and worried more about suicide risk, while patients reported more social and work problems. The authors recommended offering self-management support early and helping caregivers deal with suicide risk. The sample was mainly Dutch and highly educated, and caregivers were few. The wider role of relatives is discussed under Family, Partners and Support.

Discussion

The evidence reviewed here supports several conclusions about persistent depressive disorder. Years-long depression is slow to lift: when adults with early-onset dysthymic disorder were followed for 10 years, median recovery took 52 months, and among those who did recover, the estimated chance of slipping back into a further chronic depressive period stood at 71.4% (Klein et al., 2006). The chronic forms of non-bipolar depression resemble one another more than they resemble nonchronic depression, from which they differ in comorbidity, impairment and suicidality (Klein, 2010). Childhood maltreatment is associated with a recurrent or persistent course and with poorer response or remission, in a meta-analysis that concerns depression in general rather than persistent depressive disorder (Nanni et al., 2012). Antidepressants outperform placebo in dysthymia, with patients 1.75 times as likely to respond to a drug as to placebo (Levkovitz et al., 2011). Pooled individual-patient data from three trials found the combination of CBASP and medication ahead of either alone (Furukawa et al., 2018).

Four questions remain contested. The first is the category itself. Klein concluded only that the chronic forms could possibly be merged, while noting that the evidence on subtyping was still accumulating (Klein, 2010), and a later review doubted the validity of dysthymia and warned that persistent depressive disorder is at similar risk of being heterogeneous (Rhebergen & Graham, 2014). The manuals still differ even on the name: DSM-5-TR keeps the single category (American Psychiatric Association, 2022), ICD-11 keeps dysthymic disorder (World Health Organization, 2024), and a recent review emphasises that future studies should view the condition dimensionally, in terms of its course (Schramm et al., 2020). Whether duration marks a distinct condition remains open, and long prospective cohorts that compare the chronic forms on course and treatment response, the test the double-depression literature set itself, are what would settle it.

The second is the CBASP model. A 2022 test found empathy in persistent depressive disorder reduced only under stress, and higher after a 12-week inpatient CBASP course, but in 22 patients with only fifteen retested (Guhn et al., 2022). The theory-of-mind results conflict between studies, most tests are small and cross-sectional, and the model's standing therefore remains contested. Controlled trials that change the proposed process and measure whether symptoms follow would decide it.

The third is whether maltreatment should select the treatment. A retrospective analysis of the large combined-treatment trial found that, in patients with childhood trauma, CBASP outperformed nefazodone and the further gain from adding the drug was not significant (Nemeroff et al., 2003). The later randomised follow-up of CBASP against supportive psychotherapy found that the presence of any maltreatment did not significantly moderate long-term outcome, with a larger advantage for CBASP after one year among patients who retrospectively reported emotional abuse (Bausch et al., 2020). On the stronger design, maltreatment is not a general guide to treatment, and the question remains open for specific forms of abuse. Much of this evidence rests on adults recalling their childhoods, which may be subject to recall bias, although adults' recall of trauma is reported to be relatively reliable (Negele et al., 2015).

The fourth is whether cognition and personality cause chronicity. Rumination, low extraversion and an external locus of control distinguished chronic from nonchronic depression in baseline data (Wiersma et al., 2011), but baseline data of this kind cannot show whether these features cause the transition from episodic to chronic depression.

Long-lasting depression carries a real risk of suicide. Anyone who is thinking about suicide can get help now, for example from the 988 Suicide & Crisis Lifeline in the United States or a local emergency service; the Support Organizations section lists further services.

Common Misconceptions

Persistent depressive disorder is just a mild form of depression.
Duration, not mildness, defines it. In a five-year follow-up, outpatients with early-onset dysthymia had higher symptom levels, poorer functioning, more suicide attempts and more hospitalisations than patients with episodic major depression (Klein et al., 2000). In a national survey, fewer people with dysthymic disorder worked full time than people with acute major depression, and more received Supplemental Security Income (Hellerstein et al., 2010).
Dysthymia and persistent depressive disorder are the same thing.
The DSM-5 category is broader. It takes in chronic major depression as well as the low-grade form once called dysthymia, and a review of dysthymic disorder doubted its validity and warned that persistent depressive disorder is at similar risk of being a heterogeneous diagnosis (Rhebergen & Graham, 2014). In a US national survey, chronic major depressive disorder was more than three times as common over the lifetime as dysthymic disorder (3.1% against 0.9%), so most cases in the merged category would not have met the older diagnosis (Blanco et al., 2010).
Long-lasting low mood is simply a person's personality.
Depressive personality has been studied as a separate construct, and it overlapped only partly with dysthymia in an outpatient sample, with preliminary evidence of validity (Klein, 1990). Akiskal argued that dysthymia behaves like a subaffective mood disorder, while acknowledging that its validity had been questioned from positions placing it nearer major depression and nearer personality disorder (Akiskal, 1994). The relation between personality and persistent low mood remains open.
Chronic depression does not respond to treatment.
In a meta-analysis of placebo-controlled trials, 17 of the 194 included concerning dysthymic disorder, patients with dysthymia were 1.75 times as likely to respond to an antidepressant as to placebo (Levkovitz et al., 2011). In a 12-week trial of 681 adults with chronic major depression, 73 percent responded to combined CBASP and nefazodone, against 48 percent with either alone (Keller et al., 2000).

Glossary

Alexithymia.
Difficulty identifying and describing one's own feelings; in one cross-sectional comparison it was higher in chronic than in episodic depression.
CBASP.
The Cognitive Behavioral Analysis System of Psychotherapy, a psychotherapy McCullough built specifically for chronic depression around techniques such as Situational Analysis and the Interpersonal Discrimination Exercise.
Character spectrum disorder.
Akiskal's label for the subtype of characterological depression that showed more alcohol and drug abuse and a worse outcome than subaffective dysthymia.
Chronic major depression.
The older research label for a major depressive episode that lasts through a long period of low mood, usually two years or more in the studies; DSM-5 merged it into persistent depressive disorder, where it corresponds to the persistent major depressive episode specifier.
Cyberball.
A computerised ball-tossing game in which the participant is left out by the other players, used to stage social exclusion in the laboratory.
Depressive personality.
A trait construct going back to Schneider that sits at the boundary of persistent low mood and personality; in one outpatient study it was assessed reliably, showed preliminary validity and overlapped only partly with dysthymia.
Double depression.
A major depressive episode superimposed on dysthymia or another chronic depressive disorder, a research label introduced by Keller and Shapiro whose standing as a separate subtype is contested.
Dysthymia.
The older name for long-lasting, low-grade depressed mood, from Greek roots and in psychiatric use since the nineteenth century; it remains a MeSH entry term.
Dysthymic disorder.
The formal diagnostic category of DSM-III and DSM-IV, merged into persistent depressive disorder in DSM-5 and kept as a category name in ICD-11 and as the MeSH heading.
Early onset.
The onset specifier recording that persistent depressive disorder began at a younger age, at a cut-off the manual sets; individual studies used their own cut-offs, such as before age 21 or before age 22.
Hostile-submissiveness.
An interpersonal style combining hostility with submissiveness, more pronounced in chronic depression than in major depressive disorder in a meta-analysis that its authors called preliminary.
Interpersonal psychotherapy.
A psychotherapy, often abbreviated IPT, tested alone and alongside medication in dysthymia and chronic depression; most head-to-head trials favoured medication, and a pilot trial favoured CBASP on remission.
Number needed to treat.
The number of patients who must receive one treatment instead of another for one additional patient to respond, calculated as the reciprocal of the difference in response rates.
Pure dysthymic syndrome.
The DSM-5-TR course specifier for years of low mood during which no full major depressive episode has occurred, the closest modern descendant of dysthymic disorder.
REM latency.
The time from falling asleep to the first period of rapid eye movement sleep; Akiskal's group found it shortened in subaffective dysthymia, while other recordings found REM sleep unchanged in dysthymia.
Remission.
In trials, the stricter outcome in which symptoms fall far enough on a rating scale to meet the trial's remission criterion, reached by fewer patients than response; as a manual specifier, partial or full remission records a period of improvement.
Response.
In trials, the share of patients whose rating-scale scores improve enough to meet the trial's response criterion, a lower bar than remission.
Rumination.
Repetitive thinking that dwells on distress and its causes; in one cohort it remained associated with a chronic course after other traits were taken into account.
Specifier.
A label added to a diagnosis to record its course, onset or features, such as the course specifiers that record whether and how major depressive episodes appear within persistent depressive disorder.
Subaffective dysthymia.
Akiskal's label for the subtype of characterological depression that looked like an attenuated mood disorder, with shortened REM latency, more superimposed depressive episodes and better response to tricyclics or lithium.
Theory of mind.
The ability to infer other people's mental states; studies of chronic depression have given conflicting results on whether it is impaired beyond general cognitive slowing.

Key Researchers

Hagop S. Akiskal

(1944–2021). Psychiatrist at the University of California, San Diego, who proposed chronic depressive subtypes, separated subaffective dysthymia from character spectrum disorders with sleep EEG findings and revisited Kraepelin's temperaments. Wikipedia - Wikidata

Pim Cuijpers

Clinical psychologist at Vrije Universiteit Amsterdam who meta-analysed psychotherapy for chronic major depression and dysthymia. ORCID - Google Scholar - Faculty Page

Martin B. Keller

Psychiatrist and professor emeritus at Brown University who described double depression and led the trial of nefazodone, CBASP and their combination in chronic depression. Wikipedia

Daniel N. Klein

Psychologist at Stony Brook University who led the five- and ten-year naturalistic follow-ups of dysthymic disorder and family studies of early-onset dysthymia. ORCID

James H. Kocsis

Psychiatrist at Weill Cornell Medicine who ran trials of medication and psychotherapy for dysthymia and chronic depression, including the REVAMP trial. Faculty Page

Levente Kriston

Researcher at the University Medical Center Hamburg-Eppendorf who led a network meta-analysis of acute treatments for persistent depressive disorder. ORCID

John C. Markowitz

Psychiatrist at Columbia University and the New York State Psychiatric Institute who compared psychotherapy and pharmacotherapy for pure dysthymia. ORCID - Wikipedia - Faculty Page

James P. McCullough

A Virginia Commonwealth University psychologist, now professor emeritus, who created the Cognitive Behavioral Analysis System of Psychotherapy as a treatment for chronic depression. Faculty Page

Elisabeth Schramm

Psychologist at the University of Freiburg Medical Center who led trials of CBASP against supportive psychotherapy and wrote a review of dysthymia and persistent depressive disorder. ORCID

Frequently Asked Questions

Is persistent depressive disorder the same as dysthymia?

Not exactly. Dysthymia, or dysthymic disorder, was the DSM-IV diagnosis, and DSM-5 replaced it with persistent depressive disorder, a broader category that also takes in chronic major depression. A review of the evidence on dysthymic disorder doubted its validity and warned that the newer category is at similar risk of being heterogeneous (Rhebergen & Graham, 2014).

How long does depression have to last to be persistent depressive disorder?

Duration is the defining feature, and research on chronic depression sets the line at an episode lasting at least two years. A secondary analysis of an Australian national household survey classed depression as chronic on that threshold and found it in 4.6% of respondents over the lifetime (Murphy & Byrne, 2012).

What is double depression?

Double depression is a major depressive episode superimposed on a chronic depressive disorder. In Keller and Shapiro's clinical cohort, 26% of patients with major depression had an underlying chronic depression of at least two years, recovery rates for those with both disorders depended greatly on whether recovery was counted from the major episode only or from both disorders, and they relapsed more often immediately after recovery than those without the underlying disorder (Keller & Shapiro, 1982).

How common is persistent depressive disorder?

Estimates depend on the definition each survey used. In a cross-sectional US survey of 43,093 adults, dysthymic disorder had a lifetime prevalence of 0.9% and chronic major depressive disorder of 3.1%, and dysthymic disorder stood out as especially undertreated (Blanco et al., 2010).

Does persistent depression get better?

Many people recover, but slowly, and relapse is common. Following 97 adults with early-onset dysthymic disorder naturalistically over 10 years, the researchers estimated that 73.9% recovered, with a median of 52 months before recovery, and put the risk that a recovered patient would relapse into a fresh chronic depressive period at 71.4% (Klein et al., 2006).

Is persistent depressive disorder linked to childhood adversity?

Childhood maltreatment is associated with a worse course of depression, though the strongest evidence concerns depression in general. A meta-analysis found that maltreated people had more than twice the odds of a recurrent or persistent depression (odds ratio 2.27) and were less likely to respond or remit in treatment trials (Nanni et al., 2012).

How does persistent depression affect relationships and social thinking?

People with chronic depression tend to show a more hostile and submissive way of relating to others than people with episodic major depression. A meta-analysis of twelve studies found this style more pronounced in chronic depression, while its authors called the evidence preliminary because few studies concerned chronic depression and their quality was generally low (Bird et al., 2018).

What treatments work for persistent depressive disorder?

Antidepressants, psychotherapy and their combination all have trial support, and the combination has done best. An individual-patient network meta-regression of three trials found CBASP plus medication better than either alone on efficacy and acceptability, with CBASP and medication alone broadly similar (Furukawa et al., 2018).

Support Organizations

Organizations that provide information, peer support and helplines for persistent depression and related mood conditions.

Depression and Bipolar Support Alliance — a peer-led nonprofit offering support groups, education and wellness tools for people with mood disorders. (United States)

National Alliance on Mental Illness — a grassroots mental health organisation with a helpline, education programmes and local affiliates. (United States)

988 Suicide & Crisis Lifeline — free, confidential crisis support by call, text or online chat, available at any hour. (United States)

Mind — a mental health charity providing information, an infoline and local services. (United Kingdom)

References

Akiskal, H., Lemmi, H., Dickson, H., King, D., Yerevanian, B., & VanValkenburg, C. (1984). Chronic depressions: Part 2. Sleep EEG differentiation of primary dysthymic disorders from anxious depressions. Journal of Affective Disorders, 6(3-4), 287-295. https://doi.org/10.1016/s0165-0327(84)80007-5

Akiskal, H. S. (1981). Subaffective disorders: Dysthymic, cyclothymic and bipolar II disorders in the "borderline" realm. Psychiatric Clinics of North America, 4(1), 25-46. https://doi.org/10.1016/s0193-953x(18)30935-3

Akiskal, H. S. (1983). Dysthymic disorder: Psychopathology of proposed chronic depressive subtypes. American Journal of Psychiatry, 140(1), 11-20. https://doi.org/10.1176/ajp.140.1.11

Akiskal, H. S. (1994). Dysthymia: Clinical and external validity. Acta Psychiatrica Scandinavica, 89(s383), 19-23. https://doi.org/10.1111/j.1600-0447.1994.tb05879.x

Akiskal, H. S. (2001). Dysthymia and cyclothymia in psychiatric practice a century after Kraepelin. Journal of Affective Disorders, 62(1-2), 17-31. https://doi.org/10.1016/s0165-0327(00)00347-5

Akiskal, H. S., Judd, L. L., Gillin, J. C., & Lemmi, H. (1997). Subthreshold depressions: Clinical and polysomnographic validation of dysthymic, residual and masked forms. Journal of Affective Disorders, 45(1-2), 53-63. https://doi.org/10.1016/s0165-0327(97)00059-1

Akiskal, H. S., Rosenthal, T. L., Haykal, R. F., Lemmi, H., Rosenthal, R. H., & Scott-Strauss, A. (1980). Characterological depressions: Clinical and sleep EEG findings separating 'subaffective dysthymias' from 'character spectrum disorders'. Archives of General Psychiatry, 37(7), 777-783. https://doi.org/10.1001/archpsyc.1980.01780200055006

Ambresin, G., Strippoli, M.-P. F., Vandeleur, C. L., de Roten, Y., Despland, J.-N., & Preisig, M. (2023). Correlates of chronic depression in the general population: Results from the CoLaus|PsyCoLaus study. Social Psychiatry and Psychiatric Epidemiology, 58(8), 1179-1191. https://doi.org/10.1007/s00127-023-02462-8

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Association Publishing. https://doi.org/10.1176/appi.books.9780890425787

Anand, A., Mathew, S. J., Sanacora, G., Murrough, J. W., Goes, F. S., Altinay, M., Aloysi, A. S., Asghar-Ali, A. A., Barnett, B. S., Chang, L. C., Collins, K. A., Costi, S., Iqbal, S., Jha, M. K., Krishnan, K., Malone, D. A., Nikayin, S., Nissen, S. E., Ostroff, R. B., . . . Hu, B. (2023). Ketamine versus ECT for nonpsychotic treatment-resistant major depression. New England Journal of Medicine, 388(25), 2315-2325. https://doi.org/10.1056/NEJMoa2302399

Angst, J., Gamma, A., Rössler, W., Ajdacic, V., & Klein, D. N. (2009). Long-term depression versus episodic major depression: Results from the prospective Zurich study of a community sample. Journal of Affective Disorders, 115(1-2), 112-121. https://doi.org/10.1016/j.jad.2008.09.023

Anisman, H., Ravindran, A. V., Griffiths, J., & Merali, Z. (1999). Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Molecular Psychiatry, 4(2), 182-188. https://doi.org/10.1038/sj.mp.4000436

Arnow, B. A., Steidtmann, D., Blasey, C., Manber, R., Constantino, M. J., Klein, D. N., Markowitz, J. C., Rothbaum, B. O., Thase, M. E., Fisher, A. J., & Kocsis, J. H. (2013). The relationship between the therapeutic alliance and treatment outcome in two distinct psychotherapies for chronic depression. Journal of Consulting and Clinical Psychology, 81(4), 627-638. https://doi.org/10.1037/a0031530

Arriaga, F., & Paiva, T. (1990). Clinical and EEG sleep changes in primary dysthymia and generalized anxiety: A comparison with normal controls. Neuropsychobiology, 24(3), 109-114. https://doi.org/10.1159/000119471

Arriaga, F., Rosado, P., & Paiva, T. (1990). The sleep of dysthymic patients: A comparison with normal controls. Biological Psychiatry, 27(6), 649-656. https://doi.org/10.1016/0006-3223(90)90533-8

Barnhofer, T., Crane, C., Hargus, E., Amarasinghe, M., Winder, R., & Williams, J. M. G. (2009). Mindfulness-based cognitive therapy as a treatment for chronic depression: A preliminary study. Behaviour Research and Therapy, 47(5), 366-373. https://doi.org/10.1016/j.brat.2009.01.019

Bauer, M., & Döpfmer, S. (1999). Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies. Journal of Clinical Psychopharmacology, 19(5), 427-434. https://doi.org/10.1097/00004714-199910000-00006

Bausch, P., Fangmeier, T., Meister, R., Elsaßer, M., Kriston, L., Klein, J. P., Zobel, I., Hautzinger, M., Härter, M., & Schramm, E. (2020). The impact of childhood maltreatment on long-term outcomes in disorder-specific vs. nonspecific psychotherapy for chronic depression. Journal of Affective Disorders, 272, 152-157. https://doi.org/10.1016/j.jad.2020.03.164

Berndt, E. R., Koran, L. M., Finkelstein, S. N., Gelenberg, A. J., Kornstein, S. G., Miller, I. M., Thase, M. E., Trapp, G. A., & Keller, M. B. (2000). Lost human capital from early-onset chronic depression. American Journal of Psychiatry, 157(6), 940-947. https://doi.org/10.1176/appi.ajp.157.6.940

Bird, T., Tarsia, M., & Schwannauer, M. (2018). Interpersonal styles in major and chronic depression: A systematic review and meta-analysis. Journal of Affective Disorders, 239, 93-101. https://doi.org/10.1016/j.jad.2018.05.057

Blanco, C., Okuda, M., Markowitz, J. C., Liu, S.-M., Grant, B. F., & Hasin, D. S. (2010). The epidemiology of chronic major depressive disorder and dysthymic disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry, 71(12), 1645-1656. https://doi.org/10.4088/jcp.09m05663gry

Brieger, P., & Marneros, A. (1997). Dysthymia and cyclothymia: Historical origins and contemporary development. Journal of Affective Disorders, 45(3), 117-126. https://doi.org/10.1016/s0165-0327(97)00053-0

Brinkmann, E., Glanert, S., Hüppe, M., Moncada Garay, A. S., Tschepe, S., Schweiger, U., & Klein, J. P. (2019). Psychometric evaluation of a screening question for persistent depressive disorder. BMC Psychiatry, 19(1), 119. https://doi.org/10.1186/s12888-019-2100-0

Brockmeyer, T., Kulessa, D., Hautzinger, M., Bents, H., & Backenstrass, M. (2015). Differentiating early-onset chronic depression from episodic depression in terms of cognitive-behavioral and emotional avoidance. Journal of Affective Disorders, 175, 418-423. https://doi.org/10.1016/j.jad.2015.01.045

Brown, G. W., Ban, M., Craig, T. K. J., Harris, T. O., Herbert, J., & Uher, R. (2013). Serotonin transporter length polymorphism, childhood maltreatment, and chronic depression: A specific gene-environment interaction. Depression and Anxiety, 30(1), 5-13. https://doi.org/10.1002/da.21982

Browne, G., Steiner, M., Roberts, J., Gafni, A., Byrne, C., Dunn, E., Bell, B., Mills, M., Chalklin, L., Wallik, D., & Kraemer, J. (2002). Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. Journal of Affective Disorders, 68(2-3), 317-330. https://doi.org/10.1016/s0165-0327(01)00343-3

Bus, B. A. A., Molendijk, M. L., Tendolkar, I., Penninx, B. W. J. H., Prickaerts, J., Elzinga, B. M., & Voshaar, R. C. O. (2015). Chronic depression is associated with a pronounced decrease in serum brain-derived neurotrophic factor over time. Molecular Psychiatry, 20(5), 602-608. https://doi.org/10.1038/mp.2014.83

Buszewicz, M., Griffin, M., McMahon, E. M., Walters, K., & King, M. (2016). Practice nurse-led proactive care for chronic depression in primary care: A randomised controlled trial. British Journal of Psychiatry, 208(4), 374-380. https://doi.org/10.1192/bjp.bp.114.153312

Byers, A. L., Covinsky, K. E., Barnes, D. E., & Yaffe, K. (2012). Dysthymia and depression increase risk of dementia and mortality among older veterans. The American Journal of Geriatric Psychiatry, 20(8), 664-672. https://doi.org/10.1097/jgp.0b013e31822001c1

Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, H. V., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry, 3(7), 619-627. https://doi.org/10.1016/S2215-0366(16)30065-7

Constantino, M. J., Laws, H. B., Arnow, B. A., Klein, D. N., Rothbaum, B. O., & Manber, R. (2012). The relation between changes in patients' interpersonal impact messages and outcome in treatment for chronic depression. Journal of Consulting and Clinical Psychology, 80(3), 354-364. https://doi.org/10.1037/a0028351

Constantino, M. J., Laws, H. B., Coyne, A. E., Greenberg, R. P., Klein, D. N., Manber, R., Rothbaum, B. O., & Arnow, B. A. (2016). Change in patients' interpersonal impacts as a mediator of the alliance-outcome association in treatment for chronic depression. Journal of Consulting and Clinical Psychology, 84(12), 1135-1144. https://doi.org/10.1037/ccp0000149

Cuijpers, P., van Straten, A., Schuurmans, J., van Oppen, P., Hollon, S. D., & Andersson, G. (2010). Psychotherapy for chronic major depression and dysthymia: A meta-analysis. Clinical Psychology Review, 30(1), 51-62. https://doi.org/10.1016/j.cpr.2009.09.003

Devanand, D. P., Nobler, M. S., Singer, T., et al. (1994). Is dysthymia a different disorder in the elderly? American Journal of Psychiatry, 151(11), 1592-1599. https://doi.org/10.1176/ajp.151.11.1592

Domes, G., Normann, C., & Heinrichs, M. (2016). The effect of oxytocin on attention to angry and happy faces in chronic depression. BMC Psychiatry, 16(1), 92. https://doi.org/10.1186/s12888-016-0794-9

Ernst, M., Kallenbach-Kaminski, L., Kaufhold, J., Negele, A., Bahrke, U., Hautzinger, M., Beutel, M. E., & Leuzinger-Bohleber, M. (2020). Suicide attempts in chronically depressed individuals: What are the risk factors? Psychiatry Research, 287, 112481. https://doi.org/10.1016/j.psychres.2019.112481

Forsell, Y. (2007). A three-year follow-up of major depression, dysthymia, minor depression and subsyndromal depression: Results from a population-based study. Depression and Anxiety, 24(1), 62-65. https://doi.org/10.1002/da.20231

Furukawa, T. A., Efthimiou, O., Weitz, E. S., Cipriani, A., Keller, M. B., Kocsis, J. H., Klein, D. N., Michalak, J., Salanti, G., Cuijpers, P., & Schramm, E. (2018). Cognitive-Behavioral Analysis System of Psychotherapy, drug, or their combination for persistent depressive disorder: Personalizing the treatment choice using individual participant data network metaregression. Psychotherapy and Psychosomatics, 87(3), 140-153. https://doi.org/10.1159/000489227

Gaynes, B. N., Lloyd, S. W., Lux, L., Gartlehner, G., Hansen, R. A., Brode, S., Jonas, D. E., Swinson Evans, T., Viswanathan, M., & Lohr, K. N. (2014). Repetitive transcranial magnetic stimulation for treatment-resistant depression: A systematic review and meta-analysis. The Journal of Clinical Psychiatry, 75(5), 477-489. https://doi.org/10.4088/jcp.13r08815

Goodman, S. H., Schwab-Stone, M., Lahey, B. B., Shaffer, D., & Jensen, P. S. (2000). Major depression and dysthymia in children and adolescents: Discriminant validity and differential consequences in a community sample. Journal of the American Academy of Child & Adolescent Psychiatry, 39(6), 761-770. https://doi.org/10.1097/00004583-200006000-00015

Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., . . . Malievskaia, E. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine, 387(18), 1637-1648. https://doi.org/10.1056/NEJMoa2206443

Guhn, A., Merkel, L., Heim, C., Klawitter, H., Teich, P., Betzler, F., Sterzer, P., & Köhler, S. (2022). Impaired empathic functioning in chronic depression: Behavioral evidence for the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) model. Journal of Psychiatric Research, 152, 79-85. https://doi.org/10.1016/j.jpsychires.2022.06.020

Guhn, A., Sterzer, P., Haack, F. H., & Köhler, S. (2018). Affective and cognitive reactivity to mood induction in chronic depression. Journal of Affective Disorders, 229, 275-281. https://doi.org/10.1016/j.jad.2017.12.090

Gureje, O. (2011). Dysthymia in a cross-cultural perspective. Current Opinion in Psychiatry, 24(1), 67-71. https://doi.org/10.1097/yco.0b013e32834136a5

Harkness, K. L., & Wildes, J. E. (2002). Childhood adversity and anxiety versus dysthymia co-morbidity in major depression. Psychological Medicine, 32(7), 1239-1249. https://doi.org/10.1017/s0033291702006177

Harris, T., Brown, G. W., & Robinson, R. (1999). Befriending as an intervention for chronic depression among women in an inner city: 1: Randomised controlled trial. British Journal of Psychiatry, 174(3), 219-224. https://doi.org/10.1192/bjp.174.3.219

Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018). Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry, 75(4), 336-346. https://doi.org/10.1001/jamapsychiatry.2017.4602

Hayden, E. P., & Klein, D. N. (2001). Outcome of dysthymic disorder at 5-year follow-up: The effect of familial psychopathology, early adversity, personality, comorbidity, and chronic stress. American Journal of Psychiatry, 158(11), 1864-1870. https://doi.org/10.1176/appi.ajp.158.11.1864

Haykal, R. F., & Akiskal, H. S. (1999). The long-term outcome of dysthymia in private practice: Clinical features, temperament, and the art of management. The Journal of Clinical Psychiatry, 60(8), 508-518. https://doi.org/10.4088/jcp.v60n0802

Hellerstein, D. J., Agosti, V., Bosi, M., & Black, S. R. (2010). Impairment in psychosocial functioning associated with dysthymic disorder in the NESARC study. Journal of Affective Disorders, 127(1-3), 84-88. https://doi.org/10.1016/j.jad.2010.04.013

Hellerstein, D. J., Hunnicutt-Ferguson, K., Stewart, J. W., McGrath, P. J., Keller, S., Peterson, B. S., & Chen, Y. (2017). Do social functioning and symptoms improve with continuation antidepressant treatment of persistent depressive disorder? An observational study. Journal of Affective Disorders, 210, 258-264. https://doi.org/10.1016/j.jad.2016.12.026

Hellerstein, D. J., Stewart, J. W., McGrath, P. J., Deliyannides, D. A., Batchelder, S. T., Black, S. R., Withers, A., O'Shea, D., & Chen, Y. (2012). A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression. The Journal of Clinical Psychiatry, 73(7), 984-991. https://doi.org/10.4088/jcp.11m07230

Hölzel, L., Härter, M., Reese, C., & Kriston, L. (2011). Risk factors for chronic depression — A systematic review. Journal of Affective Disorders, 129(1-3), 1-13. https://doi.org/10.1016/j.jad.2010.03.025

Hung, C.-I., Liu, C.-Y., & Yang, C.-H. (2019). Persistent depressive disorder has long-term negative impacts on depression, anxiety, and somatic symptoms at 10-year follow-up among patients with major depressive disorder. Journal of Affective Disorders, 243, 255-261. https://doi.org/10.1016/j.jad.2018.09.068

Imel, Z. E., Malterer, M. B., McKay, K. M., & Wampold, B. E. (2008). A meta-analysis of psychotherapy and medication in unipolar depression and dysthymia. Journal of Affective Disorders, 110(3), 197-206. https://doi.org/10.1016/j.jad.2008.03.018

Jobst, A., Brakemeier, E.-L., Buchheim, A., Caspar, F., Cuijpers, P., Ebmeier, K. P., Falkai, P., Jan van der Gaag, R., Gaebel, W., Herpertz, S., Kurimay, T., Sabaß, L., Schnell, K., Schramm, E., Torrent, C., Wasserman, D., Wiersma, J., & Padberg, F. (2016). European Psychiatric Association Guidance on psychotherapy in chronic depression across Europe. European Psychiatry, 33, 18-36. https://doi.org/10.1016/j.eurpsy.2015.12.003

Jobst, A., Sabass, L., Palagyi, A., Bauriedl-Schmidt, C., Mauer, M. C., Sarubin, N., Buchheim, A., Renneberg, B., Falkai, P., Zill, P., & Padberg, F. (2015). Effects of social exclusion on emotions and oxytocin and cortisol levels in patients with chronic depression. Journal of Psychiatric Research, 60, 170-177. https://doi.org/10.1016/j.jpsychires.2014.11.001

Keller, M. B., & Shapiro, R. W. (1982). "Double depression": Superimposition of acute depressive episodes on chronic depressive disorders. American Journal of Psychiatry, 139(4), 438-442. https://doi.org/10.1176/ajp.139.4.438

Keller, M. B., Gelenberg, A. J., Hirschfeld, R. M. A., Rush, A. J., Thase, M. E., Kocsis, J. H., Markowitz, J. C., Fawcett, J. A., Koran, L. M., Klein, D. N., Russell, J. M., Kornstein, S. G., McCullough, J. P., Davis, S. M., & Harrison, W. M. (1998). The treatment of chronic depression, part 2: A double-blind, randomized trial of sertraline and imipramine. The Journal of Clinical Psychiatry, 59(11), 598-607. https://doi.org/10.4088/jcp.v59n1107

Keller, M. B., Hirschfeld, R. M. A., & Hanks, D. (1997). Double depression: A distinctive subtype of unipolar depression. Journal of Affective Disorders, 45(1-2), 65-73. https://doi.org/10.1016/s0165-0327(97)00060-8

Keller, M. B., Kocsis, J. H., Thase, M. E., Gelenberg, A. J., Rush, A. J., Koran, L., Schatzberg, A., Russell, J., Hirschfeld, R., Klein, D., McCullough, J. P., Fawcett, J. A., Kornstein, S., LaVange, L., & Harrison, W. (1998). Maintenance phase efficacy of sertraline for chronic depression: A randomized controlled trial. JAMA, 280(19), 1665-1672. https://doi.org/10.1001/jama.280.19.1665

Keller, M. B., Lavori, P. W., Endicott, J., Coryell, W., & Klerman, G. L. (1983). "Double depression": Two-year follow-up. American Journal of Psychiatry, 140(6), 689-694. https://doi.org/10.1176/ajp.140.6.689

Keller, M. B., Lavori, P. W., Mueller, T. I., Endicott, J., Coryell, W., Hirschfeld, R. M., & Shea, T. (1992). Time to recovery, chronicity, and levels of psychopathology in major depression: A 5-year prospective follow-up of 431 subjects. Archives of General Psychiatry, 49(10), 809-816. https://doi.org/10.1001/archpsyc.1992.01820100053010

Keller, M. B., Lavori, P. W., Rice, J., Coryell, W., & Hirschfeld, R. M. A. (1986). The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: A prospective follow-up. American Journal of Psychiatry, 143(1), 24-28. https://doi.org/10.1176/ajp.143.1.24

Keller, M. B., McCullough, J. P., Klein, D. N., Arnow, B., Dunner, D. L., Gelenberg, A. J., Markowitz, J. C., Nemeroff, C. B., Russell, J. M., Thase, M. E., Trivedi, M. H., & Zajecka, J. (2000). A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. New England Journal of Medicine, 342(20), 1462-1470. https://doi.org/10.1056/nejm200005183422001

Klein, D. N., & Santiago, N. J. (2003). Dysthymia and chronic depression: Introduction, classification, risk factors, and course. Journal of Clinical Psychology, 59(8), 807-816. https://doi.org/10.1002/jclp.10174

Klein, D. N. (1990). Depressive personality: Reliability, validity, and relation to dysthymia. Journal of Abnormal Psychology, 99(4), 412-421. https://doi.org/10.1037/0021-843x.99.4.412

Klein, D. N. (2010). Chronic depression: Diagnosis and classification. Current Directions in Psychological Science, 19(2), 96-100. https://doi.org/10.1177/0963721410366007

Klein, D. N., Arnow, B. A., Barkin, J. L., Dowling, F., Kocsis, J. H., Leon, A. C., Manber, R., Rothbaum, B. O., Trivedi, M. H., & Wisniewski, S. R. (2009). Early adversity in chronic depression: Clinical correlates and response to pharmacotherapy. Depression and Anxiety, 26(8), 701-710. https://doi.org/10.1002/da.20577

Klein, D. N., Riso, L. P., Donaldson, S. K., Schwartz, J. E., Anderson, R. L., Ouimette, P. C., Lizardi, H., & Aronson, T. A. (1995). Family study of early-onset dysthymia: Mood and personality disorders in relatives of outpatients with dysthymia and episodic major depression and normal controls. Archives of General Psychiatry, 52(6), 487-496. https://doi.org/10.1001/archpsyc.1995.03950180073010

Klein, D. N., Schatzberg, A. F., McCullough, J. P., Keller, M. B., Dowling, F., Goodman, D., Howland, R. H., Markowitz, J. C., Smith, C., Miceli, R., & Harrison, W. M. (1999). Early- versus late-onset dysthymic disorder: Comparison in out-patients with superimposed major depressive episodes. Journal of Affective Disorders, 52(1-3), 187-196. https://doi.org/10.1016/S0165-0327(98)00079-2

Klein, D. N., Schwartz, J. E., Rose, S., & Leader, J. B. (2000). Five-year course and outcome of dysthymic disorder: A prospective, naturalistic follow-up study. American Journal of Psychiatry, 157(6), 931-939. https://doi.org/10.1176/appi.ajp.157.6.931

Klein, D. N., Shankman, S. A., & Rose, S. (2006). Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. American Journal of Psychiatry, 163(5), 872-880. https://doi.org/10.1176/ajp.2006.163.5.872

Klein, D. N., Shankman, S. A., & Rose, S. (2008). Dysthymic disorder and double depression: Prediction of 10-year course trajectories and outcomes. Journal of Psychiatric Research, 42(5), 408-415. https://doi.org/10.1016/j.jpsychires.2007.01.009

Klein, J. P., Becker, B., Hurlemann, R., Scheibe, C., Colla, M., & Heuser, I. (2014). Effect of specific psychotherapy for chronic depression on neural Responses to emotional faces. Journal of Affective Disorders, 166, 93-97. https://doi.org/10.1016/j.jad.2014.04.055

Klein, J. P., Roniger, A., Schweiger, U., Späth, C., & Brodbeck, J. (2015). The association of childhood trauma and personality disorders with chronic depression: A cross-sectional study in depressed outpatients. The Journal of Clinical Psychiatry, 76(6), e794-e801. https://doi.org/10.4088/jcp.14m09158

Kocsis, J. H., & Frances, A. J. (1987). A critical discussion of DSM-III dysthymic disorder. American Journal of Psychiatry, 144(12), 1534-1542. https://doi.org/10.1176/ajp.144.12.1534

Kocsis, J. H., Friedman, R. A., Markowitz, J. C., Leon, A. C., Miller, N. L., Gniwesch, L., & Parides, M. (1996). Maintenance therapy for chronic depression: A controlled clinical trial of desipramine. Archives of General Psychiatry, 53(9), 769-774. https://doi.org/10.1001/archpsyc.1996.01830090013002

Kocsis, J. H., Gelenberg, A. J., Rothbaum, B. O., Klein, D. N., Trivedi, M. H., Manber, R., Keller, M. B., Leon, A. C., Wisniewski, S. R., Arnow, B. A., Markowitz, J. C., Thase, M. E., & REVAMP Investigators. (2009). Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: The REVAMP Trial. Archives of General Psychiatry, 66(11), 1178-1188. https://doi.org/10.1001/archgenpsychiatry.2009.144

Kocsis, J. H., Zisook, S., Davidson, J., Shelton, R., Yonkers, K., Hellerstein, D. J., Rosenbaum, J., & Halbreich, U. (1997). Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: Psychosocial outcomes. American Journal of Psychiatry, 154(3), 390-395. https://doi.org/10.1176/ajp.154.3.390

Koekkoek, B., van Meijel, B., Schene, A., & Hutschemaekers, G. (2008). Clinical problems in the long-term care of patients with chronic depression. Journal of Advanced Nursing, 62(6), 689-697. https://doi.org/10.1111/j.1365-2648.2008.04645.x

Köhler, S., Chrysanthou, S., Guhn, A., & Sterzer, P. (2019). Differences between chronic and nonchronic depression: Systematic review and implications for treatment. Depression and Anxiety, 36(1), 18-30. https://doi.org/10.1002/da.22835

Komossa, K., Depping, A. M., Gaudchau, A., Kissling, W., & Leucht, S. (2010). Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database of Systematic Reviews, (12), CD008121. https://doi.org/10.1002/14651858.cd008121.pub2

Kornstein, S. G., Schatzberg, A. F., Thase, M. E., Yonkers, K. A., McCullough, J. P., Keitner, G. I., Gelenberg, A. J., Davis, S. M., Harrison, W. M., & Keller, M. B. (2000). Gender differences in treatment response to sertraline versus imipramine in chronic depression. American Journal of Psychiatry, 157(9), 1445-1452. https://doi.org/10.1176/appi.ajp.157.9.1445

Kornstein, S. G., Schatzberg, A. F., Thase, M. E., Yonkers, K. A., McCullough, J. P., Keitner, G. I., Gelenberg, A. J., Ryan, C. E., Hess, A. L., Harrison, W., Davis, S. M., & Keller, M. B. (2000). Gender differences in chronic major and double depression. Journal of Affective Disorders, 60(1), 1-11. https://doi.org/10.1016/s0165-0327(99)00158-5

Kovacs, M., Akiskal, H. S., Gatsonis, C., & Parrone, P. L. (1994). Childhood-onset dysthymic disorder: Clinical features and prospective naturalistic outcome. Archives of General Psychiatry, 51(5), 365-374. https://doi.org/10.1001/archpsyc.1994.03950050025003

Kovanen, L., Kaunisto, M., Donner, K., Saarikoski, S. T., & Partonen, T. (2013). CRY2 genetic variants associate with dysthymia. PLoS ONE, 8(8), e71450. https://doi.org/10.1371/journal.pone.0071450

Kriston, L., von Wolff, A., Westphal, A., Hölzel, L. P., & Härter, M. (2014). Efficacy and acceptability of acute treatments for persistent depressive disorder: A network meta-analysis. Depression and Anxiety, 31(8), 621-630. https://doi.org/10.1002/da.22236

Lara, M. E., & Klein, D. N. (1999). Psychosocial processes underlying the maintenance and persistence of depression: Implications for understanding chronic depression. Clinical Psychology Review, 19(5), 553-570. https://doi.org/10.1016/s0272-7358(98)00066-x

Leader, J. B., & Klein, D. N. (1996). Social adjustment in dysthymia, double depression and episodic major depression. Journal of Affective Disorders, 37(2-3), 91-101. https://doi.org/10.1016/0165-0327(95)00076-3

Leuzinger-Bohleber, M., Hautzinger, M., Fiedler, G., Keller, W., Bahrke, U., Kallenbach, L., Kaufhold, J., Ernst, M., Negele, A., Schoett, M., Küchenhoff, H., Günther, F., Rüger, B., & Beutel, M. (2019). Outcome of psychoanalytic and cognitive-behavioural long-term therapy with chronically depressed patients: A controlled trial with preferential and randomized allocation. The Canadian Journal of Psychiatry, 64(1), 47-58. https://doi.org/10.1177/0706743718780340

Levkovitz, Y., Tedeschini, E., & Papakostas, G. I. (2011). Efficacy of antidepressants for dysthymia: A meta-analysis of placebo-controlled randomized trials. Journal of Clinical Psychiatry, 72(4), 509-514. https://doi.org/10.4088/jcp.09m05949blu

Lewinsohn, P. M., Rohde, P., Seeley, J. R., & Hops, H. (1991). Comorbidity of unipolar depression: I. Major depression with dysthymia. Journal of Abnormal Psychology, 100(2), 205-213. https://doi.org/10.1037/0021-843x.100.2.205

Liu, Y., Li, G., Zhong, J., Wu, Y., Yuan, M., Zeng, X., Nie, L., Lu, J., & Yang, W. (2025). Global, regional, and national burden for major depressive disorders and dysthymia in adults aged 55 years and older, 1990-2021. Acta Psychologica, 261, 105985. https://doi.org/10.1016/j.actpsy.2025.105985

Lizardi, H., Klein, D. N., Ouimette, P. C., Riso, L. P., Anderson, R. L., & Donaldson, S. K. (1995). Reports of the childhood home environment in early-onset dysthymia and episodic major depression. Journal of Abnormal Psychology, 104(1), 132-139. https://doi.org/10.1037/0021-843x.104.1.132

Machmutow, K., Meister, R., Jansen, A., Kriston, L., Watzke, B., Härter, M. C., & Liebherz, S. (2019). Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults. Cochrane Database of Systematic Reviews, 2019(5), CD012855. https://doi.org/10.1002/14651858.cd012855.pub2

Markkula, N., Suvisaari, J., Saarni, S. I., Pirkola, S., Peña, S., Saarni, S., Ahola, K., Mattila, A. K., Viertiö, S., Strehle, J., Koskinen, S., & Härkänen, T. (2015). Prevalence and correlates of major depressive disorder and dysthymia in an eleven-year follow-up: Results from the Finnish Health 2011 Survey. Journal of Affective Disorders, 173, 73-80. https://doi.org/10.1016/j.jad.2014.10.015

Markowitz, J. C., Kocsis, J. H., Bleiberg, K. L., Christos, P. J., & Sacks, M. (2005). A comparative trial of psychotherapy and pharmacotherapy for "pure" dysthymic patients. Journal of Affective Disorders, 89(1-3), 167-175. https://doi.org/10.1016/j.jad.2005.10.001

Martin, D. J., Oren, Z., & Boone, K. (1991). Major depressives' and dysthymics' performance on the Wisconsin Card Sorting Test. Journal of Clinical Psychology, 47(5), 684-690. https://doi.org/10.1002/1097-4679(199109)47:5<684::aid-jclp2270470509>3.0.co;2-g

Mathias, L., Quagliato, L. A., Carta, M. G., Nardi, A. E., & Cheniaux, E. (2024). Challenges in the treatment of dysthymia: A narrative review. Expert Review of Neurotherapeutics, 24(7), 633-642. https://doi.org/10.1080/14737175.2024.2360671

Mattern, M., Walter, H., Hentze, C., Schramm, E., Drost, S., Schoepf, D., Fangmeier, T., Normann, C., Zobel, I., & Schnell, K. (2015). Behavioral evidence for an impairment of affective theory of mind capabilities in chronic depression. Psychopathology, 48(4), 240-250. https://doi.org/10.1159/000430450

McCullough, J. P., Braith, J. A., Chapman, R. C., Kasnetz, M. D., Carr, K. F., Cones, J. H., Fielo, J., Shoemaker, O. S., & Roberts, W. C. (1990). Comparison of early and late onset dysthymia. The Journal of Nervous and Mental Disease, 178(9), 577-581. https://doi.org/10.1097/00005053-199009000-00004

McCullough, J. P., Jr. (2003). Treatment for chronic depression using Cognitive Behavioral Analysis System of Psychotherapy (CBASP). Journal of Clinical Psychology, 59(8), 833-846. https://doi.org/10.1002/jclp.10176

McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., Ly-Uson, J., Mansur, R. B., McAllister-Williams, R. H., Murrough, J. W., Nemeroff, C. B., Nierenberg, A. A., Rosenblat, J. D., Sanacora, G., Schatzberg, A. F., Shelton, R., Stahl, S. M., Trivedi, M. H., Vieta, E., Vinberg, M., Williams, N., Young, A. H., & Maj, M. (2023). Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry, 22(3), 394-412. https://doi.org/10.1002/wps.21120

McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., Iosifescu, D. V., Lopez Jaramillo, C., Kasper, S., Kratiuk, K., Lee, J. G., Lee, Y., Lui, L. M. W., Mansur, R. B., Papakostas, G. I., Subramaniapillai, M., Thase, M., Vieta, E., Young, A. H., Zarate, C. A., Jr., & Stahl, S. (2021). Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. American Journal of Psychiatry, 178(5), 383-399. https://doi.org/10.1176/appi.ajp.2020.20081251

Meister, R., Jansen, A., Härter, M., Nestoriuc, Y., & Kriston, L. (2017). Placebo and nocebo reactions in randomized trials of pharmacological treatments for persistent depressive disorder: A meta-regression analysis. Journal of Affective Disorders, 215, 288-298. https://doi.org/10.1016/j.jad.2017.03.024

Meister, R., von Wolff, A., Mohr, H., Härter, M., Nestoriuc, Y., Hölzel, L., & Kriston, L. (2016). Comparative safety of pharmacologic treatments for persistent depressive disorder: A systematic review and network meta-analysis. PLoS ONE, 11(5), e0153380. https://doi.org/10.1371/journal.pone.0153380

Michalak, J., Schultze, M., Heidenreich, T., & Schramm, E. (2015). A randomized controlled trial on the efficacy of mindfulness-based cognitive therapy and a group version of cognitive behavioral analysis system of psychotherapy for chronically depressed patients. Journal of Consulting and Clinical Psychology, 83(5), 951-963. https://doi.org/10.1037/ccp0000042

Miller, I. W., Keitner, G. I., Schatzberg, A. F., Klein, D. N., Thase, M. E., Rush, A. J., Markowitz, J. C., Schlager, D. S., Kornstein, S. G., Davis, S. M., Harrison, W. M., & Keller, M. B. (1998). The treatment of chronic depression, part 3: Psychosocial functioning before and after treatment with sertraline or imipramine. The Journal of Clinical Psychiatry, 59(11), 608-619. https://doi.org/10.4088/jcp.v59n1108

Murphy, J. A., & Byrne, G. J. (2012). Prevalence and correlates of the proposed DSM-5 diagnosis of chronic depressive disorder. Journal of Affective Disorders, 139(2), 172-180. https://doi.org/10.1016/j.jad.2012.01.033

Nanni, V., Uher, R., & Danese, A. (2012). Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: A meta-analysis. American Journal of Psychiatry, 169(2), 141-151. https://doi.org/10.1176/appi.ajp.2011.11020335

Negele, A., Kaufhold, J., Kallenbach, L., & Leuzinger-Bohleber, M. (2015). Childhood trauma and its relation to chronic depression in adulthood. Depression Research and Treatment, 2015, 650804. https://doi.org/10.1155/2015/650804

Negt, P., Brakemeier, E.-L., Michalak, J., Winter, L., Bleich, S., & Kahl, K. G. (2016). The treatment of chronic depression with cognitive behavioral analysis system of psychotherapy: A systematic review and meta-analysis of randomized-controlled clinical trials. Brain and Behavior, 6(8), e00486. https://doi.org/10.1002/brb3.486

Nemeroff, C. B., Heim, C. M., Thase, M. E., Klein, D. N., Rush, A. J., Schatzberg, A. F., Ninan, P. T., McCullough, J. P., Jr., Weiss, P. M., Dunner, D. L., Rothbaum, B. O., Kornstein, S., Keitner, G., & Keller, M. B. (2003). Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proceedings of the National Academy of Sciences, 100(24), 14293-14296. https://doi.org/10.1073/pnas.2336126100

Nübel, J., Guhn, A., Müllender, S., Le, H. D., Cohrdes, C., & Köhler, S. (2020). Persistent depressive disorder across the adult lifespan: Results from clinical and population-based surveys in Germany. BMC Psychiatry, 20, 58. https://doi.org/10.1186/s12888-020-2460-5

Nuñez, N. A., Joseph, B., Pahwa, M., Kumar, R., Gardea Resendez, M., Prokop, L. J., Veldic, M., Seshadri, A., Biernacka, J. M., Frye, M. A., Wang, Z., & Singh, B. (2022). Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. Journal of Affective Disorders, 302, 385-400. https://doi.org/10.1016/j.jad.2021.12.134

Oehler, C., Görges, F., Rogalla, M., Rummel-Kluge, C., & Hegerl, U. (2020). Efficacy of a guided web-based self-management intervention for depression or dysthymia: Randomized controlled trial with a 12-month follow-up using an active control condition. Journal of Medical Internet Research, 22(7), e15361. https://doi.org/10.2196/15361

Paradiso, S., Lamberty, G. J., Garvey, M. J., & Robinson, R. G. (1997). Cognitive impairment in the euthymic phase of chronic unipolar depression. The Journal of Nervous and Mental Disease, 185(12), 748-754. https://doi.org/10.1097/00005053-199712000-00005

Pearson, M., Brewin, C. R., Rhodes, J., & McCarron, G. (2008). Frequency and nature of rumination in chronic depression: A preliminary study. Cognitive Behaviour Therapy, 37(3), 160-168. https://doi.org/10.1080/16506070801919224

Pepper, C. M., Klein, D. N., Anderson, R. L., Riso, L. P., Ouimette, P. C., & Lizardi, H. (1995). DSM-III-R axis II comorbidity in dysthymia and major depression. American Journal of Psychiatry, 152(2), 239-247. https://doi.org/10.1176/ajp.152.2.239

Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., Molero, P., Vieta, E., Bajbouj, M., Manji, H., Drevets, W. C., & Singh, J. B. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. American Journal of Psychiatry, 176(6), 428-438. https://doi.org/10.1176/appi.ajp.2019.19020172

Posner, J., Hellerstein, D. J., Gat, I., Mechling, A., Klahr, K., Wang, Z., McGrath, P. J., Stewart, J. W., & Peterson, B. S. (2013). Antidepressants normalize the default mode network in patients with dysthymia. JAMA Psychiatry, 70(4), 373-382. https://doi.org/10.1001/jamapsychiatry.2013.455

Priestley, J., McPherson, S., & Davies, F. (2018). Couples' disease: The experience of living with a partner with chronic depression. Journal of Couple & Relationship Therapy, 17(2), 128-145. https://doi.org/10.1080/15332691.2017.1372833

Quiñones, A. R., Thielke, S. M., Beaver, K. A., Trivedi, R. B., Williams, E. C., & Fan, V. S. (2014). Racial and ethnic differences in receipt of antidepressants and psychotherapy by veterans with chronic depression. Psychiatric Services, 65(2), 193-200. https://doi.org/10.1176/appi.ps.201300057

Ravindran, A. V., Anisman, H., Merali, Z., Charbonneau, Y., Telner, J., Bialik, R. J., Wiens, A., Ellis, J., & Griffiths, J. (1999). Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: Clinical symptoms and functional impairments. American Journal of Psychiatry, 156(10), 1608-1617. https://doi.org/10.1176/ajp.156.10.1608

Ravindran, A. V., Smith, A., Cameron, C., Bhatla, R., Cameron, I., Georgescu, T. M., & Hogan, M. J. (2009). Toward a functional neuroanatomy of dysthymia: A functional magnetic resonance imaging study. Journal of Affective Disorders, 119(1-3), 9-15. https://doi.org/10.1016/j.jad.2009.03.009

Renner, F., Arntz, A., Peeters, F. P., Lobbestael, J., & Huibers, M. J. (2016). Schema therapy for chronic depression: Results of a multiple single case series. Journal of Behavior Therapy and Experimental Psychiatry, 51, 66-73. https://doi.org/10.1016/j.jbtep.2015.12.001

Renner, F., DeRubeis, R., Arntz, A., Peeters, F., Lobbestael, J., & Huibers, M. J. H. (2018). Exploring mechanisms of change in schema therapy for chronic depression. Journal of Behavior Therapy and Experimental Psychiatry, 58, 97-105. https://doi.org/10.1016/j.jbtep.2017.10.002

Renner, F., Siep, N., Arntz, A., van de Ven, V., Peeters, F. P. M. L., Quaedflieg, C. W. E. M., & Huibers, M. J. H. (2017). Negative mood-induction modulates default mode network resting-state functional connectivity in chronic depression. Journal of Affective Disorders, 208, 590-596. https://doi.org/10.1016/j.jad.2016.10.022

Rhebergen, D., & Graham, R. (2014). The re-labelling of dysthymic disorder to persistent depressive disorder in DSM-5: Old wine in new bottles? Current Opinion in Psychiatry, 27(1), 27-31. https://doi.org/10.1097/yco.0000000000000022

Rhebergen, D., Beekman, A. T. F., de Graaf, R., Nolen, W. A., Spijker, J., Hoogendijk, W. J., & Penninx, B. W. J. H. (2009). The three-year naturalistic course of major depressive disorder, dysthymic disorder and double depression. Journal of Affective Disorders, 115(3), 450-459. https://doi.org/10.1016/j.jad.2008.10.018

Rhebergen, D., Beekman, A. T. F., de Graaf, R., Nolen, W. A., Spijker, J., Hoogendijk, W. J. H., & Penninx, B. W. J. H. (2010). Trajectories of recovery of social and physical functioning in major depression, dysthymic disorder and double depression: A 3-year follow-up. Journal of Affective Disorders, 124(1-2), 148-156. https://doi.org/10.1016/j.jad.2009.10.029

Rhodes, J. E., Hackney, S. J., & Smith, J. A. (2019). Emptiness, engulfment, and life struggle: An interpretative phenomenological analysis of chronic depression. Journal of Constructivist Psychology, 32(4), 390-407. https://doi.org/10.1080/10720537.2018.1515046

Riso, L. P., du Toit, P. L., Blandino, J. A., Penna, S., Dacey, S., Duin, J. S., Pacoe, E. M., Grant, M. M., & Ulmer, C. S. (2003). Cognitive aspects of chronic depression. Journal of Abnormal Psychology, 112(1), 72-80. https://doi.org/10.1037/0021-843x.112.1.72

Riso, L. P., Miyatake, R. K., & Thase, M. E. (2002). The search for determinants of chronic depression: A review of six factors. Journal of Affective Disorders, 70(2), 103-115. https://doi.org/10.1016/s0165-0327(01)00376-7

Sanderson, W. C., Beck, A. T., & Beck, J. (1990). Syndrome comorbidity in patients with major depression or dysthymia: Prevalence and temporal relationships. American Journal of Psychiatry, 147(8), 1025-1028. https://doi.org/10.1176/ajp.147.8.1025

Satyanarayana, S., Enns, M. W., Cox, B. J., & Sareen, J. (2009). Prevalence and correlates of chronic depression in the Canadian Community Health Survey: Mental Health and Well-Being. Canadian Journal of Psychiatry, 54(6), 389-398. https://doi.org/10.1177/070674370905400606

Schatzberg, A. F., Rush, A. J., Arnow, B. A., Banks, P. L. C., Blalock, J. A., Borian, F. E., Howland, R., Klein, D. N., Kocsis, J. H., Kornstein, S. G., Manber, R., Markowitz, J. C., Miller, I., Ninan, P. T., Rothbaum, B. O., Thase, M. E., Trivedi, M. H., & Keller, M. B. (2005). Chronic depression: Medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Archives of General Psychiatry, 62(5), 513-520. https://doi.org/10.1001/archpsyc.62.5.513

Schmaling, K. B., Dimidjian, S., Katon, W., & Sullivan, M. (2002). Response styles among patients with minor depression and dysthymia in primary care. Journal of Abnormal Psychology, 111(2), 350-356. https://doi.org/10.1037/0021-843x.111.2.350

Schramm, E., Klein, D. N., Elsaesser, M., Furukawa, T. A., & Domschke, K. (2020). Review of dysthymia and persistent depressive disorder: History, correlates, and clinical implications. The Lancet Psychiatry, 7(9), 801-812. https://doi.org/10.1016/S2215-0366(20)30099-7

Schramm, E., Kriston, L., Elsaesser, M., Fangmeier, T., Meister, R., Bausch, P., Zobel, I., Bailer, J., Wambach, K., Backenstrass, M., Klein, J. P., Schoepf, D., Schnell, K., Gumz, A., Löwe, B., Walter, H., Wolf, M., Domschke, K., Berger, M., Hautzinger, M., & Härter, M. (2019). Two-year follow-up after treatment with the Cognitive Behavioral Analysis System of Psychotherapy versus supportive psychotherapy for early-onset chronic depression. Psychotherapy and Psychosomatics, 88(3), 154-164. https://doi.org/10.1159/000500189

Schramm, E., Kriston, L., Zobel, I., Bailer, J., Wambach, K., Backenstrass, M., Klein, J. P., Schoepf, D., Schnell, K., Gumz, A., Bausch, P., Fangmeier, T., Meister, R., Berger, M., Hautzinger, M., & Härter, M. (2017). Effect of disorder-specific vs nonspecific psychotherapy for chronic depression: A randomized clinical trial. JAMA Psychiatry, 74(3), 233-242. https://doi.org/10.1001/jamapsychiatry.2016.3880

Schramm, E., Schneider, D., Zobel, I., van Calker, D., Dykierek, P., Kech, S., Härter, M., & Berger, M. (2008). Efficacy of interpersonal psychotherapy plus pharmacotherapy in chronically depressed inpatients. Journal of Affective Disorders, 109(1-2), 65-73. https://doi.org/10.1016/j.jad.2007.10.013

Schramm, E., Zobel, I., Dykierek, P., Kech, S., Brakemeier, E.-L., Külz, A., & Berger, M. (2011). Cognitive behavioral analysis system of psychotherapy versus interpersonal psychotherapy for early-onset chronic depression: A randomized pilot study. Journal of Affective Disorders, 129(1-3), 109-116. https://doi.org/10.1016/j.jad.2010.08.003

Schramm, P. J., Zobel, I., Mönch, K., Schramm, E., & Michalak, J. (2016). Sleep quality changes in chronically depressed patients treated with Mindfulness-based Cognitive Therapy or the Cognitive Behavioral Analysis System of Psychotherapy: A pilot study. Sleep Medicine, 17, 57-63. https://doi.org/10.1016/j.sleep.2015.09.022

Seemüller, F., Kolter, M., Musil, R., Schennach, R., Adli, M., Bauer, M., Brieger, P., Laux, G., Riedel, M., Falkai, P., Möller, H.-J., & Padberg, F. (2022). Chronic vs non-chronic depression in psychiatric inpatient care - Data from a large naturalistic multicenter trial. Journal of Affective Disorders, 299, 73-84. https://doi.org/10.1016/j.jad.2021.11.042

Seidl, E., Padberg, F., Bauriedl-Schmidt, C., Albert, A., Daltrozzo, T., Hall, J., Renneberg, B., Seidl, O., & Jobst, A. (2020). Response to ostracism in patients with chronic depression, episodic depression and borderline personality disorder: A study using Cyberball. Journal of Affective Disorders, 260, 254-262. https://doi.org/10.1016/j.jad.2019.09.021

Serretti, A., Jori, M. C., Casadei, G., Ravizza, L., Smeraldi, E., & Akiskal, H. (1999). Delineating psychopathologic clusters within dysthymia: A study of 512 out-patients without major depression. Journal of Affective Disorders, 56(1), 17-25. https://doi.org/10.1016/s0165-0327(99)00056-7

Shankman, S. A., Campbell, M. L., Klein, D. N., Leon, A. C., Arnow, B. A., Manber, R., Keller, M. B., Markowitz, J. C., Rothbaum, B. O., Thase, M. E., & Kocsis, J. H. (2013). Dysfunctional attitudes as a moderator of pharmacotherapy and psychotherapy for chronic depression. Journal of Psychiatric Research, 47(1), 113-121. https://doi.org/10.1016/j.jpsychires.2012.09.018

Solis, E. C., Carlier, I. V. E., Kamminga, N. G. A., & van Hemert, A. M. (2025). Self-management strategies and care needs of patients with persistent depressive disorder and their informal caregivers: A multi-perspectives qualitative interview study. Frontiers in Psychiatry, 16, 1505396. https://doi.org/10.3389/fpsyt.2025.1505396

Stangier, U., Frick, A., Thinnes, I., Arens, E. A., & Hofmann, S. G. (2021). Metta-based therapy for chronic depression: A wait list control trial. Mindfulness, 12(12), 2929-2942. https://doi.org/10.1007/s12671-021-01753-y

Stratmann, M. W., König, H.-H., & Hajek, A. (2025). Prevalence and associated factors of chronic depression among older adults: A systematic review, meta-analysis, and meta-regression. International Journal of Geriatric Psychiatry, 40(10), e70160. https://doi.org/10.1002/gps.70160

Strauss, C., Hayward, M., & Chadwick, P. (2012). Group person-based cognitive therapy for chronic depression: A pilot randomized controlled trial. British Journal of Clinical Psychology, 51(3), 345-350. https://doi.org/10.1111/j.2044-8260.2012.02036.x

Struck, N., Gärtner, T., Kircher, T., & Brakemeier, E.-L. (2021). Social cognition and interpersonal problems in persistent depressive disorder vs. episodic depression: The role of childhood maltreatment. Frontiers in Psychiatry, 11, 608795. https://doi.org/10.3389/fpsyt.2020.608795

Sumner, J. A., Griffith, J. W., Mineka, S., Rekart, K. N., Zinbarg, R. E., & Craske, M. G. (2011). Overgeneral autobiographical memory and chronic interpersonal stress as predictors of the course of depression in adolescents. Cognition and Emotion, 25(1), 183-192. https://doi.org/10.1080/02699931003741566

Tagliaferri, S. D., Han, L. K. M., Khetan, M., Nguyen, J., Markulev, C., Rice, S., Cotton, S. M., Berk, M., Byrne, E. M., Rickwood, D., Davey, C. G., Koval, P., Ratheesh, A., McGorry, P. D., Alvarez-Jimenez, M., & Schmaal, L. (2026). Systematic review and meta-analysis: Predictors of relapsing, recurrent, and chronic depression in young people. Journal of the American Academy of Child & Adolescent Psychiatry, 65(2), 206-230. https://doi.org/10.1016/j.jaac.2025.03.019

Thase, M. E., Fava, M., Halbreich, U., Kocsis, J. H., Koran, L., Davidson, J., Rosenbaum, J., & Harrison, W. (1996). A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Archives of General Psychiatry, 53(9), 777-784. https://doi.org/10.1001/archpsyc.1996.01830090023004

Tyrer, P., Seivewright, H., & Johnson, T. (2004). The Nottingham Study of Neurotic Disorder: Predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder. Psychological Medicine, 34(8), 1385-1394. https://doi.org/10.1017/s0033291704002569

Uher, R., Payne, J. L., Pavlova, B., & Perlis, R. H. (2014). Major depressive disorder in DSM-5: Implications for clinical practice and research of changes from DSM-IV. Depression and Anxiety, 31(6), 459-471. https://doi.org/10.1002/da.22217

van Randenborgh, A., Hüffmeier, J., Victor, D., Klocke, K., Borlinghaus, J., & Pawelzik, M. (2012). Contrasting chronic with episodic depression: An analysis of distorted socio-emotional information processing in chronic depression. Journal of Affective Disorders, 141(2-3), 177-184. https://doi.org/10.1016/j.jad.2012.02.039

Vehlen, A., Kellner, A., Normann, C., Heinrichs, M., & Domes, G. (2023). Reduced eye gaze during facial emotion recognition in chronic depression: Effects of intranasal oxytocin. Journal of Psychiatric Research, 159, 50-56. https://doi.org/10.1016/j.jpsychires.2023.01.016

Vilgis, V., Chen, J., Silk, T. J., Cunnington, R., & Vance, A. (2014). Frontoparietal function in young people with dysthymic disorder (DSM-5: Persistent depressive disorder) during spatial working memory. Journal of Affective Disorders, 160, 34-42. https://doi.org/10.1016/j.jad.2014.01.024

Visentini, C., Cassidy, M., Bird, V. J., & Priebe, S. (2018). Social networks of patients with chronic depression: A systematic review. Journal of Affective Disorders, 241, 571-578. https://doi.org/10.1016/j.jad.2018.08.022

von Wolff, A., Hölzel, L. P., Westphal, A., Härter, M., & Kriston, L. (2013). Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: A systematic review and meta-analysis. Journal of Affective Disorders, 144(1-2), 7-15. https://doi.org/10.1016/j.jad.2012.06.007

Watson, S., Gallagher, P., Del-Estal, D., Hearn, A., Ferrier, I. N., & Young, A. H. (2002). Hypothalamic-pituitary-adrenal axis function in patients with chronic depression. Psychological Medicine, 32(6), 1021-1028. https://doi.org/10.1017/s0033291702005998

Weissman, M. M., Leaf, P. J., Bruce, M. L., & Florio, L. (1988). The epidemiology of dysthymia in five communities: Rates, risks, comorbidity, and treatment. American Journal of Psychiatry, 145(7), 815-819. https://doi.org/10.1176/ajp.145.7.815

Wells, K. B., Burnam, M. A., Rogers, W., Hays, R., & Camp, P. (1992). The course of depression in adult outpatients: Results from the Medical Outcomes Study. Archives of General Psychiatry, 49(10), 788-794. https://doi.org/10.1001/archpsyc.1992.01820100032007

Wiersma, J. E., Hovens, J. G. F. M., van Oppen, P., Giltay, E. J., van Schaik, D. J. F., Beekman, A. T. F., & Penninx, B. W. J. H. (2009). The importance of childhood trauma and childhood life events for chronicity of depression in adults. Journal of Clinical Psychiatry, 70(7), 983-989. https://doi.org/10.4088/jcp.08m04521

Wiersma, J. E., van Oppen, P., van Schaik, D. J. F., van der Does, A. J. W., Beekman, A. T. F., & Penninx, B. W. J. H. (2011). Psychological characteristics of chronic depression: A longitudinal cohort study. The Journal of Clinical Psychiatry, 72(3), 288-294. https://doi.org/10.4088/jcp.09m05735blu

Wiersma, J. E., Van Schaik, D. J. F., Hoogendorn, A. W., Dekker, J. J., Van, H. L., Schoevers, R. A., Blom, M. B. J., Maas, K., Smit, J. H., McCullough, J. P., Jr., Beekman, A. T. F., & Van Oppen, P. (2014). The effectiveness of the Cognitive Behavioral Analysis System of Psychotherapy for chronic depression: A randomized controlled trial. Psychotherapy and Psychosomatics, 83(5), 263-269. https://doi.org/10.1159/000360795

Wilbertz, G., Brakemeier, E.-L., Zobel, I., Härter, M., & Schramm, E. (2010). Exploring preoperational features in chronic depression. Journal of Affective Disorders, 124(3), 262-269. https://doi.org/10.1016/j.jad.2009.11.021

Williams, J. W., Jr., Barrett, J., Oxman, T., Frank, E., Katon, W., Sullivan, M., Cornell, J., & Sengupta, A. (2000). Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults. JAMA, 284(12), 1519. https://doi.org/10.1001/jama.284.12.1519

Witte, T. K., Timmons, K. A., Fink, E., Smith, A. R., & Joiner, T. E. (2009). Do major depressive disorder and dysthymic disorder confer differential risk for suicide? Journal of Affective Disorders, 115(1-2), 69-78. https://doi.org/10.1016/j.jad.2008.09.003

Wolf, J., Wörz, K., Cronau, A., Midderhoff, F., Kunz, J. I., Merscher, A.-S., Vögele, C., Jobst, A., Goerigk, S., Padberg, F., & Reinhard, M. A. (2026). Sustained high-loneliness states in persistent depressive disorder: An ecological momentary assessment study. Annals of the New York Academy of Sciences, 1564(1), e70436. https://doi.org/10.1111/nyas.70436

World Health Organization. (2024). Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders (CDDR). World Health Organization.

Zobel, I., Werden, D., Linster, H., Dykierek, P., Drieling, T., Berger, M., & Schramm, E. (2010). Theory of mind deficits in chronically depressed patients. Depression and Anxiety, 27(9), 821-828. https://doi.org/10.1002/da.20713